var title_f38_52_39744="Buckle fracture radius";
var content_f38_52_39744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal buckle fracture of distal radius in 5-year-old child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 525px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAINAaUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooqzbwLKhLEjBxxQBWoq99kT1ak+yJ6tQBSoq79kT1aj7Inq1AFKirv2RPVqPsierUAUqKu/ZE9Wo+yJ6tQBSoq79kT1aj7LH/eagClRVz7NH6tR9mj/vNQBToq59mj9Wpfs0f95qAKVFXfssf95qX7JH6t+dAFGir/ANkj9X/MUfY4/wC836UAUKK0Pscf95vzFH2KP+835igDPorRFjH/AHn/ADFUZVCyOo6AkUAMoorV03Torq28yRnDbiPlI/woAyqK3/7Gt/78v5j/AAo/sa3/AL8v5j/CgDAorf8A7Gt/78v5j/Ck/se3/vy/mP8ACgDBorcOkwD+OX8x/hTTpUA/jk/Mf4UAYtFdRbeHbeWMM0k2T6Ef4VKPDVorgSS3AU98j/CgDkqK7WHwpZNId0lyYx/dZc/yratPAOkzLlp74fR0/wDiaAPMKK+ifCXwb8H61CTcX+uRSLwwSeLGfxjrqLn9m3wq1ok1lqmubs4ZJZYuvbB8ugD5Oor6Qf4D6BFeNBNfaumRlcyRg59D8lWoPgD4YnV0XUdZScLuUNJFj/0XzQB8y0V6B4s8Bx6FeXFt5lwXiPBcjkdj0rkPsKK5VmYEe9AGdRWummwt1eT8x/hUy6Rbn+OX8x/hQBhUV0H9i2/9+X8x/hS/2Lbf35vzH+FAHPUV0I0W3/vy/mP8KP7Ft/8AnpL+Y/woA56iuh/sS2/56S/mP8KX+xLb+/N+Y/woA52iui/sS2/56TfmP8KytVtUs7lY4yxBUN831NAFKiiigAq7Zf6o/wC9VKrtl/qj/vUAWkVnZVQFmJwABkk1peIvD+q+G9R+wa7YzWN5sEnlTDBKnofpwa3fhH/Y8fxB0m78SXUdrpdlIbuVn/jMY3IgHclgox6Zrs/jf4p8PeOvD2ja1pmoXUmsWtzPaXEN9Gkc7wsxlRgqMy7ELFBz36UAeOUUUUAFFJQTQAZpC1NY1GWoAkLc0wtSIryHCKT9KvW2kXVxIiKvzOcAUAUdxoAY9jXo2hfDi6uCDdSGFMZ5XrXRT/DVoYw8AW5x/dkxQB4z5cmPumghl6givUbvwiIHKTRtAQMnjP4VG/g6G6RRaz/vG6LIuAfxoA8yD08Nmt7WvDd3p0rLdW7xHs2OD+NYMsEkJ+YcetADgadmoVbFSA5oAfnilzTKUUASDtWRP/r5P94/zrWH86yZ/wDXSf7x/nQBHXQ6Ef8AQj/vmueroNE/48f+Bn+lAHRaDoupeINQFjotnLeXZUuIohkkDqal8R+Gta8NXEUOvabc2Ekqlo/OTAcDrg9DjjP1FdV8DNV07R/G8lxrFzbW1q9jPDvuSRGWZcAMRzg+1aHxg1XRbzw54X0/TrzT5LvTxOj22lPK9nDG7BgVMoDFyevXp9KAPLgaQ0UhoAaajc8U81G55oA6rQIxIqeu3itDUbYGFmx0qh4e3K0eP7p/lWxNllORkEEGgDmIp5LecBW+UjBBrQtNbaA7JVOR3Ws3UUKuRnkGqckoZlI6kYIoA9X8DeIR9tYQvyy/dPqK9u8Fa/FfW8trKSYpRwGP3D6ivkjSZJYL6KWJyjA9q9e8G+IFjeIPmOfOcjo59KAPZLyJnkMVwAxjPDd/zquke2R4ScSJ80TZ/Spp7k3dklzFxKFw6kdvWrtoEmtYJAFbYBux1AoA8w+LXh/+09LXUoIv9Ih4k2jqvf8Axr5v17T2gcyoPkzX27fWaxPIjJ5lpMOnsf6ivnL4leE20PU5Aq79PuMtE2OMd1PuKAPHYmq3E/HvUN/bNZ3JT+A8qfakiagC8pp1QI1SigB1ANJSg0AKKKSigB2a57xD/wAfqf8AXMfzNdBXP+IP+P1P+uY/maAMuiiigAq7Zf6o/wC9VKrtl/qj9aALNFJRQAUtJQaAEJxUZalY1ExoAVm5q9pdg15OiYzk9zgVFY6fPdsNinaTjP8AhXufw++HX7iO4ktzI5AJMnQfhQBiaD4LsViSSYvO3pGu2P8A76711lrZ6LppRrfyFvEbjJziu5n8H3kluq2zxNgcIGxj6VwXiXwjcwsxuLCWMjq6g/zFAHq/hzV7G6slDtazkD5o1wadd2uh3DkrbvBIT1ibAr5euftdleE6bPMjRnO5WKmty1+IGqfZ/s99cP5ijiTGCfrQB7Lq2i20cbTxSM8Y5PmYIxXGaiLVXwsPlL13p/hWHYeOrm4kCSO06k7Qh6KPWu5TTV1zS3MBXzQpKnHOfSgDgZri5DNFK6y27H+IbhisPxD4ej8nz4ogmf4B159qZrtxdaVcMr5XDZZT/Ormia612m3G5y24nv7UAee6ppZgJKqQR1FZQP516x4p09ZtLkuygWWPG4D0NeVXSeXcMB0zkUAKDmlFRqeakoAUVlzf65/941qCsub/AFr/AO8aAGV0Gif8eX/AjXP1v6J/x5f8CNAF+ikNFACmkopKAENQt1NSt0qE0AddoT7dnuMV008SGDcW5b0WuR0hyIkK9cV1UbXTQgMIVyMg7eRQBy+qxkSEkYrGTaJCvGc11GsWbxje7Ft3euRu8xTo46BuaANu1UDYxHQ11mh3MaXsJblTIDnOMc1y9oQyj3rTt7mS22mPG4dDjkUAfUFtKpslZdinbyCOTRY3Rt5EYAkZ5X1Fcj4VMuoaXZ3LTP5mwZOc/nXT4IUHBBHJ5oA7FPJuLIpI+yNhlHPGDXn/AIp0qPUobixu42eLOQW6qfUVu6bcPLE0bfMUOVyau34hmtQs20yAcD19qAPk7xx4VmtfNQDeEJKsB+ledplWKtwRwa+oPFumhvNxHt7gGvnrxdp32DUpWQYQnP50AZsTVYU5FUo2q1GaAJaKQc0D3oAcKKTNLQAtc/4g/wCP1P8ArmP5mt+sDX/+PxP+uY/maAMyiiigAq7Zf6o/WqVXbL/VH60AWKKSigBaRqKaaAGMa2PDHhy/8QX4gsYt2OWJ6CshAGlUHoTXq/wt8Rp4ZvN5h8yGTG/BwfrQB3fg/wADf2JYq8zpFc4yZPJ3sPYZ6fWti88QXOgxuLW1keI9WY/riuq0jxZpOtQHZIvmEfdc9a5fx7rGjWdm7mRftH/PFOS/+FAGcPi8YoGins1hbGBMjZwfpXL6p4i1nUpzKNWlkt2PyojYH4ivONavRf3jyxgQDORFmorPU3hUr5m0DsTQB2et30nkRtJHG7dC4GCfwrhdUu98zKImDdia2Ib99RAjByRxmqF/bhoH2glo8nP86AF8IzbdTSScnYGAI9q+j9DtCkENxA5G4ZG0183aAAXLDkA8/Svoj4fXYn0FIywLxZGc/lQByHxP8GOtxLMHkk84echPv1FeZeFZvsetJbzDALbCDxX1bq9mmreH4j8vnW7YGfQ188fEDw/JpevW+oQpiN3AkAHQ5oA2LyNbjSNUtgdx8lmH1BzXi+pr84b8K9j0WYT6hJG3AnRk+pIIryTWIjG8sZ6oxB/A0AZqVKOlQKalWgB9Zk3+tf8A3jWnWZN/rX/3jQAyt/Rf+PI/7xrAre0X/jy/4EaAL5pKKKACiikoARulQmpm6VCaANzRpcRL6V6A5Jt0I4yAQfWvNdIb92R6GvRLGfzNGs/XBXP0oApa/G39nbic4xk1wOqD5SfTkV6Pq0Zn0edP4lAcfhXn15BJKCI1LUAW9HuRKiZPzdxW/CvAJ5ANcbpXmowR0IIOA1dbZSugG4bh60Aeu/Ce/JSSwkbkNuj68j0r0a6ikUYG0ex614joOoSW6w3tux2o2x1Xj8K9nsblNQs45YX3DvzzQAWBaOUksFHIOa3bZIxEXLqMj7w9K5mCT/iaSwHo+QPY1d0/bI7K7sGQ/dPIoAq+IoElidjhk55PWvnr4naaEbzAOoIr6a1YxCwVdu7c2ORXh3xOtlKzKB05A9OKAPCYm6VajNVSNkzr6E1YiPNAFgGnCmLTqAFpaQUtAC1ga/8A8fq/7g/ma3qwNe/4/E/3B/M0AZtFFFABV2z/ANU31qlVyz/1R+tAFjPNApOtFAATxzTacaQ0ARmr1jqklqQGG9R+dUyKYRQB2Nv4kRoh5ZdHH86tTapLqqL9obLoMZJ6+9cIjmNsqa1La4cgY496ANPVbQYXBy/t2rBaJkmIbO70NdHZL5sbbjlh3NVdYtt0SyoMsp2nFAEemXZtpkcdQeRXUCH7Rep5CbklwTnoAa4+K3YFXk4Vu1dxo0oGmwOv8BMZx6UAYVrpr6Z4gmspZMrkjOeCO1evfCsNHfT2jSFty546fWvNvFOHW11KH78Z8qUfy/Su/wDhJqEM98HZ8Haev0oA+hdFs7D7O9uwZjKuNxPfsa8/8YeHYrp3gZGLBxkkZAINddo10GOUcnFXtVjEzmRh8xXJ+oHWgD5k8R20mh65BKg2jfnHoRXn/jeBY9auzF/q5T5q/Rua9s+J2mG7jjutoUI4G7OP/wBdeM+KUBZB1ZRjPXigDjVqZT0qFhtkYe9SLQBNWZL/AK1/941pDpWbL/rX/wB40AMre0X/AI8/+BGsGt3Rv+PP/gRoAvmkoooAKKKKAGt0qFu9TN0qFqAL2kk/MPeu+01wNNtoz1GTj6muA0cZZseteieFfLZ9lweAOMmgCzJll2KpYN8tZU1ikCMiKMD1HJru5F01Yl8pWeQc8D/69c/fx7nYgcHnmgDg5Lfy55FAypOa1LMEpg9QPzqW4tv3rZHXkVJbx7DgjqKAOn+H1t9s1h7A/cnXcP8AeXn+Wa9l0+CO02pEoUZ5rzD4XwFdftLnHCE5P14r1Of5Lt0HADkUAZd3MYtYZx/DIDWqJEh1oFgArnafoaw9YONRuAeOR/IVe1Jsyhv9kEUAbutEpaBcch8ZNeRfFdMSxnH34lJ98cV7Bq7ibTIJf7+D+leVfFxD5OnP2MLD8iKAPnHUkMepTL75FEZqx4gTbqZPqoqrH0oAtLTqYtPoAcOlFJSigBRWBr//AB+J/uD+ZrfrA17/AI/E/wBwfzNAGbRRRQAVctP9UfrVOrdof3Z+tAFgUUlFABRRRQAU0inUh6UARMKtWkvO09artRFnzVC9ScUAb+nXDJcoAMhuCK7fT9LhAnhnKlpgVz2U9v1ribRREoK9fWuuadngjkUjlATj1xQBzF1EYZHhkGGUlSPQ1e0a5KQTRMSBuBFN1v8AfMLjgueH9z61SsZgmVbJ3dMUAahnGZYZPmhmXaw/ka7X4Tx/Zo9zj5/MIPuK4kkKoyUjB/ib/PP4V6F4E3tZq6oSofCt03D2FAHv3g9ELGQgCPZnLkVqajJHLDcskisVjPA6VzXhG2cWck9xuUMQoHtXQbIRbTADG9CtAHjnjubUjpsoto0whA3FAePxrxLX4bhnLXWSzd8V9G+NodukzE5UheARgV4V4odGiIyu484zQB5ldrsnPvTUqfVMeeBVZaAJ1rOl/wBa/wDvGtBKz5f9a/8AvGgBlbujf8ef/AjWFW7o3/Hn/wACNAF6iiigAooooAa9Qt0qZulQvQBoaH98/WvVPBemxzhpZRuA4ArybR5Alzj1r2HwLIGikBYYOBigDsEhhKhPLjGeMEVzGr2hikdcEDtXQKTG5JbBPGKbrdv5+nCdR/qsBue1AHn9zD+8Bxz0qJYcSqBz2rYeMOwOO9PtLPzbyNcdTQB3PhC0FjYREj5ztauxvF/4mDc9TmsK3UKqKPYCtzUTt1DHsKAMLxAdurXAPAJx+lXb85MRJ/gA/SqfiFd2uFeu8rUl7MGk2g+woA6S7Yf2FZ+3H6V558WIw+j6a47F1z+RrutRlC6VbL3DkfkK4r4kAS+GLRgc7ZyMf8BoA+bvFCbb1D6gis6PpWx4tUC4iPuaxo6ALSdBTxUadKkHSgBaUU2loAcKwde/4/E/3B/M1u5rC13/AI/F/wBwfzNAGbRRRQAVbtP9WfrVSrdp/qz9aAJ6KKKACiiigApDS0lADGogOJk+tI1IvEin3oA6OEjbW5YzpJGqMcbRiucsi8uAn4k1pQwDIDMSScUAWdXuI9nlRyKc/wAK81ikMOvArfljt0i2ogz6kVFo2lPq2o+TGCY1OWx/KgC14Q0CTWL6BZN2yRwpJ7jvX1V4Z8LWGlWcflQKrqoAyOg/xrkvhb4UtrZluJkUtD0UjgGvVJQgjwD1/u0AWdHt0eE5KBQfukdKk1WGGOFiipu7YNVdKtd0swlJyUyB+NMurZcnYTuHagDl/G6PHpUodUcNHnBGR0r5u8TN5mmSzGONNpA4UA/nX1L4xtxLF5PpGAfyr5f+JEP2DT4rYcNJK5I9hwP50AeS3zFrimJRdcztQnWgCZKz5f8AWv8A7xrQSs+X/Wv/ALxoAZW7o3/Hn/wI1hVu6N/x5/8AAjQBeooooAKKKSgAbpULYqaomFAEcMnlTo/oea9M8F6mttdRlz+6fCsfT3rzGQVveHLzH7tjyOKAPdpVKykE8cEH1FWbO6ULJDMN0Uq7WFc94fvxfaWiSNmWH5c56r2/wrRCtgN3HWgDNu7Q2ly8LHIH3W/vDsauaREPNhcjkuPyq3eIl3ZbGGLiPlG9R3BpdKiIji3DDKOR6GgDq7FfNuoE7bgT+FTX90zXbMfWqNhMUulbjABH40l45abjnNAFq5/f6hb3B7IRn3HSsx9z3aY/vD+dXInBtHwcsDkfSoIgBeB/4ScgntQBs6u+2xgQ9d24n61ynjY48NhGPzeeCM/Q10944lCqANvGP8a4nx3cA2scIYEhix70AeGeL8ebHj+8axI62vFhzKn+8axY6ALCHinimR9KfQAtFFFACisLXP8Aj7X/AHB/M1u1ha7/AMfa/wC4P5mgDOooooAKt2n+rP1qpVu0/wBWfrQBPSGlpDQAUUGg0AGaQniikJoAaaYTzTmpq8uB70AdHpmEiRcduavSHGCM1Bp8eFUgckVfeI4y35UATM2IwGQnI4yeteu/D/w15GiwXDRATSkEnHPNec6Fpz6tNpsCDJaTY+PQHP8AKvpfTbNLfRtoUZRl7UAWtBhS2uI4V+66lT9ccVpxNucKeuayLN9t7ARwQ4/nWmjY1KRB0BNAGraSOrXL5/5ZEfrTNJBnnVGOSx5qCNyIblj6Bas6IwjW6uj0hiZgffFAHP6/diW/lHX5iBXzP8anA8TzW6n5YI1X8Tyf519BlvMuzI5G0ZZj7Dk18xfEi/F/r17df89HJ/DPFAHnE5zO/wBacnaoycux9TUiUATLWfL/AK1/941oLWfL/rX+poAZW7o3/Hn/AMCNYVbujf8AHn/wI0AXqKKSgAooooAKYwp9BHFAFdxRazG3uFfPHensMVC60AeleGdSNvIrg/KwwQPSvQ7CdbiL5G5x9414doN6UVUY8qcV3ui6m0WNjDB7UAd/GsKjB57k56VPajJJHUmuetNQEh3HJJ7dBXX6RsW2R+CzDJPvQA2NvLb5gfpUjzrgMFkYY/hXpS6g6naFxu9qjjmAhAPYUAIJRKrrGHUnj5u1ENtPISqzfiV6VLgMq4zkjJNWYXCIwBySOKAKktk8QObpiT/s8Vw3iwPDJtkOSc85613F5OWmHfArz/xjLuuWTIyv6UAeU+Jm3TJ9TWVHWj4hOZl+prOj6UATp0qSmJ0p9AAOtKKSloAUe1Yeu/8AH4v+4P5mtzvWFrv/AB+L/uD+ZoAzqKKKACrdp/qz9aqVbtP9WfrQBMaKKQUAHag/Wig0AFNpe1IaAGmlthuuEHqaa1TaeM3aUAddpy8LjtWhKvAqpp65XA61vWNmXG9+dvQUAegfA7SQ6anezrnyioiHoT1/pXr6HOmXIPUYOPxrivhlAltp6wA482Nnb65zXYwSBhLF/eUrQBXtGzeW65PLita0bztYwOrMRWBYSf6cp/uAt+Na/hlhJrCuxyxJVR7nvQBbvJDFZ9fmlYvj26Cr0x+x+DrvcQJJNqn2yen5VnzAvctJKBsi4VfU1T8S3zJ4fjjLEtJcAk+oANAHK+LNQGmeHL64B+Yp5Sn3NfLXiW53NI3rzXtnxW1Rv7MtbVWwGy5H6CvANem3Ntz1NAGQlTpUSe9TJQBIKz5f9a/1NX6oS/6x/qaAGVu6N/x5/wDAjWFW5o3/AB5n/eNAF+iiigBKKWkNABRSfjRQA1xUbDipjURoAjikaF9y10Gl6k2VIPH8q55xTrSUxXC+hOCKAPUNN1InaO/rXb6NfF4gNxUexrynSJjuAIrudLnCoByKAO3tw1w2F7d6ZdQvFIFc9fSqGm6isRw5yD3q/dXyXAQIfu98UAaFuvQD060SyhJME4HXPTFUor9I15Bz7VBNdC5mVB8qE8+poAdfXBYMYVLueQR0Fee6yG3SF87iTnPXNeiFkUEdh0zXDeKcfaHwMHHOPWgDyzxAMTL9azUrS8Rf68D3rNTpQBYTpTqYnSn0ALRRQKAFFYeuf8fa/wC4P5mtysPXP+Ptf9wfzNAGdRRRQAVatPuH61Vq1a/6s/WgCaig0UAB70lFA96AA0hpaaaAGmp9MH+lrUDVPpn/AB+LQB3mjIGODXV6bGBCdxzmuT0ltrpzXZ2pyI1HUCgD0rwXMouLaMHG6MgfXFdF5hSfOeQa870G7Mc6gNjZjFdf9ticBt2Sey8mgDTiAj1CSRT8hUkfj1rW8OSxwvLKMednAOegrl0uZvPXbG2w8YPetuO3CBWiUK5680Aad9KZJJD2zxiuU8T3pMcEecBMmr99fy25COOCM8VwfijWJWkYAKgA4IoA85+I1+J9SZVbKxrsznv3ryfUn33OM9K7HxFOXnlJOck1xEp3zM3vQALUq1GtSrQA6qEv+tf6mr9UJf8AWN9TQAytzRv+PM/7xrDrc0b/AI8z/vGgC/RSGigAoopO1AB3oo7Cjv2oASmtTqRhxQBC44qLo6kdc1M9RAZlQepFAHX6ONzKK7eyOEXrXG6IpMgrttKjMrKi9T3oA39JRHyXGQOMVvpYwOmQvXuO1UbPSLuCPzIRHOp5IzgitiynWMHzFeLjBDrkfmKAKiWOxWO0SYPQ9cVRvXhSIny1Qjpt65roJ5LcglZAO+PWuR1xVFzvXPzdQaAIm1KREOFXd/eNcprErOrs5yxJJPrW1L0NYWqjcmMcUAeda+f9KUfU1QSr/iJSLtD7GqEdAE6dKfTEzin0AFLSUUALWJrf/H2v+4P5mtusPW/+Ptf9wfzNAGfRRRQAVatf9WfrVWrVt/qz9aAJaDS9BSUAFBpKKACg0UhoAaafZttukPvimGmq21wfQ0Ad5pr4KnPTmuq0+c9cnJrh9JnBRea6rT5hjigDqtPuMPxnPWus8P3avMUc/ORla4a1kwoPOT+tdJZWkqeXIj/vBghaAO6spN7MxyFX5QPep7m7kiQbXxWbo92jxnd9/d37Ve1YJ5W2NssF79M0AYPiTVwqpub52GfrXnGt6i0zyN0XGMA1sa/O0src5A4zXF6g+I5cfSgDkNamGHP41zC1t64/yMKxFoAkUVIKYtPH0oAdWfJ/rG+pq+OlUJP9Y31NADa3NG/48z/vGsOtzRv+PM/7xoAv0lFFABSUvakoAKKSigAppp1MPWgBj9KbbjNzH9ac/Slshm7T86AO00Vec122iYWaI57gVxmjjAzXYaXwqEdiDQB6LpUrxKu0/ga3YpY3H7yJeawrYADPTNaCEr0OPTNAE11FbOhzGpA/OuL160jjlLxdPeurnYqCSeo6VirJZ31wVkUuFODzwTQBzaRRFN0rhcfw+tYOsIhU+UMKK9IkstPERVbdSD3bmuZ1+0s/srsIQhAJ+WgDxLxOP9IjPuay461vFGPNX/erIjoAnSpKiQ1JQAtFFFAC1h63/wAfa/7g/ma26xNb/wCPtf8AcH8zQBn0UUUAFWrb/Vn61Vq1a/cP1oAlpKWjFABSUUUAFJS0UANNRt0qQ1G1AGrocpztLHg12+mOuASD6VwmgoWnJ/Cu602P7ooA6i3kG1T6YrstJLXmDEeTzn0riol2xD+Vaml3MlrKJEY+hGetAHVaotzZTxSxICSMOV5B+tVbvXbmSAxhVU4wSOtLHq5nASGJ5JT2qa08NajqchkdREhOWY9BQByl6Moc1x+p5COK9e1jw1aW1jKyXLSTKCSQeOK8h1g8vQBwmuE5x6msta0NaOXH1NZ60ASLT6atOoAWqEn+sb6mr4qhJ/rG+poAbW5o3/Hmf941h1uaN/x5n/eNAF6ig0lABSUtJ1oAKKKT+VAB2pppxphoAY9S6YM3f0FQyVa0hczscdqAOz0ZeBXXaav7tD7Vy+jD5fcV1tiuIh9KAPQLX5oYm9VBq8D/APrqvaJiztj3MamrUS7zx60AZ3iGUwWJOcM2FFcvYS+VdDrtkO36Vr+M5Qt9Fb9fLXcQPU1gwFjcRH0cH9aAOmDnv0rnvFLCPTp37YI/E8V0LJhiT3rmPHLBNJRf4pJP0A/+vQB4r4lOWT/erJj7Vq+JDl0H+1WVHQBMnWpRUSVKDQAtFFFABWJrf/H2v+4P5mtusTWv+Ptf9wfzNAGfRRRQAVatv9WfrVWrVt9w/WgCWiiigBKKKKACjtRRQA1qjantUbUAbnhxM8+9egaRFwGPauL8OxYRc+legaQmEUfiaAL8ifuxgVr6ZY+fFuLYycADr9afpNpBd3yQzkhWHy/WvQdH0mwtSAVX5jjd6UAY3h24S1AjisJdw6sItxb3ya37m8uJoQptL5geOFGB+ArTmiNopMTAr6Gm22pSAYBX0NAHA+I7i8Fo8Ntp10obgyOteR63lGdWGGHBB619H6pqRMb7wvTrXzz42ULq14CNvzk4oA821f8A1i896pLV7VV3OoUEknAAqa/8Pazpmn299qWlX1nZ3DbYZriBo1kOM/KSOePSgDPFPFMWnfWgB1UJP9Y31NXxVCT/AFjfU0ANrc0b/jzP+8aw63NG/wCPM/7xoAvUn86WkNAAaSjtQaAEooooAQ0004009KAInq/oi/M596oSe5rS0MfIT6tQB22j/wCqIHcV1toAI1+lcno/RRXXWa5KqO+BQB6NGpSztxj/AJZj+VWbFN8yDr81Jcp5cUa/7AFS2zCC1uJzwI4i2fwoA4DXJvtOs3cmSV8wgfQcVDaLm6iGOrCoRl3J7nmrmmIGvoh6HNAHRTL+8x3ri/iM+yGyix/AzfqK7a6B88gdjXn3xLlP2+GMdEixQB5H4iOZEHvWbHV7XyTcIPrVGOgCZOtSjoKiXrUgoAWlpKWgArE1r/j7X/cH8zW3WJrf/H2v+4P5mgDPooooAKs23+rP1qtVm2+4frQBLRRRQAUUUUAFJS0hoAa1R4ywHqae1JEMzoPegDsdDjwi13mnjCDvmuK0JQdv1ruLFP3a0Aa1vL5NxFKrY2MGz+Nek3LbFOOh5FeZYG3HbFejg79NspM53QLz74oAu6hdFtPtiPvP98/SqlpJycdeoqCSTGLduoTzAD9cUR5QY6GgCa52GC4mlOIII2kf6CvGTqemR63Le+INIbVbeR9xtxdNBxn+8ozXsOquV8Ma4/b7MV/M14DqxHln6UAe9+Avi58JtJMaR6Ivhy5+75z2Yl/8iruc/iBUvx/8feAb7w1otzc6fY+MrZrlwkVvqzW5t22/eby8nnphgK+R9X6j61QWgD1YeNPhn/0Sb/y5Ln/4msrxT4l8E6losttoHgD+xdQYqUvf7ZnudgBBI2MMHIyPbNcEKcKAHCqEn+sb6mr4qhJ/rG+poAbW5o3/AB6H/fNYdbmjf8ef/AjQBepp9qcaae1AAaQ0tJQAGikz+dGKAENNNONNPSgCJ619EX9yvuax371vaMuII/egDsNEXJFdlpahriBexcD9a5LQV4J9K7fw3GH1WzQ8jeDj1xQB6DqagSqvTCiqutyfZ/DF2x4MmEFXdT5vSMeg/Ssbx3L5Wj2UH8UjbiPYUAcWCM8cVqeH08zUEz0A7Vkr0rf8KJmaWQ9sCgDVlGbhq8v+JEpbXJBnhUAFepjmYHpzivIfH0m/XrzngNj9KAPMtaObwD2qvHUuq/8AH8eewqNKAJFqUVGtPoAWlpKWgArE1r/j7X/cH8zW3WJrX/H2v+4P5mgDPooooAKs23+rP1qtVm2+4frQBLQaKKACiiigApDRQaAGNTrXm6SmNUljk3QoA7nw+ASuQK7u0UBBxxXDeHvvr+Fd3bfdHt6UAWE7GvSLVc6Dpx/6ZgV5ugx0r0myUnw7YHvtoAo3r7fE+mxnADwMtXJ1CyEDr0xWVr7eV4l0hv8AYA/M1t364mPX1zQBU147fBOskcZiH868B1jiEive/E/HgLUz0LFR+teBa2cL1zQBxOrcEfWqK1b1Ukuo96qLQBIKdTRSjrQA8VQk/wBY31NXx0qhJ/rG+poAbW5o3/Hmf941h1uaN/x5/wDAjQBdNFBpM0AIaKKDQAlFBpDQAGmN0p1NbpQBDIa6XSlxHGAO1c1jLqPU11ump90CgDr9CTEIPqa73wXF5mvWwIzjJrjNGjxBHgda9C+HsO7V3fsidaAOovQZL+THPzVzHxFkB1K3gHSOL9f8iurtxv1FcdC9cT42kMviG477cLigDBX7oFdR4aXbYuR1bJrmQOK6zRF2aZ06qKALcQzIpJ714x4zYHWL0r03kV7XEuOT2Ga8L8USeZf3LY6yN/OgDz7UyDfP9KZHRfHN7J9aE6UASp1p4xTFp4oAWiiigBaxNa/4+1/3B/M1t1ia1/x9r/uD+ZoAz6KKKACrNt9w/Wq1Wbb7h+tAEtFHaigBKKWkoAWmmlpDQAxqm07/AI+fwqFqn0zm5P0oA7rw/wD6xOh6V3Vryo7VwmgD94td3afdFAFmPO44r060THh+wBH8FeZLxzxivUo8roGne6jj8BQBynjiT7PrOmsf4Y1OPxrqtVXIBH8SA/pXHfEo41O0YdRF/KuzuyJrCwlycPAp/SgDJ8UgD4f6hngblr581tq+h/Fgx8Pr/PPzD+Yr5z1s8mgDj9UOZVqqtT6iczLUC0APFOpBS0AOFUZP9Y31NXlqjJ/rG+poAbW5o/8Ax5n/AHjWHW5o3/Hmf940AXTSHrS5pDQAlIaU0negApKWkoAQ0x6eelRyUAFsN11GPfNdjpqcrXJaYC16D6Cu00tNzoPU0AdppqgRpj0r0T4dxnfdv/CAB+lcFYp8oNek+A4/K0i6lPVmNAGvpS774sf4cmvO/EMhm1i7kPeUgfhxXpGjAKLmU/woa8su3MtxK56s5J/E0ARnhOOprsrRPL09B34rj4ly6L6kCu42bbeNfoaAJMbbeVuwQ/yr5+1191xMfVif1r3++bytJumHUIf5V896wTvc96AOGujm7lPvTo6ZP/x9Sf7xp8dAEq9ad9aatPoABS0d6KAFrE1r/j7X/cH8zW1WLrX/AB9r/uD+ZoAz6KKKACrNt9w/Wq1Wbb7h+tAEtFFFABSUtFACUjUtIaAI2q1pYHnNVU1c0kZkagDt9AH75ce1dzajC9K4vw8mZRxXb24+U0ATkfLmvVol/wCKd04nn5RivLMDy69ZtkB8NaX6bB/KgDhPiWB9rtj/ABGM/h0rsLY+Z4d0eQ97cVyvxMUC5tCe6kZH0FdVpH7zwjozHtFgUAU/F4x8P9Qxzk/4V82a4f3hHoK+l/GK48A3+P8APIr5m1w/v3+lAHH35/f/AIVEtS33/Hx+FRLQBIKUUgpaAHLVGT/WN9TV0VSk/wBY31NADa3NG/49P+BGsOtzR/8AjzP+8aALp60lFB6UAIaSg0Z5oAD70lFJQAGoX6VI3SoX6UAaGhpumdvwrttIjzMnoDXJ+H48RbvU13GhxgyjPpQB1dmuEWvT/DMZh8MKTwXGfzNebW68YxxivU4E8jQ7aL0QZ/KgCSFvJ0PUJh/dP8q8sNem6sfK8G3bZxvBH58V5oRz0xQBLp8e+9hH+1XcPGN0a5rk9Cj36gmR0Fde4zMB6UAUPEbmLQLxhx+7IzXz/q+Sz17z43fy/DU+DjcQP1rwXViMvQBw8vNxJ/vGpEHeom/1z/7xqZOlAEi0+mLT+1AAKWkooAdWJrX/AB9r/uD+ZrarF1r/AI+1/wBwfzNAGfRRRQAVZtvuH61WqzbfcP1oAlooooASloooASmmnGmtQAxq0NGGSfrWc3StbRV+UH1zQB3fhlMtkV2cA+XgVy3hdflrq4PuD86AJT9ztXrdiA3hbSyP7o/lXkvrj9K9b0U7/BunE9QKAOP+KCDbYnsVPP4V0Hh3nwVpR9mH61i/FBf9E05uoPA/KtrwoN/gfTSexb+ZoAZ4yH/FB3+PT/CvmLXB++f6V9QeNVH/AAgV/k9s/qK+YteXFw30oA4y/wD9f+FRLUuof8fA+lRLQBIKWminUAOFUpf9Y/1NXFqnJ/rG+poAZW5o3/Hmf94/0rDrc0f/AI8z/vGgC4aaadTTQAlFFFACdqDS0hoAY3SoZDUr02BfMuI065NAHTaLDsgjGO1dxoMXylselctpkeQtdxpEW2JfrmgDcsIy88SDncwH616lfLshiT0WvPfDkPm6varjgPk/hXoeqEcD2FAFDxYdnhFVHG5wP1rzwqD0rv8Ax023QbGP+8wOPwNcERxQBs+F483LOcYXiulx+9Y9xWL4Tiyjue5rcQ5Pu2aAOZ+IrbNCiQnq4rw3Vf4+K9r+Jj7LW0jPU5P6V4nqxxvoA4k8ysfc1OlQD77fWp06UASLTqatO70ALSikpaACsXWv+Ptf9wfzNbdYmtf8fa/7g/maAM+iiigAqzbfcP1qtVm2+4frQBLRRRQAlFFFABTWp1MagBjdK3dGXEa1gt6V02jpwgoA7/w3HiJciuliXCjHSsbQo9sCcdea3YhgUACjH1r1rw6d3guxJ7V5Oor1bwzz4Jss84Yj9aAOd+KC/wDEo0xuvzY/Q1seDRnwNYf7z/zNZ3xOXPh6wbPSQf1rV8GrjwRYY7lv50AReOQB4BvgfTA/MV8x+IAPtB+lfT3jrA8A3oPI6fqK+ZvES4nH0oA4XUhicVAtWdUH7xfxqstADxTqaKdQA4VRk/1jfU1eFUZP9Y31NADa29H/AOPM/wC8axK29G/49G/3z/IUAXO9BNLSGgBtBoooAKQ0GmseKAI3NW9Gj8y5LY4XiqTng1u6BBiJSRyxzQB1WjQbmUV29hHtCiuc0K36H8K621j2g0AdF4NiL6upPRVJrrtQbfPgduK5/wADxf6RO56gAVtM3mXh9zQBT+IZ222nRDrgn9BXEN3rs/iM3+m2cYwSsRP8q40jnFAHXeGkCaeG7mtGAZIz2Gah0yMRaaigYOKt2y7iR2OBQBwvxRkzcwIBysZNeMawflc/WvXfiZLu1WUDokYH868f1vIik9gaAOOTk59anXpVeOrK9KAHrTqatOoAWlFJS0AFYutf8fa/7g/ma2qxda/4+1/3B/M0AZ9FFFABVm2+4frVarNt9w/WgCWiiigBKKWkoASmtTjTGoAaozIo9667Q48yRiuUthuuEFdt4djzcJx0oA9B0pMW6mtZB8oPaqVimIlwMcVfUYAoAFAwa9T8LAnwLbnriQ4/M15cvAz3Neo+D+fBEIH/AD0b+ZoAyviSu7wlbPxkTj+ta3hMbPBen9M4NZ3j8BvAqN/duBj8619BQr4Q09eh2D+VAFHxwNvgK8wM5P8AUV80+JVw4OPWvpfx3keArjHXdg/mK+cfE8fyg+9AHnusDBX61RWtLWVwAfes1KAJBTqaKdQA4daoyffb6mrwqi/32+tADa3NH/48z/vGsOtzR/8AjzP+8aALh602nH6U00AJRRRQAhpj081E9ADFUySKg/iOK7XR4PuLjpXKaTF5t5nqFrv9Dgyy8UAdTotvtC8cjmughTAzVPS4QsecDPStRFwAAOaAOq8ILssriTvnj8qv2C+ZeKMfxCq+gL5ehlu7N/WtDR1zdocdSKAOf+ITbtdVf7kQH61zdtHvuY1P96tvxq/meIbnnIUKv6VnaSga/T2GaAOvUbLZQPSrVkMuuPWq8n/LMe1XbJQpJ9M0AeR/EKYyarekdA2B+VeU6+2IJT04NejeL5PMu7pyfvSsf1rzTxEcW0tAHKxVZUcCq8Y4qwvSgCRcUopFpaAFFL3pBS0AFYutf8fa/wC4P5mtqsXWv+Ptf9wfzNAGfRRRQAVZt/uH61WqzbfcP1oAlooooASig0UAIaY1OamN0oAn05d1xn0rv/DEZMufoK4fR0y5PvXpPhWH5QcdTQB2dooCLx0qyBlSR0z61HCuFUY7VYQYjJNAERNepeDDnwXHjs7H9TXlnSvVfBYH/CFxge5+vJoApeNI8+AHxyfOB/8AHhW3YoY9AsY+m1B/Ks7xMnm+A2XuZ1H/AI8K1pvksbaPuEFAGD4/OPAsg7tKo/Wvn/xNF/o5PXmvefiS2PCVqgOC8+fqBXiPiKMtbP7UAeY60v7tqxk6Vv6uuYn+lYC9KAJFp4pi08UAOHaqL/fb61eFUG+8frQAlbej/wDHmfZz/SsStvRh/oh93P8ASgC7Tad+lN96AEpDS0hoAQ1A54qVzUL5JAHU8UAbfh2D5d5H3jXougwDAOK4/RLfYiLjoAK9C0iHZCg6UAdFZJthWriDqaiiXai/SrKj5cd6AOuslEWhwLjqMmr+kj9+mPWoJUCWkEfGQlWdKH77PZVNAHB+IX8zW7xuxkI/Kn+HUL3jY9BVXUm36hcse8jfzrT8JJuuZSPQUAdBIM3IHZVFXIz5dpcyf3YyaqSjEzEntxUmqyeR4cvpBwfLxQB4f4gbdkk8kk1534kYC3f3IFd5rzcjntivPfEjfugPVqAMGOrC9KgjqdelAEi0uKQdKWgBeKWkpaACsXWv+Ptf9wfzNbVYutf8fa/7g/maAM+iiigAqzbfcP1qtVm2+4frQBLRRRQAlFFFADTUb1I1RNQBs6HHlV9+a9R8MQ7YFOOtedaJFwg+leqaBFi3TjigDdhXpmpyPkxSRL0pz9PSgCtIeK9V8IEr4NtOPvEj+deVS9BXqvhzKeENOzxzn9KALF/D53hQJj/l5GfzFWdRIBRR/CAKmsYvN0RlPO2bcaqXrbrhh70Acz8TzjRtLTuWLfzryDWowbaTr0r1z4psoh0qLHRCa8v1SMGBqAPKtVX5HH1rmFrrtXTlx71yJGJGHvQBIKeKjWpBQA4ZqgeSa0BWeetACVuaP/x5/wDAjWHW5o//AB5n/eNAFzNNpx702gBDSGlNNJ4oAjY9afp8fm3iei8mo3NaegQbizkdTgUAdfocG51GOK73TYsFB71zHh+3wisR19q7Kwjw65/GgDSVcnFWrdd9zEo7sB+tQQjoav6Um/ULcf7YNAHW6h8pjHsBU+ncRzP6IaraoMzrjoCKsRHbpl04HIU0Aea3J3TSN6sf510ngqPd9pc9BxXMtyCT1rsPBUeNNuZSOrHH5UAXn+aTpVbxi/k+FJBnl3Ax+NTx8yZrL+I8nk6HZx55ds/pQB4vrr5kIHTFef8AiNs7F967jWXxI4rgfEDZuEX0zQBnx5qcVDGOlTCgB6npS0i0tACilpO3NLQACsXWv+Ptf9wfzNbVYutf8fa/7g/maAM+iiigAqzbfcP1qtVm2+4frQBLRRRQAlFFBoAY1MHLgeppzUtuN1wg96AOu0OPLxjHevVNGj2woPavN/Dse6eMV6lpqbYxgdqANBRSN09KcoHJpkvBx/KgCtPwDk16tp37rwlpseOSmf0ryif7teuhRDounx+kVAG5oce7RZx/wKsOU7rw+mT/ADrp9BT/AIp+7boAtc1BHvuox64FAHJfFCQNqllCP+WcJP5mvP8AUU+Q8dq7L4gOZ/Fd0ufliCoPyrlb1Mp060AeVa7HtmlHvXEzjbO4969E8UxkXUnHUZrz++XbdNQAxaeKjWpFoAeOhqgetX+x+lUKAErc0f8A48z/ALx/pWHW5o//AB5/8CNAFs+1IacaaaAG01zTjUbmgCJ+T/Kus0S32RxriuZsovOu0XsDk13uhW+6ROPegDrtHg2RIMV0lmvzZxmsyxiwq5rbs04JHagCzGOK1fD6btVgz6k1m9q2PDS/8TeEexoA379cyZ98024k2aFeYOPlP8qfeH5mHc1T1Bs6DejoAKAOCJ+X04rufDifZ/DIJGN+W/M1wbnjHqK9Fkj+z6HbRf7IB/KgCO1G5sCub+K0oBsou6oTXSWHMuMc7sVxXxXnB1dEB+5Fz+dAHk+rPlmJ61wOsNuvcegrttVcnPSuDvW33sp96AEQVKKZGOKkFACjpT+1NFKKAF60tJS0AFYutf8AH2v+4P5mtqsXWv8Aj6X/AHB/M0AZ9FFFABVm2+4frVarNt9w/WgCWiiigApppaQ0AMNS2AzdL7VC3SrOlDNzx6UAegeFY83CewzXpVkPkGe9efeEo8zZ9BXo1oMIM+lAE5yMio5Mgn1qRjjI9agkPJ4oAhC754l/vOF/WvYNQXbDaJjgRgV5NpaedrNnGBnMoP8AWvW9aO10UdkUUAdLpOF8JXrHoRisDS1D3itjgGt+1xH4HnPXf/8AWrD0njc/bBP6UAeW+IZPO8QX8hyczN+Q4rGu1yua0r1g99ctnIMrH9apXIytAHnPi6LEwb1GK831RcXOfavVfGMf7tW968u1gYmBoAprUi1GtSLQA4/dP0qhV88I30qhQAVuaP8A8eZ/3jWHW5o//Hmf940AXDTSacaYeDQA01E561IxqCQ0Aa/h6DczSEdTgV6N4ctsHcRxXH6Bb7IYxjnFekaFbhIVzQBs2kfTita3XCVTtUwM1oxjCCgBeD1ra8L86zGP9lqxepwK3PCuf7YGOixsTQBr3jfv25qnd/Not+h/u5FS3TZmBB5zxTCubW6TGQyHigDhrKMz3ttGB9+RR+teka3hfJj9Fya4jwlb+frcJxxF83412euHN4OeFFAEWmf8fkY7lq82+J84fXrgDHyoBXpejgG+U+gJryP4gzGTXbw9twAz9KAPOdWfCsfauGzukY+pJrrvEMmy3lOcEiuQjFAE6DipBTF6U8UAOFKKQUvtQAtLSUooAKxda/4+l/3B/M1tVi61/wAfa/7g/maAM+iiigAqzbfcP1qtVm2+4frQBLRS0lACUhp1NagCNqvaMuZmqi1aehDLE+poA9K8IRgknv0rvYF2qBXF+EF+ViPWu1tx8vvQA8nGSRUD96nboaryY2n2oA0vBMJn8UWwxkIGc/livRdVJa6b04H6Vx3wwg36vdXDfdijxn65rspENxeqg5LY/WgDq7oGHwGuf48H8zWBYN5djdOf+WcRrpfGAFt4Zt4EGB8q/kK48y+Voepv6Q4oA8yzlicdSTk/Wq0/C1Zj6Cq8/Q0AcX4wX/RScd68q1ofMD716z4s5tH+ma8p1wcfjQBlrUq1EtSLQA9v9W30qhV5/wDVt9Ko0AFbmj/8ef8AwI1h1t6QcWf/AAI0AXTUZpS2aYzUANc0lshmuo0Hc0yRqv6BAXuDIeg4FAHaaHBudBivQtPj2RLxXJeHYACC3Su2tB90DoOtAGnboAtWQMLk1FEAAAOtWAMrz0oAYoxknqa2fCuf7Qlb0iY1jcZz2rZ8KjN1cknOIsfmaALl3IAw/wBnr9aeZMRyMOm05/Kq14waUkLToUaeGfB6oRigCDwLbbFkuW6t0+laGpyB7pm+gp+nqtvZbUGNq4qkW3k7vWgDT0hceZIeykCvEPGkvm6veNnrIa9vgPk2r567C1fP/iWbzLu4f+8xP60AcD4pl/dhO7NWBGK0fEUu+7VP7ozVCPtQBKtPFNFPFABSigUnegBwpaQUtABWLrX/AB9r/uD+ZrarF1r/AI+1/wBwfzNAGfRRRQAVZtvuH61WqzbfcP1oAlooNFABTTTqaaAI2rZ0BeAfU1it0roNBT5EyKAPTPCIxC3rursoRgA1yXhNMW5Pq1dhGpC8UAMk7+9Vp8bTk1Zk4J5qncnCn86APQPhlbiPRr+6b+Nto/QV2PhmAXWtgkfKnJrE8JwC08GwDGDIdxrpvAhAubmYgHgD8TQBa+Is+LW2ToGfJrjNUYx+FL5gR8wC103xKcefZx59TgVynin9z4SKg/6yVR+HWgDglOAKqXB5+tWM8VSnYY6/jQBzHirm1f6da8q1v7p+or1LxO5+zP8ASvLtaOUagDIFSrUS1KtACyf6l/pVGr0v+pb6VRoAK19MbFp/wI1kVo2LYgx70AXmfmo2enx20833I2I9eladpoUshHmH8BQBkwxPPIFQZPr6V2mgaYVVVAqxpmhpGBtTFdZpen+VgsBxQBb0e1CheOOv1ro7RMHOKpWiZYYGK1reM5yBxQBZhB44qc/dpYl6U4jFAEJX5R/Ktzw4BDa3MzDliEH0FYpre09lktUjtwTjqvfNACT4IOO57Vo6RbN9jnYjBZcjNT2mlEN5lzxjkL/jV8sghmVD/DQBkzxiOBR06kkVnoR69a0LuTcRkgL0rNTHmBSOBQBcv5fK0q6kPAWHAr5416UbmJNe6eL7kw+Gro5++Ag/GvnrxNcCOOVvQUAcLfSedeyt1GcCljqBMk5PU1YQUAPp4popw6UAFL3oo69aAAU6kpRQAVi61/x9r/uD+ZrarF1r/j7X/cH8zQBn0UUUAFWbb/Vn61Wqzbf6s/WgCakpaSgANMan0xqAI3rqNDTAT2xXMKMuo9TXZaLHgLQB6P4ViItUJ7811K8L3rF8PxBbRBjpitvsaAIJTnrVUKZp0iHVmCgfjViXv2rV8FacdQ8QpkEpAN5/pQB6UsHk6RDAowFjHHpWj4Mba1yF6jaajvItoKsMEdPpTfCbgS3jL0Uc/hQBH4/k8y9sR/snNcr44JTQdPQnlpST74FdB4zJa+sT04wK574gDOlaSeoDMKAODlbbVGd8KcVbuTge9ZtwxCmgDnPEr5t2rzXWT8jV6H4jbMTe1ed6z9xvrQBkrUq1EKlWgBZv9S30qjV2f/UtVKgArt/Bumrc6YZSgJ8wjOPpXEV7T8ItPS48K+ay5P2hx+goAjtNILYATP4VuWWjAY3fkBXTR2Kp0UCpUtyT8uAPWgDKiskjOAgyKvwWZJBIq/FbKg4Gfc1ZVPTAoArwW4U+pFaUa4AwBiolCqOvNSRtz70AWVAAznFNdxjjmo2Yd6jkfCmgBWIzyeKn0+7t4JC08UpYdHjfaRVeCGS5bagO3qWI4xWpHpcWzBUsR1yaAOksdat7iJfLuZ1B7SoCP0pjXDvIcMhXoWUY4rlyjadIJIyWhzhwece9byOrRK4AZT1oAr3RYx4ycnPPbNV7PO5c9jU9xzKUB3AcZxT7KBi/ODyT1zxQBzPxMuvL0y3txwXcsfoBXz34yuOBGDy7foK9k+KN6JNUMS/dhQLj36mvBfEdx9o1NwPux/KPrQBnxCp1GKjjHSphQA5RTu9IKWgAopcUUAApaKKAFrE1r/j7X/cH8zW3WJrX/H2v+4P5mgDPooooAKtW3+rP1qrVq1/1bfWgCWkpTRQAhqNqkNRtQAtuN1zGD613Whx5CjHpXE6cu67WvQdAjzIgx3FAHpOkgC3UDpWln91mqWnDEWBV0seAPwoAruCZAAM9uK9S8CaN/Y2kvcXI/wBLuyDt/uqK5Twrb2qyfaJ4zJIG+Qdh7+9egfaoXhjIZgSNuD39aAG6pdbvNbOCE2j8TTPD48i0dyQHnf8AICqd4d1u5Bzu7+9Q6bfiIRxOpZR0I+vSgC14qxJJDjnBIFYniJDd6Q8IGWjIkT8Ov6V0Oqo86RMIVABzudwK5PxJJc20GMQRq5xlH3MaAOGuh8vPYVj3Dcn0rbvfunHAFYV0eTQBzGv/AOrbnrXA6yPkb8K7zXuYm9K4PWP9WfrQBkrUi1GKkWgAn/1LVSq7cf6k/hVKgAr6D+B6BvAxOM/6VJ/Ja+fK+h/gYQPAZ/6+5P5LQB25i9eBTlRQKcx5zTSCxwOnvQAM2DgU4cDJo2gDmkYk85AFADSSx9KfkCo4UmuJvLtIZJ5Om2Ncmup0rwDqt4gm1KRNPhPO0/M5/CgDlJbpIxgHcfQVY02xu9QcEqyRHqx449q9P0PwLosZITfPMOsj81oTaNZWNwiKGnfPAPQfhQBlaBpv2KwSWaAeTKcK5wTxTdb0+O3PmQbQCM7R0NdrujktRbzEdOgHSud8SWy2WnSEyK8ePk9QaAODvgrI6noQRVvRYmOgxs/3gOM96oXIaeZY+h7n2rWkkUWiwRj5QAMDvQBUmCMTu+91BzwavJssdMmuZjhY1LZNNs7TewMmdvvXK/EfXoxbf2daOCg/1jA5HHagDyfxtqhZrm5kPzMS/P6V5KWMkjOx+YnJrpfGuo+fceQrZGcmucQcUASIOKlFNUcVIooABTqT6d6WgAozRS0AFFAooAWsTWv+Ptf9wfzNbdYmtf8AH2v+4P5mgDPooooAKtWv3D9aq1atf9WfrQBNRR70UANPSo2qRqjagC5oy5uz7CvRfDyYli4715/oAzctXo+gD97GR6igDvrLiI49MVZJOelQW/EIH408ndxQBu+HrgrJs6DNdpbXSzBVIDKgzyO9cDor/v2HoOv4V2OlkgAkgEA4OKANK+IjhwU2jaTx3zWFESlw5IAz71vSnchHU8DB9OtY9zGtssr5yxztJPSgDl9anuby7fyhN5EfyrjOD71kM0it8xfd0+auzsoC0fGSSfzqn4ks1+wSTfxIu7NAHG3km1DzWJO2c5NW7+Xk5rNkbJz60AYmtgeW9cFrP3D9a73WB+5euB1n7p+ooAyVqRaYKkWgBLj/AFJ/CqVXbn/Un61SoAK+h/gYM+BCP+nqT+S188V9P/s5eHL3V/ALTQukcAvJFLHrnC0AdG4A5Jz9aarM7BIVaRj2QE16BaeDtOtub6Zrhv7oPFbVqNP09AlpaRg/SgDgNO8J6vqO0rD5KHvJ/hXXab4CsLTEmq3JmI52dBWu+pykAb1Vc/dHWq8xlmWQLv357n9KALy3FhpcQXTbaOHtuCjNZd1qUs7gzynHrVUWd9O3lwW0r8YII+6a19L8Nzj97rDxrEvO3dz9CaANfRHFrpZuGx+8Py+4rOv9bZN5jUE/3j1p2salC8a29kp8qMbQQMD8K5i5hnnJVyQPQGgDTg1oEkudx68GsjxRqolsHDNjPCgHPNU7lEtEJeQAjv8A0rlr6d55ic/IOg9KALWn3SmU/aHKgdDitOfWbO2GUJlb0A4/OuWllCde1Z15ehQSGoA2tZ8S3M0bJERDGeynn868u8VausUT/N265q9rWrqqMob8jXmHiG/NzP5anI70AZU8jXFw8jHljmnoKYi1OBQAoFPHTpQo4paAAUe9LRQAUUUUAApaKKACsTWv+Ptf9wfzNbdYmtf8fa/7g/maAM+iiigAq3af6s/WqlW7T/Vn60ATUlLQelADDUbVK1RNQBo6DxcN+Fek+H2G+Ik9xxXmWjNtujXoWiy7fLPoaAPWNB09r+du0SAFiP5VsTaZCHEaKuT/ABelZ/ha9HkiFAWd2zgd+K7ewsCrLNLjcoyFz/OgDJ0nw/BbEtM7uzkcHgCuts7eCFQyJtA7VTPlqpZzwO1Zep+KorNAhj3DoDQB0lyYJlzkBh0rBv4YpD5LY65yD0rm5/GZyfLgGKuWt/FeL5innGWBoA17awZY8k4I5yOgrG8WxTNpbwxMHduuPSuq0cxvYSyAEhRyaz9TuY1ikVIxnGOfegDw68ZhKyuCCOCDUKgt9MVv+L7QJcRThcB8g/UViKNqFj6YoAw9c4gYZ/GvP9bPH413PiCUYK561wOsNmRRnvQBQFSJUa1KlADLr/VfjVOrl1/qvxqnQAV9e/svTMnwsK5O37fMcZ9kr5Cr7D/ZVs/tHwuLEEj7fMMD6JQB6az725bApfIk3jZjnvW9BpW0ZZSvu1OlFnaoTJOo9qAMq1015ATJ931rWtrG0gcTyNucc+1Yt/4r02yBCzAsPQ1zWoeOlfIt4Sc9zwKAPRbzWfKUrbxqPQn/AArn7/UZ5+Z51A9D0H4V53d+KL6fOHWMf7NZU2pSSHM0zN9TQB6DNrNnbqw80u2f4eayLvxAWz5EW0HuxrjG1JEB5HFZd/4ijhyA4LegoA6q9vDId875+tYd7q0aA7MfWuOvfEcshIzx9awLzV5GyC5/CgDs73WQM5cVzOp65tzhv1rl77WBGp3Nz6A1z15qEtySPur6UAaur6yZWKRnJ/lWIAWYk8k9aai1Mq0ACjFSKM0KKkAxQAUUtFACUClooAKKKKACiilxQAlYmtf8fa/7g/ma3MVh63/x9r/uD+ZoAz6KKKACrdp/qz9aqVbtP9WfrQBPSUtFADGqNqlao2oAm007bse4r0HRjlRXnVmcXUZ98V6J4fOdlAHo/hO9a2uYc84H5ivZvD0kV0FLHckq5U14hpsfMbAYKntXofgjVBDKLWY/u3PyMf4T/wDXoA7W/wBNYqw74Ix2rg9X0OWSMA/Kyt3r0+K53wmKTggc8VkX8CyFgc57Z6UAeRXOkXMcpVuVz1roPDekXEo8uMEnI5/xrpXtoS+5kBjz37GrtrcJbI0cACsT1FAGqbaLTtLW0Q75Mb5GB6tjpXO3tv5hbP8AFjJrYhYziQknJHNE8KpExJBPAAoA8s8bRqtvaxA5JZnzXFXpCQtXZ+L5vP1WVR92L5Rj1715/wCIZ9pEa9ev0oA5fV5vMkZu3auL1J91zj0FdTqT4Vq4+dt87t70AItSrUYFSgdKAIrv/VD61Tq5e/6tfrVOgBa+h/gb8adF8A/D9tHvYrp703ck+Y48rtYKBzn2NfO9FAH1Tqf7Rmn3mRHLdxKfSHP9a5y8+Mej3RJlutQfPrFj+tfPNFAHvJ+Kfh/t9r/79f8A16hf4o6Efu/av+/X/wBevDKKAPa5PidpDfda6/79/wD16qyfEjSyDtNyf+2f/wBevHqKAPT7rx/aTcKZ1H+7/wDXrMl8W2bnIM3/AHzXB0UAdhN4lt3Jx5n5VnXWub8iLcB6kc1gUUAXzdozFnLEnuRT1u4QOd35Vm0UAa638A/vflTxqNuO7/lWLRQBujU7b/b/ACo/tO39X/75rCooA3v7Tt/V/wAqP7TtvV/++awaKAN7+07b1f8AKj+07b1f8qwaKAN7+07b1b/vml/tO29W/wC+awKKAN/+1Lb1b/vmj+07b1f/AL5rAooA6D+1LX1f/vmsvU50uLhXiJ2hQORjuap0UAFFFFABVu0/1Z+tVKuWf+rP1oAmopcUlACGo3FSmomoAYh2yofRhXo3hw5C15u1d/4XlzHGc9hQB6TpRIdO9dVaIQm5DhgcjFcxohyyjucCuss1xIQehoA9H0e7GoaYky/6xRtce4qeeMvG/XOOBXPeDrg22p+S/wDqphj8a7a5tNhyCdp6GgDmJ4NsJ4J5GBUMNrtyQQQx610k1oSgUgbxwFpkdoVyroBg5YUAVraExo24fNxUWrEW1rJI2MKpat63tA0g67c5Oetcz47Pl2JjHDSvg/SgDx/Vi293c8sSxz7155qkhlnkc9zgV6V4ij2QSEdcV5zfxbVNAHI6vJtRq5UcnPrXR+IiUhYfhXOLQBItSimIKlAoAr3v3F+tU6uXv3V+tU6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACpYpmjUhQMZzzUVFAFj7U/ov5Ufan9FqvRQBObl/RaaZ2PZaiooAeZCfStTTtfu7BVEKQkDpuBP9ayKKAO2tfiRrNqQY4LE49Y2/+KrRj+MHiBHDC10zI9Yn/wDi684ooA9Si+N3iaKRHS10kMhBB8qTt/wOt8/tMeMzEqHT9Awoxn7PLn/0bXh1FAHtv/DSfjLJIsdCBPU/Z5f/AI5UkH7S/jOIEHT9AlH/AE0t5T/7Vrw6igD3eP8Aaf8AGkYO3S/Dgzx/x7zf/HaxtX+P3ivVHRriy0VdmcBIJAP1kryGigD0G/8Aivrt6hWW200A/wB2J/8A4usefxvqUwIaGzH0Rv8A4quWooA0L/VZ73/WrGP90H/GqYlYdhUdFAEwuHHZad9qf0Wq9FAEsszSgbgOPSoqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this radiograph, buckling of the bony cortex is evident on lateral view (white arrow). This patient had bony tenderness over the fracture site but a relatively intact range of motion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39744=[""].join("\n");
var outline_f38_52_39744=null;
var title_f38_52_39745="Classification tooth injury";
var content_f38_52_39745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classification of tooth injuries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tooth fractures may involve enamel, dentin, or pulp and may occur in the crown or the root.",
"    <div class=\"footnotes\">",
"     PDL: periodontal ligament.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 3rd ed, W.B. Saunders, Philadelphia 1999. Copyright &copy; 1999 W.B. Saunders Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39745=[""].join("\n");
var outline_f38_52_39745=null;
var title_f38_52_39746="Adrenal mass in primary aldo";
var content_f38_52_39746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aldosterone-producing adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal CT scan shows a hypodense 1.5-cm right adrenal mass in a patient with biochemically confirmed primary aldosteronism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William F Young, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39746=[""].join("\n");
var outline_f38_52_39746=null;
var title_f38_52_39747="Enuresis alarm";
var content_f38_52_39747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Enuresis alarm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 686px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enuresis alarms are activated when a sensor, placed in the undergarments or on a bed pad, detects moisture. The arousal device is usually an auditory alarm and/or a vibrating belt or pager.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39747=[""].join("\n");
var outline_f38_52_39747=null;
var title_f38_52_39748="U-S complete hydatid mole";
var content_f38_52_39748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound complete hydatid mole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 530px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complete hydatidiform mole: Ultrasound shows a 20 week size uterus. The endometrial cavity is filled with vesicular echogenic material. No fetus is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39748=[""].join("\n");
var outline_f38_52_39748=null;
var title_f38_52_39749="Lown Ganong Levine ECG";
var content_f38_52_39749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lown-Ganong-Levine syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG of a patient with the Lown-Ganong-Levine syndrome shows a short PR interval of 0.10 second and a normal QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39749=[""].join("\n");
var outline_f38_52_39749=null;
var title_f38_52_39750="Activated charcoal: Drug information";
var content_f38_52_39750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Activated charcoal: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/33/21012?source=see_link\">",
"    see \"Activated charcoal: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"    see \"Activated charcoal: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actidose&reg; with Sorbitol [OTC];",
"     </li>",
"     <li>",
"      Actidose&reg;-Aqua [OTC];",
"     </li>",
"     <li>",
"      Charcoal Plus&reg; DS [OTC];",
"     </li>",
"     <li>",
"      CharcoCaps&reg; [OTC];",
"     </li>",
"     <li>",
"      EZ-Char&reg; [OTC];",
"     </li>",
"     <li>",
"      Kerr Insta-Char&reg; in Aqueous Base [OTC];",
"     </li>",
"     <li>",
"      Kerr Insta-Char&reg; in Sorbitol Base [OTC];",
"     </li>",
"     <li>",
"      Requa&reg; Activated Charcoal [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Charac-25 [OTC];",
"     </li>",
"     <li>",
"      Charac-50 [OTC];",
"     </li>",
"     <li>",
"      Charactol-25 [OTC];",
"     </li>",
"     <li>",
"      Charactol-50 [OTC];",
"     </li>",
"     <li>",
"      Charcodote Susp [OTC];",
"     </li>",
"     <li>",
"      Charcodote TFS [OTC];",
"     </li>",
"     <li>",
"      Charcodote-Aqueous Sus;",
"     </li>",
"     <li>",
"      Premium Activated Charcoal [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acute poisoning:",
"     </b>",
"     Oral, NG:",
"     <b>",
"      Note:",
"     </b>",
"     Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is",
"     <b>",
"      not",
"     </b>",
"     recommended. Some clinicians still recommend dosing activated charcoal in a 10:1 (charcoal:poison) ratio for optimal efficacy (Gude, 2009); however, the amount of poison ingested is commonly unknown, which makes this approach challenging and often impractical (Chyka, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Single dose (Chyka, 2005): 25-100 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multidose: Initial dose: 50-100 g followed by 25-50 g every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"      see \"Activated charcoal: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acute poisoning:",
"     </b>",
"     Oral, NG:",
"     <b>",
"      Note:",
"     </b>",
"     Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is",
"     <b>",
"      not",
"     </b>",
"     recommended. Some clinicians still recommend dosing activated charcoal in a 10:1 (charcoal:poison) ratio for optimal efficacy (Gude, 2009); however, the amount of poison ingested is commonly unknown, which makes this approach challenging and often impractical (Chyka, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Single dose (Chyka, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &lt;1 year: 10-25 g;",
"     <b>",
"      Note:",
"     </b>",
"     Although dosing by body weight is reported in children (0.5-1 g/kg) and published in many resources, there are no data or scientific rationale to support this recommendation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-12 years: 25-50 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multidose: Initial dose: 25-50 g; followed by multiple doses of 10-25 g every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CharcoCaps&reg;: 260 mg [dietary supplement]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pellets for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EZ-Char&reg;: 25 g/bottle (1s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: USP: 100% (30 g, 240 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actidose&reg;-Aqua: 15 g (72 mL); 25 g (120 mL); 50 g (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerr Insta-Char&reg; in Aqueous Base: 25 g (120 mL); 50 g (240 mL) [contains propylene glycol (in flavoring packet), sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerr Insta-Char&reg; in Aqueous Base: 50 g (240 mL) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [with sorbitol]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actidose&reg; with Sorbitol: 25 g (120 mL); 50 g (240 mL) [contains sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerr Insta-Char&reg; in Sorbitol Base: 25 g (120 mL); 50 g (240 mL) [contains propylene glycol (in flavoring packet), sodium benzoate, sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Requa&reg; Activated Charcoal: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Charcoal Plus&reg; DS: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Powder",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flavoring agents (eg, chocolate, concentrated fruit juice) or thickening agents (eg, bentonite, carboxymethylcellulose) can enhance charcoal's palatability. Check for presence of bowel sounds before administration. I.V. antiemetics may be required to reduce the risk of vomiting. The activated charcoal container should be agitated thoroughly before administration. The container should be rinsed with a small quantity of water to insure that the patient has received all of the activated charcoal (Krenzelok, 1991).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Capsules and tablets should not be used for the treatment of poisoning.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Activated charcoal is a nonabsorbable adsorbent that may be considered in the management of poisonings when gastrointestinal decontamination of drugs or chemicals is indicated (eg, presentation to a treatment facility within 1 hour of ingestion). Activated charcoal is generally an effective adsorbent of drugs and chemicals with a molecular weight range of 100-1000 daltons. Multidose activated charcoal may be considered if a patient has ingested a life-threatening amount of carbamazepine, dapsone, phenobarbital, quinine, or theophylline (Vale, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules, tablets: Digestive aid",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Actidose&reg; may be confused with Actos&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appendicitis, bowel obstruction, constipation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Corneal abrasion (with direct contact)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Aspiration, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Fecal discoloration (black)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no absolute contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) consider the following to be contraindications to the use of charcoal  (Chyka, 2005; Vale, 1999): Presence of intestinal obstruction or GI tract not anatomically intact; patients at risk of GI hemorrhage or perforation; patients with an unprotected airway (eg, CNS depression without intubation); if use would increase the risk and severity of aspiration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vomiting: Charcoal may cause vomiting; the risk appears to be greater when charcoal is administered with sorbitol (Chyka, 2005). I.V. antiemetics may be required to reduce the risk of vomiting or to control vomiting to facilitate administration (Vale, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased peristalsis: Use with caution in patients with decreased peristalsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ipecac: Ipecac should not be administered routinely in the management of poisoned patients (AACT, 2004b). In addition, use may delay the administration of or decrease the effectiveness of activated charcoal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cathartics (eg, sorbitol, mannitol, magnesium sulfate): Coadministration of a cathartic is",
"     <b>",
"      not",
"     </b>",
"     recommended; cathartics have not been demonstrated to change patient outcome and have no role in the management of the poisoned patient. Cathartics subject the patient to the risk of developing significant fluid and electrolyte abnormalities (AACT, 2004a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Capsules: Not recommended for use in the treatment of poisoning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propylene glycol: Commercial charcoal products may contain propylene glycol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is",
"     <b>",
"      not",
"     </b>",
"     recommended. Do not use products containing sorbitol in patients with a genetic intolerance to fructose or in patients who are dehydrated; may cause excessive diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tablets: Not recommended for use in the treatment of poisoning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not effective in the treatment of poisonings due to the ingestion of low molecular weight compounds such as cyanide, iron, ethanol, methanol, or lithium. Avoid use in hydrocarbon and caustic ingestions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Efficacy: Most effective when administered within 30-60 minutes of ingestion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multidose administration: Based on experimental and clinical studies, multidose activated charcoal, in most acute poisonings, has not been shown to reduce morbidity or mortality (Vale, 1999). It may be considered if a patient has ingested a life-threatening amount of carbamazepine, dapsone, phenobarbital, quinine, or theophylline, although no controlled studies have demonstrated clinical benefit.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Charcoal, Activated may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to charcoal when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Charcoal, Activated may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to charcoal when possible. Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: The addition of some flavoring agents (eg, milk, ice cream, sherbet, marmalade) are known to reduce the adsorptive capacity, and therefore the efficacy, of activated charcoal and should be avoided in preference to activated charcoal-water slurries; nevertheless, these flavoring agents do not completely compromise the effectiveness of activated charcoal and may be necessary in some circumstances (eg, administration in pediatric patients) to enhance compliance (Cooney, 1995; Dagnone, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13657798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activated charcoal is not absorbed systemically following oral administration. Systemic absorption would be required in order for activated charcoal to cross the placenta and reach the fetus. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13658389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activated charcoal is not absorbed systemically following oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Charcoal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $4.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CharcoCaps Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     260 mg (36): $5.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Kerr Insta-Char in Sorbitol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 g/120 mL (120 mL): $10.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 g/240 ml (240 mL): $11.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Kerr Insta-Char Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 g/120 mL (120 mL): $10.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 g/240 ml (240 mL): $10.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Char-Flo with Sorbitol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-48 g/120 mL (120 mL): $6.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Charcoal Activated Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (125): $10.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Charcoal Plus DS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (36): $5.30",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bekarbon (ID);",
"     </li>",
"     <li>",
"      Ca-R-Bon (TH);",
"     </li>",
"     <li>",
"      Carbo Medicinalis (PL);",
"     </li>",
"     <li>",
"      Carbomix (FR, SE);",
"     </li>",
"     <li>",
"      Carbon Natural (UY);",
"     </li>",
"     <li>",
"      Carbosorb (NZ);",
"     </li>",
"     <li>",
"      Carbosorb S (NZ);",
"     </li>",
"     <li>",
"      Carbosorb X (AU);",
"     </li>",
"     <li>",
"      Carbosorb XS (AU);",
"     </li>",
"     <li>",
"      Carbotural (MX);",
"     </li>",
"     <li>",
"      Charcodote (GB, HK, KP);",
"     </li>",
"     <li>",
"      Charcotrace (AU);",
"     </li>",
"     <li>",
"      Deltacarbon (TH);",
"     </li>",
"     <li>",
"      Mamograf (AR);",
"     </li>",
"     <li>",
"      Norit (IL);",
"     </li>",
"     <li>",
"      RCOL (IN);",
"     </li>",
"     <li>",
"      Ultracarbon (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adsorbs toxic substances, thus inhibiting GI absorption",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Feces (as charcoal)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alasp&auml;&auml; AO, Kusima MJ, Hoppu K, et al, &ldquo;Feasibility Study on Activated Charcoal Given Prehospital by Emergency Medical System (EMS) in Acute Intoxications,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2002, 40(3):312-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), \"Position Paper: Cathartics,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004a, 42(3):243-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/15362590/pubmed\" id=\"15362590\" target=\"_blank\">",
"        15362590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), \"Position Paper: Ipecac Syrup,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004b, 42(2):133-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/15214617/pubmed\" id=\"15214617\" target=\"_blank\">",
"        15214617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bond GR, \"The Role of Activated Charcoal and Gastric Emptying in Gastrointestinal Decontamination: A State-of-the-Art Review,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2002, 39(3):273-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/11867980/pubmed\" id=\"11867980\" target=\"_blank\">",
"        11867980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Christophersen AB, Hoegberg LC, Angelo HR, et al, &ldquo;Activated Charcoal in a Simulated Paracetamol Overdose: Downscaling of Dose to 10 Grams - Preliminary Results,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2002, 40(5):696.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chyka PA, Seger D, Krenzelok EP, et al, American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists, &ldquo;Position Paper: Single-Dose Activated Charcoal,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2005, 43(2):61-87 (review).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooney DO, &ldquo;Development of Palatable Formulations,&rdquo;",
"      <i>",
"       Activated Charcoal in Medical Applications",
"      </i>",
"      , Cooney DO, ed, New York, NY: Marcel Dekker, Inc, 1995, 397-417.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper GM, Le Coteur DG, Richardson DB, et al, &ldquo;A Randomized Clinical Trial of Activated Charcoal for the Routine Management of Oral Drug Overdose,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 2002, 9(5):487.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dagnone D, Matsui D, and Reider MJ, &ldquo;Assessment of the Palatability of Vehicles for Activated Charcoal in Pediatric Volunteers,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2002, 18(1):19-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/11862132/pubmed\" id=\"11862132\" target=\"_blank\">",
"        11862132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorrington CL, Johnson DW, Brant R, &ldquo;The Frequency of Complications Associated With the Use of Multiple-Dose Activated Charcoal,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2003, 41(3):370-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/12605204/pubmed\" id=\"12605204\" target=\"_blank\">",
"        12605204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Francis RC, Schefold JC, Bercker S, et al, \"Acute Respiratory Failure After Aspiration of Activated Charcoal With Recurrent Deposition and Release From an Intrapulmonary Cavern,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2009, 35(2):360-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/18795259/pubmed\" id=\"18795259\" target=\"_blank\">",
"        18795259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gude AB, Hoegberg LC, Angelo HR, et al, \"Dose-Dependent Adsorptive Capacity of Activated Charcoal for Gastrointestinal Decontamination of a Simulated Paracetamol Overdose in Human Volunteers,\"",
"      <i>",
"       Basic Clin Pharmacol Toxicol",
"      </i>",
"      , 2010, 106(5):406-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/20002061/pubmed\" id=\"20002061\" target=\"_blank\">",
"        20002061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heard K, \"Gastrointestinal Decontamination,\"",
"      <i>",
"       Med Clin N Am",
"      </i>",
"      , 2005, 89(6):1067-78 (review).",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/16227054/pubmed\" id=\"16227054\" target=\"_blank\">",
"        16227054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higgins T, Curry S, Brooks D, et al, &ldquo;Iatrogenic Administration of Propylene Glycol With Activated Charcoal,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2000, 38(5):529.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes C, Schauben J, and Hasan MY, &ldquo;An Evaluation of the Incidence of Emesis Following Oral Bolus Dosing vs Gradual Administration Regimens of Activated Charcoal,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1998, 36(5):431-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK and Kumar VV, \"Indications for Single-Dose Activated Charcoal Administration in Acute Overdose,\"",
"      <i>",
"       Curr Opin Crit Care",
"      </i>",
"      , 2011, 17(4):351-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/21716104/pubmed\" id=\"21716104\" target=\"_blank\">",
"        21716104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      J&uuml;rgens G, Hoegberg LC, and Graudal NA, \"The Effect of Activated Charcoal on Drug Exposure in Healthy Volunteers: A Meta-analysis,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2009, 85(5):501-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/19194372/pubmed\" id=\"19194372\" target=\"_blank\">",
"        19194372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Justice HM, Knapp BJ, Pianalto DA, et al, \"Failure of Emergency Medical Services Providers to Administer Activated Charcoal Add to Emergency Delay,\"",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 2006, 13(5):S180.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keyes C and DeTamble L, &ldquo;Prehospital Activated Charcoal: A Prospective Randomized Trial,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1999, 37(5):610.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krenzelok EP and Lush RM, \"Container Residue After the Administration of Aqueous Activated Charcoal Products,\"",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1991, 9(2):144-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/1994942/pubmed\" id=\"1994942\" target=\"_blank\">",
"        1994942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merigian KS and Blaho KE, &ldquo;Single-Dose Oral Activated Charcoal in the Treatment of the Self-Poisoned Patient: A Prospective, Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2002, 9(4):301-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/12115019/pubmed\" id=\"12115019\" target=\"_blank\">",
"        12115019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seger D, &ldquo;Single-Dose Activated Charcoal-Backup and Reassess,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004, 42(1):101-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/52/39750/abstract-text/15083946/pubmed\" id=\"15083946\" target=\"_blank\">",
"        15083946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vale JA, Krenzelok EP and Barceloux GD et al, American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists, &ldquo;Position Statement and Practice Guidelines on the Use of Multiple-Dose Activated Charcoal in the Treatment of Acute Poisoning,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1999, 37(6):731-51.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9237 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39750=[""].join("\n");
var outline_f38_52_39750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149199\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149200\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149214\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149202\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149210\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149203\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149185\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149172\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149187\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149186\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149220\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149212\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149190\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149176\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299010\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149180\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149196\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657798\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149206\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13658389\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323056\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149192\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149175\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149189\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/33/21012?source=related_link\">",
"      Activated charcoal: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=related_link\">",
"      Activated charcoal: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_52_39751="Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder";
var content_f38_52_39751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Kimberly A Yonkers, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Robert F Casper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39751/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/52/39751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The premenstrual syndrome (PMS) is characterized by the presence of both physical and behavioral symptoms that occur repetitively in the second half of the menstrual cycle and interfere with some aspects of the woman's life. The American Psychiatric Association defines premenstrual dysphoric disorder (PMDD) as a severe form of PMS in which symptoms of anger, irritability, and internal tension are prominent (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Evaluation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and diagnosis of PMS and PMDD. The epidemiology, pathogenesis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28935?source=see_link\">",
"     \"Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84547200\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women of reproductive age experience one or more mild emotional or physical symptoms for one to two days before the onset of menses (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"mobipreview.htm?14/16/14601\">",
"     figure 1",
"    </a>",
"    ). These symptoms, such as breast soreness and bloating, are mild, do not cause distress or functional impairment, and are not considered to represent premenstrual syndrome (PMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, clinically significant premenstrual syndrome (PMS) is defined by the American College of Obstetricians and Gynecologists as at least one symptom associated with &ldquo;economic or social dysfunction&rdquo; that occurs during the five days before the onset of menses and is present in at least three consecutive menstrual cycles (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"mobipreview.htm?14/16/14601\">",
"     figure 1",
"    </a>",
"    ). Symptoms may be affective (eg, angry outbursts, depression) or physical (eg, breast pain and bloating) (",
"    <a class=\"graphic graphic_table graphicRef86227 \" href=\"mobipreview.htm?19/49/20240\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768183\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with premenstrual syndrome (PMS) experience a wide variety of cyclic and recurrent physical, emotional, behavioral, and cognitive symptoms that begin in the luteal phase (second half) of the menstrual cycle and resolve shortly after the onset of menses (the follicular phase) (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"mobipreview.htm?14/16/14601\">",
"     figure 1",
"    </a>",
"    ). However, the core symptoms include affective symptoms such as depression, angry outbursts, irritability, and anxiety, and somatic symptoms such as breast pain, bloating and swelling, and headache (",
"    <a class=\"graphic graphic_table graphicRef86227 \" href=\"mobipreview.htm?19/49/20240\">",
"     table 1",
"    </a>",
"    ). The core feature is the recurrent expression of symptoms during the end of the luteal phase of the menstrual cycle with a symptom-free period shortly after the onset of menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most women, the types of symptoms are fairly consistent across cycles and last for an average of six days per month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/1\">",
"     1",
"    </a>",
"    ]. Analysis of prospective symptom surveys in women with premenstrual dysphoric disorder (PMDD) suggest that mood and physical symptoms are typically most severe (and accompanied by functional impairment) in the four days before through the first two to three days of menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371524783\">",
"    <span class=\"h2\">",
"     Most common symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 150 physical, behavioral, emotional, and cognitive symptoms have been ascribed to PMS in the literature. However, the number of symptoms seen in the vast majority of patients is much more limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. By definition, affective symptoms predominate in women with PMDD, although most women with this condition also have physical symptoms (",
"    <a class=\"graphic graphic_table graphicRef86227 \" href=\"mobipreview.htm?19/49/20240\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14174872\">",
"     'DSM-IV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common affective or",
"      <strong>",
"       behavioral",
"      </strong>",
"      symptom of PMS is mood swings. Other frequent behavioral complaints include irritability,",
"      <span class=\"nowrap\">",
"       anxiety/tension,",
"      </span>",
"      sad or depressed mood, increased",
"      <span class=\"nowrap\">",
"       appetite/food",
"      </span>",
"      cravings, sensitivity to rejection, and diminished interest in activities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The most common",
"      <strong>",
"       physical",
"      </strong>",
"      manifestations of PMS are abdominal bloating and an extreme sense of fatigue. Other common symptoms include breast tenderness, headaches, hot flashes, and dizziness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371524819\">",
"    <span class=\"h2\">",
"     Impact on quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe PMS symptoms have been associated with reductions in health-related quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], as well as a decrease in work productivity, increase in work absenteeism, and an increase in visits to ambulatory healthcare providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174310171\">",
"    <span class=\"h2\">",
"     Suicide risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some work suggests that women with PMDD, especially those with more severe symptoms, have an elevated risk of suicidal ideation and attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/11\">",
"     11",
"    </a>",
"    ]. Clinicians may want to ask patients if depression or mood symptoms &ldquo;ever become so severe that she (the patient) thinks she would be better off if she were not around or not alive.&rdquo; Any positive response should trigger referral to a mental health professional.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371524835\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMS symptoms, which may begin any time after menarche, typically continue throughout reproductive life (if untreated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/12\">",
"     12",
"    </a>",
"    ]. Some women experience more severe symptoms in the late reproductive years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/13\">",
"     13",
"    </a>",
"    ], and women with premenstrual disorders appear to be at higher risk for developing mood disorders during the menopausal transition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/14\">",
"     14",
"    </a>",
"    ]. PMS resolves completely after menopause, and transiently during pregnancy or during any disruption of ovulatory cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28935?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link&amp;anchor=H952676297#H952676297\">",
"     \"Clinical manifestations and diagnosis of menopause\", section on 'Depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371524844\">",
"    <span class=\"h2\">",
"     Physical exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific abnormalities on physical exam in women with",
"    <span class=\"nowrap\">",
"     PMS/PMDD.",
"    </span>",
"    However, women who present with mood symptoms may have a disorder other than PMS (eg, thyroid disease). (See",
"    <a class=\"local\" href=\"#H774517316\">",
"     'Thyroid disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371524852\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific biochemical abnormalities associated with the disorder. Daily serum concentrations of gonadotropins and sex steroids are no different in women with PMS than women without PMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28935?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder\", section on 'Ovarian steroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371524913\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of patients with possible PMS or PMDD should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A detailed menstrual history, because the relationship between symptoms and cycle phase must be confirmed.",
"      <br/>",
"      <br/>",
"      If the patient&rsquo;s cycles are regular (25 to 35 day intermenstrual interval), detailed information about her symptoms should then be obtained (type, pattern of onset and offset, severity, presence of functional impairment, and confirmation that symptoms are recurrent).",
"      <br/>",
"      <br/>",
"      Women with",
"      <span class=\"nowrap\">",
"       PMS/PMDD",
"      </span>",
"      may also experience irregular menstrual cycles (&lt;25 or &gt;35 days) particularly during the menopausal transition. In this setting, symptoms may be more difficult to track because of cycle variability. Biochemical testing is not required in women with irregular cycles during the transition, but should be performed in younger women to determine the etiology of the irregular menstrual cycles. We suggest measuring serum hCG, TSH, prolactin, and FSH. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation of medications, including hormonal treatment &ndash; Women taking oral contraceptives should be asked if their premenstrual symptoms were present before the OC was started, or if the symptoms first began after initiation of the OC (eg, exogenous hormone-induced rather than true PMS or PMDD). Of note, OCs are sometimes used to treat premenstrual disorders, although they are not considered a first-line therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consideration of endocrine disorders that can cause similar symptoms, such as hyper- or hypothyroidism (see",
"      <a class=\"local\" href=\"#H774517316\">",
"       'Thyroid disorders'",
"      </a>",
"      below) and cortisol excess (eg, if symptoms are severe and refractory to standard treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      are present throughout the entire menstrual cycle).",
"     </li>",
"     <li>",
"      Laboratory testing should be limited. We suggest a serum TSH to rule out hyper- and hypothyroidism, both of which can cause mood symptoms (see",
"      <a class=\"local\" href=\"#H774517316\">",
"       'Thyroid disorders'",
"      </a>",
"      below). If the patient&rsquo;s symptom history is consistent with",
"      <span class=\"nowrap\">",
"       PMS/PMDD,",
"      </span>",
"      and there is no evidence of other medical disorders, the patient should be asked to record symptoms prospectively for two months to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H774517783\">",
"       'Prospective monitoring with self-rating scale'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774517783\">",
"    <span class=\"h2\">",
"     Prospective monitoring with self-rating scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the similarity of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) symptoms to those of other disorders, a valid and reliable prospective symptom inventory is required to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/18\">",
"     18",
"    </a>",
"    ]. Several tools are available, but the Daily Record of Severity of Problems (DRSP) form, which has been validated as a prospectively self-administered questionnaire, is the most commonly used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/19\">",
"     19",
"    </a>",
"    ]. The DRSP consists of 17 common PMS symptoms, including 11 symptoms from the DSM-IV PMDD diagnostic criteria. Patients rate each symptom on a five-point scale, from zero (none) to four (severe) (",
"    <a class=\"graphic graphic_table graphicRef86743 \" href=\"mobipreview.htm?31/14/31978\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287511\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the detailed menstrual and symptom history have been taken, the prospective monitoring is complete (",
"    <a class=\"graphic graphic_table graphicRef86743 \" href=\"mobipreview.htm?31/14/31978\">",
"     table 2",
"    </a>",
"    ), exam and laboratory data are completed (and normal), we make the diagnosis of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) using the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12403237\">",
"    <span class=\"h2\">",
"     PMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We make a diagnosis of PMS if a woman has one to four symptoms or has physical and behavioral symptoms but no affective symptoms. (See",
"    <a class=\"local\" href=\"#H84547200\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12403245\">",
"    <span class=\"h2\">",
"     PMDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PMDD is made using the DSM-IV criteria (",
"    <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694433866\">",
"    <span class=\"h3\">",
"     Available diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many groups have published diagnostic criteria for premenstrual disorders including the World Health Organization (WHO), the American College of Obstetrics and Gynecology (ACOG), Royal College of Obstetricians and Gynecologists (RCOG), the International Society for Premenstrual Disorders (ISPMD), and the American Psychiatric Association (Diagnostic and Statistical Manual of Mental Disorders, fourth edition [DSM-IV]), which has published criteria for the diagnosis of premenstrual dysphoric disorder (PMDD) (",
"    <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"     table 3",
"    </a>",
"    ), but not premenstrual syndrome (PMS). Although the criteria for diagnosis of premenstrual disorders are variable, there is general agreement that the ACOG and RCOG adequately describe PMS while the DSM criteria describe the more severe syndrome, PMDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists define PMS as the presence of at least one symptom occurring in the luteal phase of the cycle, which leads to impairment in functioning. The International Society for Premenstrual Disorders identified &ldquo;core&rdquo; criteria for clinically significant PMS to include at least one symptom that is either psychological or behavioral. The symptom(s) must impair functioning in some way and the symptom must remit at menses or shortly thereafter to constitute a symptom-free interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We currently use the American Psychiatric Association DSM-IV system, which provides PMDD (",
"    <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"     table 3",
"    </a>",
"    ) but not PMS diagnostic criteria. These criteria require prospective documentation of physical and behavioral symptoms (using diaries) being present for most of the preceding year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/21\">",
"     21",
"    </a>",
"    ]. Five or more symptoms must have been present during the week prior to menses, resolving within a few days after menses starts. These criteria also specify that PMDD may be superimposed on other psychiatric disorders, provided it is not merely an exacerbation of those disorders. New criteria for PMDD will be released in 2013 as part of DSM-5; preliminary review of the criteria does not show major differences from DSM-IV criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14174872\">",
"    <span class=\"h4\">",
"     DSM-IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most menstrual cycles during the past year, five (or more) of the symptoms in the table (",
"    <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"     table 3",
"    </a>",
"    ) were present for most of the time during the last week of the luteal phase, began to remit within a few days after the onset of the follicular phase, and were absent in the week postmenses. At least one of the five symptoms must be one of the first four on the list in the table (",
"    <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84546656\">",
"    <span class=\"h2\">",
"     Women without menstruation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of premenstrual disorders is more challenging, but still possible, in women with normal ovarian function and ovulation in the absence of menstruation. These women experience the typical cyclic symptoms of",
"    <span class=\"nowrap\">",
"     PMS/PMDD,",
"    </span>",
"    but cannot use menses as a reference point for their symptoms. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who have undergone hysterectomy (with ovarian conservation) or an endometrial ablation, which results in amenorrhea in approximately 35 to 40 percent.",
"     </li>",
"     <li>",
"      Women using a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      intrauterine device (for contraception or heavy menstrual bleeding). Amenorrhea typically develops after six months of use, but ovulation persists in approximately 75 percent of women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link&amp;anchor=H19#H19\">",
"       \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Levonorgestrel-IUD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=see_link&amp;anchor=H13#H13\">",
"       \"Hormonal contraception for suppression of menstruation\", section on 'Levonorgestrel intrauterine contraception'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this setting, prospective charting is essential to document a cyclic pattern of symptoms that recur approximately every 28 to 35 days, the normal range for intermenstrual intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenstrual disorders should always be differentiated from premenstrual exacerbation of an underlying major psychiatric disorder, the menopausal transition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/23\">",
"     23",
"    </a>",
"    ], and thyroid disorders (hyper- or hypothyroidism), mood disorders such as major depressive disorder, minor depressive disorder or dysthymic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774517239\">",
"    <span class=\"h2\">",
"     Mood and anxiety disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial overlap between PMDD and psychiatric disorders, particularly mood and anxiety disorders. In some instances women with premenstrual disorders may have had an episode of a mood or anxiety disorder in the past that has resolved. Assigning a diagnosis of",
"    <span class=\"nowrap\">",
"     PMS/PMDD",
"    </span>",
"    is not difficult in this group, particularly if the patient keeps a daily calendar that demonstrates luteal phase onset of symptoms with resolution of symptoms in the follicular phase of the cycle.",
"   </p>",
"   <p>",
"    However, women who present with the complaint of premenstrual syndrome and experience significant symptoms in both the follicular and luteal phase are likely to have a mood disorder such as major, minor or dysthymic disorder rather than PMDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/24\">",
"     24",
"    </a>",
"    ]. While symptoms may worsen during the luteal phase, treatment should be geared toward ameliorating symptoms of the ongoing mood or anxiety disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774517276\">",
"    <span class=\"h2\">",
"     Menopausal transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;New mood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety symptoms in a woman in her 40s or 50s are more likely to be due to the menopausal transition than to new-onset PMS. As noted above, PMS symptoms typically start at a younger age, most often by the early 20s. (See",
"    <a class=\"local\" href=\"#H371524835\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is estimated that up to 20 percent of women develop mood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety disorders during the menopausal transition. But unlike PMS symptoms, which occur during ovulatory cycles, menopausal mood symptoms typically begin when menstrual cycles become",
"    <span class=\"nowrap\">",
"     irregular/anovulatory.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link&amp;anchor=H952676297#H952676297\">",
"     \"Clinical manifestations and diagnosis of menopause\", section on 'Depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of the menopausal transition is a clinical diagnosis, based upon the menstrual history (onset of irregular cycles) with or without menopausal symptoms such as hot flashes, and mood symptoms. Documentation of an elevated serum FSH is not necessary to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link&amp;anchor=H93667232#H93667232\">",
"     \"Clinical manifestations and diagnosis of menopause\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774517316\">",
"    <span class=\"h2\">",
"     Thyroid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both hyper- and hypothyroidism are common in women. Hyperthyroidism, in particular, may present with mood symptoms. Both disorders can be distinguished from PMS based upon other typical features of thyroid disease on history, exam, and by an undetectably low serum TSH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H774517346\">",
"    <span class=\"h2\">",
"     Substance abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that women with PMS consume more alcohol than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/25\">",
"     25",
"    </a>",
"    ], independent of cycle phase, and that women with a family history of alcoholism experience more anxiety premenstrually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/26\">",
"     26",
"    </a>",
"    ]. However, a firm link between alcoholism and PMS has never been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174310160\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medical disorders (eg, migraine, chronic fatigue syndrome, irritable bowel syndrome) are exacerbated just prior to or during menses. However, the symptoms expressed are not those typical of PMS and the timing is not usually confined to the luteal phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39751/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations underscore the importance of using strict diagnostic criteria and prospective recording in assessing patients presenting with complaint of PMS or PMDD (see",
"    <a class=\"local\" href=\"#H774517783\">",
"     'Prospective monitoring with self-rating scale'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/10/42146?source=see_link\">",
"       \"Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13510?source=see_link\">",
"       \"Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The premenstrual syndrome (PMS) is characterized by the presence of both physical and behavioral symptoms that occur repetitively in the second half of the menstrual cycle and interfere with some aspects of the woman's life (",
"      <a class=\"graphic graphic_figure graphicRef62189 \" href=\"mobipreview.htm?14/16/14601\">",
"       figure 1",
"      </a>",
"      ). The American Psychiatric Association DSM-IV defines premenstrual dysphoric disorder (PMDD) as a severe form of PMS in which symptoms of anger, irritability, and internal tension are prominent (",
"      <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H84547200\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common",
"      <strong>",
"       behavioral",
"      </strong>",
"      symptom of PMS is labile mood. Other frequent behavioral complaints include irritability,",
"      <span class=\"nowrap\">",
"       anxiety/tension,",
"      </span>",
"      sad or depressed mood, increased",
"      <span class=\"nowrap\">",
"       appetite/food",
"      </span>",
"      cravings, sensitivity to rejection, and diminished interest in activities. (See",
"      <a class=\"local\" href=\"#H371524783\">",
"       'Most common symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common",
"      <strong>",
"       physical",
"      </strong>",
"      manifestations of PMS are abdominal bloating and an extreme sense of fatigue. Other common symptoms include breast tenderness, headaches, hot flashes, and dizziness. (See",
"      <a class=\"local\" href=\"#H371524783\">",
"       'Most common symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment of patients with possible PMS or PMDD should begin with the menstrual cycle history, and the relationship between symptom expression and menstrual cycle phase. The possibility that the symptoms are due to medications or hormone treatment rather than PMS or PMDD should be evaluated. (See",
"      <a class=\"local\" href=\"#H371524913\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient&rsquo;s symptom history is consistent with",
"      <span class=\"nowrap\">",
"       PMS/PMDD,",
"      </span>",
"      and there is no evidence for other medical disorders, the patient should then record her symptoms prospectively for two months. (See",
"      <a class=\"local\" href=\"#H371524913\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptom recording, we use the Daily Record of Severity of Problems (DRSP) form (",
"      <a class=\"graphic graphic_table graphicRef86743 \" href=\"mobipreview.htm?31/14/31978\">",
"       table 2",
"      </a>",
"      ). If the patient does not demonstrate a symptom-free interval in the follicular phase, she should be evaluated for a mood or anxiety disorder. (See",
"      <a class=\"local\" href=\"#H774517783\">",
"       'Prospective monitoring with self-rating scale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using the DSM-IV criteria for diagnosis of PMDD, which requires prospective documentation of multiple recurrent symptoms that cause functional impairment (",
"      <a class=\"graphic graphic_table graphicRef87069 \" href=\"mobipreview.htm?29/7/29820\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14174872\">",
"       'DSM-IV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who show a clear symptom-free interval in the follicular phase, those who meet either the DSM-IV criteria for PMDD for severe distress",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychosocial impairment are candidates for pharmacologic therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/1\">",
"      Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008; 371:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/2\">",
"      O'Brien PM, B&auml;ckstr&ouml;m T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 2011; 14:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/3\">",
"      Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/4\">",
"      Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/5\">",
"      Freeman EW, Halberstadt SM, Rickels K, et al. Core symptoms that discriminate premenstrual syndrome. J Womens Health (Larchmt) 2011; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/6\">",
"      Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord 2005; 85:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/7\">",
"      Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990; 76:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/8\">",
"      Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt) 2006; 15:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/9\">",
"      Borenstein JE, Dean BB, Leifke E, et al. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt) 2007; 16:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/10\">",
"      Heinemann LA, Minh TD, Filonenko A, Uhl-Hochgr&auml;ber K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. Womens Health Issues 2010; 20:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/11\">",
"      Pilver CE, Libby DJ, Hoff RA. Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample. Soc Psychiatry Psychiatr Epidemiol 2013; 48:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/12\">",
"      Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res 2009; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/13\">",
"      Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002; 70:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/14\">",
"      Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. Obstet Gynecol 2004; 103:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/15\">",
"      Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006; 27:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/16\">",
"      Andersch B, Abrahamsson L, Wendestam C, et al. Hormone profile in premenstrual tension: effects of bromocriptine and diuretics. Clin Endocrinol (Oxf) 1979; 11:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/17\">",
"      Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand 1979; 60:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/18\">",
"      Mortola JF. Issues in the diagnosis and research of premenstrual syndrome. Clin Obstet Gynecol 1992; 35:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/19\">",
"      Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/20\">",
"      Rapkin AJ, Chang LC, Reading AE. Comparison of retrospective and prospective assessment of premenstrual symptoms. Psychol Rep 1988; 62:55.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th, American Psychiatric Association, Washington, DC 1994. p.715.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/22\">",
"      Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 2012; 169:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/23\">",
"      Hay AG, Bancroft J, Johnstone EC. Affective symptoms in women attending a menopause clinic. Br J Psychiatry 1994; 164:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/24\">",
"      Gallant SJ, Popiel DA, Hoffman DM, et al. Using daily ratings to confirm premenstrual syndrome/late luteal phase dysphoric disorder. Part I. Effects of demand characteristics and expectations. Psychosom Med 1992; 54:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/25\">",
"      Tobin MB, Schmidt PJ, Rubinow DR. Reported alcohol use in women with premenstrual syndrome. Am J Psychiatry 1994; 151:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39751/abstract/26\">",
"      McLeod DR, Foster GV, Hoehn-Saric R, et al. Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety. Alcohol Clin Exp Res 1994; 18:664.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin 15. ACOG 2000; Washington, DC.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7381 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39751=[""].join("\n");
var outline_f38_52_39751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84547200\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H768183\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371524783\">",
"      Most common symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371524819\">",
"      Impact on quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174310171\">",
"      Suicide risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371524835\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371524844\">",
"      Physical exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371524852\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371524913\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H774517783\">",
"      Prospective monitoring with self-rating scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287511\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12403237\">",
"      PMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12403245\">",
"      PMDD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H694433866\">",
"      - Available diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14174872\">",
"      DSM-IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84546656\">",
"      Women without menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H774517239\">",
"      Mood and anxiety disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H774517276\">",
"      Menopausal transition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H774517316\">",
"      Thyroid disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H774517346\">",
"      Substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174310160\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7381|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/16/14601\" title=\"figure 1\">",
"      Menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/49/20240\" title=\"table 1\">",
"      Mean effect size symptom rating PMDD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/14/31978\" title=\"table 2\">",
"      DRSP form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/7/29820\" title=\"table 3\">",
"      DSM-IV criteria PMDD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/16/28935?source=related_link\">",
"      Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13510?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/10/42146?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3241?source=related_link\">",
"      Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_52_39752="Accessory AV pathways I";
var content_f38_52_39752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73740%7ECARD%2F53773%7ECARD%2F62454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73740%7ECARD%2F53773%7ECARD%2F62454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AV conduction with a concealed accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of atrioventricular conduction. The normal pacemaker is in the sinoatrial (SA) node at the junction of the superior vena cava and the right atrium. The SA node activates the right and left atria (shown in green). In the absence of an accessory pathway (AP) or, as in this case, if the AP is concealed, ventricular activation results from the impulse traversing the AV node, the specialized infranodal conducting system (His bundle and bundle and fascicular branches, shown in red), thereby activating the ventricular myocardium (shown in yellow). The ECG shows a normal PR interval and a narrow QRS complex. The inset on the right shows the timing of SA node (SAN), right (RA) and left atrial (LA), His bundle (H), and the beginning of normal ventricular activation (V",
"    <sub>",
"     N",
"    </sub>",
"    ). All of ventricular activation (shown in yellow) is due to normal AV nodal and infranodal conduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AV conduction through an open accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to normal conduction in the preceding diagram, the accessory pathway (AP) is now open. As a result, ventricular activation results from both early activation (preexcitation) of the free wall of the left ventricle (shown in blue) and from normal activation (shown in yellow). The degree of unopposed preexcitation depends upon the time required to conduct through the right and left atria, the AP, and the ventricular myocardium as compared to conduction through the normal pathways. The inset on the right shows the ECG timing of these events. The net effect is a QRS complex that is a fusion of ventricular preexcitation (blue) and normal excitation (yellow). Early activation throught the AP (V",
"    <sub>",
"     P",
"    </sub>",
"    ) occurs at about the same time as His bundle depolarization (H). This leads to a shorter PR interval, a small delta wave (arrow), and some prolongation of the QRS duration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conduction through an accessory pathway with AV nodal delay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to conduction through an AP with normal AV node conduction, delayed conduction through the AV node allows more of the ventricular myocardium to be activated by preexcitation (shown in blue). The inset on the right shows the ECG timing of these events. The atrial to His interval is increased due to the AV nodal delay (RA to H); His activation is so delayed that is follows activation caused by the AP (V",
"    <sub>",
"     P",
"    </sub>",
"    ). The PR interval is short due to the preexcitation, the delta wave (arrow) is more pronounced due to the greater and unopposed early forces (blue), and the QRS duration is prolonged due to the later than normal ventricular activation caused by the AV nodal delay (yellow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39752=[""].join("\n");
var outline_f38_52_39752=null;
var title_f38_52_39753="Subacute and chronic low back pain: Nonsurgical interventional treatment";
var content_f38_52_39753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subacute and chronic low back pain: Nonsurgical interventional treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39753/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39753/contributors\">",
"     Roger Chou, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39753/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39753/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/52/39753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 84 percent of adults have low back pain at some time in their lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The long-term outcome of low back pain is generally favorable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/3\">",
"     3",
"    </a>",
"    ], but given how common low back pain is, persistent symptoms affect millions of individuals. Subacute low back pain is commonly defined as back pain lasting between 4 and 12 weeks and chronic low back pain as pain that persists for 12 or more weeks.",
"   </p>",
"   <p>",
"    Most patients (&gt;85 percent) who are seen in primary care have \"nonspecific low back pain,\" which is low back pain that cannot reliably be attributed to a specific disease or spinal pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/4\">",
"     4",
"    </a>",
"    ]. Rapid improvement in pain and disability, and return to work, are the norm in the first month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/5\">",
"     5",
"    </a>",
"    ]. Further improvement generally occurs over three months, after which pain, level of disability, and rates of return to work remain relatively constant. Approximately 5 percent of people with back pain disability account for 75 percent of the costs associated with low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple treatment options for subacute and chronic low back pain are available. Broadly, these are divided into pharmacologic and noninterventional treatments, nonsurgical interventional treatments, and surgical treatments (",
"    <a class=\"graphic graphic_table graphicRef72902 \" href=\"mobipreview.htm?7/38/7789\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61982 \" href=\"mobipreview.htm?38/46/39661\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77165 \" href=\"mobipreview.htm?15/17/15646\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63348 \" href=\"mobipreview.htm?43/23/44412\">",
"     table 4",
"    </a>",
"    ). This topic will address non-surgical interventional options for patients with subacute and chronic low back pain who have failed conservative management. Several of these involve the injection of medications, commonly glucocorticoids, into the spinal structures. Others involve the destruction of tissues in the back presumed to be the source of pain through the application of various types of energy.",
"   </p>",
"   <p>",
"    In general, patients with subacute nonspecific low back pain would not be considered candidates for interventional therapies, as they could still improve with non-invasive therapies and there is little evidence on efficacy of invasive therapies in this circumstance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/7\">",
"     7",
"    </a>",
"    ]. For patients with subacute or chronic radiculopathy, or severe disabling chronic nonspecific low back pain, it is difficult to categorically advise when nonsurgical interventional therapies should be considered. It may be reasonable to consider some nonsurgical interventional therapies for patients who have not responded to noninvasive therapies and who are not interested in surgery or are not considered appropriate candidates for surgery. Relatively few randomized trials have evaluated patients specifically with spinal stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], although a number of trials have evaluated mixed populations.",
"   </p>",
"   <p>",
"    Treatment of acute low back pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    .) Conservative noninterventional treatment of subacute and chronic low back pain, and surgical options and outcomes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERVENTIONAL DIAGNOSTIC PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic procedures involving injections of contrast dye or anesthetic agents, to provoke or temporarily subdue pain, are widely used to guide patient selection for interventional treatments or surgery, despite little evidence to support such a management strategy.",
"   </p>",
"   <p>",
"    Discography is a diagnostic test in which contrast is injected under fluoroscopy into the nucleus of a disc thought to be the cause of a patient's low back pain, with a positive test based on the reproduction to the patient&rsquo;s pain. Its reliability is controversial because of the absence of a clearly defined gold-standard reference test and false positive results in patients without low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. This test is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12633?source=see_link\">",
"     \"Diagnostic testing for low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our opinion, provocative discography remains unproven as a diagnostic test. Nonetheless, trials of interventional procedures targeting degenerated intervertebral discs have typically selected patients for inclusion based on results of provocative discography. Elimination of pain following injection of a local anesthetic into a degenerated disc (discoblock) has been proposed as an alternative to provocative discography. One small, randomized trial (n=42) found that patients who underwent fusion surgery based on decreased pain with discoblock experienced superior outcomes compared to those who underwent surgery based on a positive response to discography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic nerve root blocks, facet joint blocks, and sacroiliac joint blocks also have been proposed as useful methods for determining the source of low back pain and guiding choice of interventional therapies. However, as with provocative discography, there are no reliable gold standards, and few studies have evaluated whether use of these tests to identify patients for specific procedures improves clinical outcomes compared to use of non-invasive diagnostic methods alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/15\">",
"     15",
"    </a>",
"    ]. Limited evidence from one randomized trial (n = 151) found a lower likelihood of successful lumbar facet joint radiofrequency ablation in patients selected based on facet joint blocks, compared to no facet joint block to select patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/16\">",
"     16",
"    </a>",
"    ]. This suggests that proceeding to radiofrequency denervation without a diagnostic block is the preferred treatment strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID AND OTHER INJECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidural injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural glucocorticoid injections (also referred to as \"corticosteroid injections\" or \"steroid injections\") involve the administration of steroids via a catheter inserted in the space between the dura and the spine. Epidural injections can be performed by the translaminar approach (via the interlaminar space in the spine), the transforaminal approach (through the neuroforamen ventral to the nerve root), or the caudal approach (through the sacral hiatus at the sacral canal) (",
"    <a class=\"graphic graphic_figure graphicRef64964 \" href=\"mobipreview.htm?35/38/36451\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Epidural injections have been used in patients with radiculopathy, spinal stenosis, and nonspecific low back pain. Injections are administered by a number of spine specialists, including anesthesiologists, physiatrists, and interventional radiologists. Treatment may be provided as one or a series of up to three injections, at intervals of no less than one month. Additional injections are not indicated, however, if the initial injection does not improve symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/17\">",
"     17",
"    </a>",
"    ]. More than three injections at the same site within 12 months are usually not recommended because of concerns about potential suppression of the hypothalamic-pituitary-adrenal axis, though there is little objective evidence to support these parameters. The optimal steroid dose, technique or site of injection, and whether local anesthetic should also be injected have also not been firmly established in randomized trials.",
"   </p>",
"   <p>",
"    The efficacy of epidural glucocorticoids remains unclear because of conflicting results from randomized controlled trials. Many trials are flawed by important methodological shortcomings and small sample sizes, and are difficult to compare due to diversity in patient selection, number of injections, outcomes assessed, and composition and dose of the injectate. The best evidence for benefit comes from trials for patients with radiculopathy due to a herniated disc and demonstrates short-term, but not long-term, benefit. Epidural injections for non-specific low back pain and spinal stenosis are of unproven benefit.",
"   </p>",
"   <p>",
"    A systematic review of 40 trials found inconsistent results regarding the short-term (&lt;three months) benefits of epidural glucocorticoid injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For low back pain with radiculopathy, 10 of 17 trials found no difference in pain or function between epidural glucocorticoid and placebo injection. Results were more consistent after trials were stratified according to whether the control intervention was an epidural or nonepidural (soft tissue) injection. Five of six trials found an epidural steroid injection associated with short-term benefits compared with a nonepidural (primarily interspinous ligament) placebo injection. Only two of 11 trials found an epidural steroid injection associated with short-term benefits compared with epidural placebo.",
"     </li>",
"     <li>",
"      There was no convincing evidence of long-term (&gt;3 months) benefit following epidural glucocorticoid injection for radiculopathy. Only four of 17 trials reported long-term benefits following epidural steroid injection, and three of those had important methodologic shortcomings. Only two of 7 trials found epidural steroid injection associated with lower rates of subsequent surgery compared with placebo injection.",
"     </li>",
"     <li>",
"      There was limited evidence showing minimal or no efficacy of epidural steroid injection for spinal stenosis or nonspecific low back pain (without sciatica). For patients with spinal stenosis, two small trials (n = 53 and n = 100) found no difference in pain or function between an epidural injection with glucocorticoid plus a local anesthetic versus a local anesthetic alone after three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/19\">",
"       19",
"      </a>",
"      ] or one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/20\">",
"       20",
"      </a>",
"      ]. A third trial (n = 29) found no differences between an epidural steroid injection and inpatient physical therapy in pain or function through six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/21\">",
"       21",
"      </a>",
"      ]. For patients with non-specific low back pain, one small trial (n = 28) found no difference between epidural steroid injection and intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was insufficient evidence to determine whether the transforaminal approach (using fluoroscopic guidance) is superior to the traditional translaminar or caudal approaches for administering epidural steroids. One trial included in the systematic review found a lower rate of surgery at two years for patients who underwent transforaminal epidural steroid injection compared to local anesthetic injection (71 versus 33 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. However, timing of follow-up varied between patients in this trial, and baseline characteristics were poorly reported. Five-year rates of surgery from this trial also favored transforaminal epidural steroids, but are difficult to interpret because of a high rate of loss to follow-up among nonsurgical patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/23\">",
"       23",
"      </a>",
"      ]. Two other placebo-controlled trials that evaluated other (nonsurgical) outcomes found no benefit associated with transforaminal epidural glucocorticoid injections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on four randomized trials that met review criteria, the American Academy of Neurology concluded that for radicular low back pain, epidural glucocorticoid injections are more effective than placebo for improvement in pain through 6 weeks after injection, but benefits were no longer present after 3, 6, or 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/27\">",
"     27",
"    </a>",
"    ]. Similarly, guidelines from the American Pain Society based on the systematic review discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/18\">",
"     18",
"    </a>",
"    ] make a weak recommendation for discussion of risks and benefits of epidural steroid injection for patients with persistent radiculopathy due to herniated lumbar disc, based on inconsistent evidence for short-term benefits and lack of long-term benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/15\">",
"     15",
"    </a>",
"    ]. A small randomized trial in patients with subacute (less than six months) lumbar radiculopathy that compared epidural injections of glucocorticoid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (a cytokine, tumor necrosis factor-alpha), or saline found only nonsignificant improvement in leg or back pain at one month comparing glucocorticoid and saline; functional outcomes were worse for patients treated with etanercept [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials published after these reviews reported somewhat conflicting results for caudal epidural glucocorticoid injection. One randomized trial (n = 132) of patients with chronic low back pain, with or without sciatica, found that caudal epidural glucocorticoid injection was more effective than an epidural water injection for improving back-specific function, though differences were larger at one month (about 15 points on the 0 to 100 Oswestry Disability Index) than at one year (about 8 points) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/29\">",
"     29",
"    </a>",
"    ]. The other trial (n = 116) of patients with chronic radiculopathy found no differences between caudal epidural glucocorticoid injection, caudal epidural saline injection, and subcutaneous saline injection in functional status or pain at 6 through 52 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural glucocorticoid injections are associated with risk for infrequent serious adverse events, including dural puncture, infection, and bleeding. A systematic review found that only 4 of 15 trials included in the review reported on the occurrence of adverse events at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/31\">",
"     31",
"    </a>",
"    ]. One trial of 120 patients receiving epidural glucocorticoids reported the following frequency of adverse events: post-injection headache, 3.3 percent; postdural puncture headache, 0.8 percent; nausea, 1.7 percent; and other events, 4.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/17\">",
"     17",
"    </a>",
"    ]. In 2012, an outbreak of fungal meningitis in the US by the",
"    <em>",
"     Exserohilum",
"    </em>",
"    species, including a number of fatal cases, were reported and traced to a single compounding pharmacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/32\">",
"     32",
"    </a>",
"    ]. Epidural glucocorticoid injections serve as a potential vector for transmission for fungal meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18746?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intradiscal injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no convincing evidence that intradiscal glucocorticoids are effective for low back pain. In patients with MRI evidence of degenerative disc disease and a positive response to discography, two trials found no difference between intradiscal steroid and control injection (saline or local anesthetic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A third trial found that in patients with degenerative disc disease who failed an epidural steroid injection, intradiscal steroid injection was superior to discography alone only in the subgroup of patients with inflammatory endplate changes on MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/35\">",
"     35",
"    </a>",
"    ]. However, outcomes were not well defined in this trial and levels of statistical significance were poorly reported. Based on these trials, the American Pain Society guideline recommends against intradiscal glucocorticoid injection for chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of radiculopathy and discogenic back pain. A small pilot study showed that intradiscal injections of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (interferes with TNF-alpha) did not improve pain or disability scores for patients with lumbosacral radiculopathy or chronic discogenic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    is a compound used as a dye or stain and has been studied for various therapeutic purposes. A randomized trial (n = 72) found intradiscal injection of methylene blue for patients with discography-positive, presumed discogenic back pain associated with large improvements in pain (about 40 points on a 100-point pain scale) and function (about 35 points on the 0 to 100 Oswestry Disability Index) compared with a placebo intradiscal injection, with no adverse events such as increased pain, radiculopathy, or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/37\">",
"     37",
"    </a>",
"    ]. However, a smaller (n = 24) randomized trial found no difference between intradiscal methylene blue versus a placebo intradiscal injection in pain or function after one month, and over half of the patients treated with methylene blue reported severe pain immediately after the injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/38\">",
"     38",
"    </a>",
"    ]. Longer-term results are not yet available, although the trial is designed to follow patients for one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Local or trigger point injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found no clear differences between local or trigger point injections with a local anesthetic, with or without a corticosteroid, and control interventions (saline or dry needle injections, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14370?source=see_link\">",
"     ethyl chloride",
"    </a>",
"    plus acupressure) for short-term (seven days to two months) pain relief in three trials of patients with subacute or chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/39\">",
"     39",
"    </a>",
"    ]. All trials had methodological shortcomings and evaluated heterogeneous injection methods. One trial evaluated an injection over the iliac crest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/40\">",
"     40",
"    </a>",
"    ], one evaluated injections over the iliolumbar ligament [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/41\">",
"     41",
"    </a>",
"    ], and one evaluated trigger point injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/42\">",
"     42",
"    </a>",
"    ]. The limited benefit observed in heterogeneous, low quality studies does not support their widespread use.",
"   </p>",
"   <p>",
"    Trigger point injections may be beneficial in patients with tender points (in the back or elsewhere) associated with the myofascial pain syndrome, a disorder that is thought to be related to fibromyalgia and outside the scope of this review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Facet joint injection and medial branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials included in a systematic review found no clear differences between facet joint glucocorticoid and placebo injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/18\">",
"     18",
"    </a>",
"    ]. A well-designed trial (n = 101) of patients who responded to a local anesthetic injection into the facet joint found no difference in the likelihood of pain relief following randomization to glucocorticoid or saline facet joint injection at either one or three months post injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/43\">",
"     43",
"    </a>",
"    ]. A higher proportion of patients in the steroid injection group reported marked improvement after six months (46 versus 15 percent), but the benefit was attenuated after controlling for cointerventions used in the steroid group, and there is no known biologic explanation for a delayed benefit from steroids. A second, smaller trial found no differences between steroid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    injection compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/44\">",
"     44",
"    </a>",
"    ]. Based on these two trials, a guideline from the American Pain Society recommends against facet joint glucocorticoid injection for chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blocks to the medial branch of the primary dorsal ramus, innervating the facet joints have been used both diagnostically and therapeutically for presumed facet joint pain. However, there are no trials comparing efficacy of medial branch blocks to placebo injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sacroiliac joint injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sacroiliac joints are thought to be the source of low back pain in some patients. Effective methods for diagnosing and treating sacroiliac joint pain in patients without spondyloarthropathy remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periarticular steroid injection does not require radiographic guidance. One small (n = 24), randomized trial found periarticular sacroiliac joint glucocorticoid injection more effective than local anesthetic injection for pain relief (change in pain of -40 versus -13 mm on a 100 mm visual analogue scale one month after injection) in patients with chronic pain in the sacroiliac joint area and at least one physical exam finding for sacroiliac pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/46\">",
"     46",
"    </a>",
"    ]. These results should be considered preliminary, due to the small sample size and relatively short-term follow-up. There are no randomized trials of intra-articular sacroiliac joint steroid injection in patients without spondyloarthropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Piriformis syndrome injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with sciatic symptoms may have pain related to impingement of the sciatic nerve as it passes through the piriformis muscle. However, the diagnosis of piriformis syndrome is not reliably reproducible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .) Although steroid injections deeply into the area of maximum tenderness in the buttock have been used, there are no randomized trials evaluating this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHEMONUCLEOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemonucleolysis refers to the treatment of herniated discs with intradiscal injections of an enzyme, usually chymopapain extracted from papaya. The enzyme acts by digesting the jelly-like inner portion of the disc (nucleus pulposus), while leaving the outer portion (annulus fibrosis) essentially intact. Collagenase has also been used, and is less likely to induce an allergic reaction, but may be less effective than chymopapain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/47\">",
"     47",
"    </a>",
"    ]. Chemonucleolysis is usually performed on an outpatient basis, and can be performed under general or local anesthesia. Due to concerns about potentially life-threatening allergic reactions, short-term increases in pain, and because many clinicians believe that surgery is a more effective treatment, use of chemonucleolysis has declined substantially in the US, though it remains used in Europe.",
"   </p>",
"   <p>",
"    Although chemonucleolysis appears to be less effective than primary surgery for symptomatic herniated disc, it may be a reasonable option, if available, for patients who do not wish to have surgery or who wish to delay surgery. Alternatively, as is current practice in the US, patients may receive an epidural glucocorticoid injection. A systematic review found fewer patients proceeded to open discectomy following chemonucleolysis with chymopapain compared to placebo (OR = 0.41, 95% CI 0.25-0.68), and patients experienced better symptom relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/48\">",
"     48",
"    </a>",
"    ]. About 30 percent of patients receiving chemonucleolysis subsequently undergo disc surgery within two years.",
"   </p>",
"   <p>",
"    Contraindications to chemonucleolysis include spinal stenosis, complete myelographic block, free disc fragments, and prior surgery of the disc. However, there are not studies evaluating whether routine myelography is indicated prior to chemonucleolysis. Allergic reactions following chemonucleolysis with chymopapain range from mild itching and flushing to severe anaphylaxis. Estimates of the frequency of allergic reactions vary, depending on how allergic reactions are defined. In one randomized trial (n = 100), 12 percent of patients who were randomly assigned to receive chymopapain experienced allergic reactions (flushing and itching), including one case of mild anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients at high risk of allergic reactions may be identified with use of a preliminary skin test dose of chymopapain. As the incidence of anaphylaxis is fairly high, at about one out of every 200 patients, routine use of test doses is probably indicated.",
"   </p>",
"   <p>",
"    Other potential, but rare, complications of chemonucleolysis include lumbar subarachnoid hemorrhage, infection, and paraplegia. Among 135,000 patients in the US reported to the FDA between 1982 and 1991, there were 32 cases of hemorrhage, 32 neurologic complications (including paraplegia paraparesis, hemiparesis, and foot drop), and 24 infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BOTULINUM TOXIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of paravertebral injection of botulinum toxin A was evaluated in a small (n = 31) randomized trial of patients with chronic low back pain who failed standard therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/50\">",
"     50",
"    </a>",
"    ]. Botulinum toxin A was superior to placebo injection for pain relief, and improved function at three and eight weeks (50 percent pain relief at 3 weeks 73.3 versus 25 percent; at 8 weeks 60 versus 16 percent, respectively). However, in most patients benefits were no longer present after three to four months. These results should be considered preliminary, and further data from randomized trials are needed to confirm findings in a larger number of patients over a longer duration and to evaluate benefits and harms of repeated injections before this treatment can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ELECTROTHERMAL AND RADIOFREQUENCY THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intradiscal therapy: IDET and PIRFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intradiscal electrothermal therapy (IDET - also known as intradiscal electrothermal annuloplasty) is a technique designed to thermocoagulate and destroy nerves in the intravertebral disc of patients presumed to have discogenic low back pain. A catheter or electrode, placed into the intervertebral disc, is slowly heated and kept at a predetermined temperature for a predetermined time to coagulate and shrink adjacent tissues. Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) is similar to IDET, but heat is generated in surrounding tissues by an alternating radiofrequency current.",
"   </p>",
"   <p>",
"    A systematic review found that current evidence does not support either IDET or PIRFT in the treatment of low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/51\">",
"     51",
"    </a>",
"    ]. Two randomized studies have been conducted on IDET. Both trials enrolled patients with chronic back pain and positive responses to provocative discography. In one trial, patients randomized to IDET experienced moderate improvements in pain scores compared to sham IDET, but experienced no improvements in functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/52\">",
"     52",
"    </a>",
"    ]. This trial appeared to evaluate a highly selected subset of patients (only 64 patients from a potential cohort of 4253 were enrolled); additionally, data analysis was not performed on an intent-to-treat basis and did not address baseline differences in control and intervention populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/51\">",
"     51",
"    </a>",
"    ]. Another trial found no differences between IDET and sham IDET on any outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two small (n = 20 and n = 28) randomized trials found no differences between PIRFT versus a sham procedure on any assessed outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. A second trial found no improvements compared to baseline for different durations of PIRFT, but did not include a sham therapy arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiofrequency denervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency denervation involves destruction of nerves using heat generated by a radiofrequency current. A catheter or electrode is placed near or in the target nerve with position confirmed by fluoroscopy; radiofrequency current is applied to heat and coagulate adjacent tissues, including the target nerve.",
"   </p>",
"   <p>",
"    Radiofrequency denervation has been used for treatment of presumed facet joint pain (target nerve = medial branch of the primary dorsal ramus), presumed discogenic back pain (ramus communicans), and radicular back pain (dorsal root ganglia). Evidence supporting the use of radiofrequency denervation for chronic low back pain is limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only trial that enrolled patients based on controlled facet joint blocks utilized a more extensive denervation technique and found that patients who underwent radiofrequency denervation experienced moderately greater reduction (-1. 4 to -1.9 points on a 10 point scale) in generalized, back and leg pain, and analgesic use after six months, compared to patients who underwent a sham procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/57\">",
"       57",
"      </a>",
"      ]. However, the sample size was small (n = 40), there were significant differences in baseline pain scores (about 1.6 points), final pain scores were similar in the two groups, and results did not reach statistical significance for back pain. It is also unclear why radiofrequency denervation of the facet joint should improve leg (but not back) pain.",
"     </li>",
"     <li>",
"      Two studies in patients with presumed facet joint pain, based on results of uncontrolled diagnostic blocks, reported conflicting results for radiofrequency denervation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. In one trial, patients who received radiofrequency denervation experienced moderately greater improvement than patients randomized to sham treatment on scores of mean pain (-2.4 versus -0.4 on a 0 to 10 scale) and function through two months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/59\">",
"       59",
"      </a>",
"      ]. In addition, radiofrequency denervation was associated with a higher likelihood of a 2 point or greater reduction in 10 point visual analogue pain scores (67 versus 37.5 percent). In the other trial, the radiofrequency denervation group, compared to sham treatment, experienced greater improvement in one measure of functional status scores at four weeks (8.4 versus 2.2 percent improvement), but not at 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/58\">",
"       58",
"      </a>",
"      ]. There were no significant differences in the Oswestry measure of functional status or in pain scores.",
"     </li>",
"     <li>",
"      An additional trial (n = 82) of radiofrequency denervation in patients with a positive uncontrolled facet joint block found no difference between radiofrequency denervation and sham treatment on any outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/60\">",
"       60",
"      </a>",
"      ]. However, the technique used for radiofrequency denervation in this trial probably resulted in inadequate coagulation of the target nerve due to suboptimal placement of electrodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review that included the above studies concluded that the evidence for radiofrequency denervation for presumed facet joint pain is inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For presumed discogenic low back pain, a small randomized trial of radiofrequency neurotomy of the ramus communicans nerves in patients with positive discography who had failed IDET found radiofrequency associated with better mean visual analogue scale pain scores (3.8 versus 6.3 on a 0 to 10 scale), and moderately better functional status scores compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    injection after four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/63\">",
"     63",
"    </a>",
"    ]. However, this trial had a small sample size (n = 49) and some methodological shortcomings.",
"   </p>",
"   <p>",
"    For patients with chronic (&gt;6 months) radicular pain and a positive selective nerve root block, one trial (n = 83) found no differences between radiofrequency denervation of the dorsal root ganglia and sham treatment on any outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiofrequency denervation appears relatively safe, though there is a trend toward increased pain immediately after radiofrequency denervation compared to sham denervation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/60,64\">",
"     60,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiofrequency denervation was studied in one small trial (n=20) of patients with a presumed diagnosis of chronic sacroiliac joint pain (&gt;6 months of lower back or buttock pain with tenderness over the sacroiliac joints and &gt;75 percent reduction in pain scores following sacroiliac joint blocks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/65\">",
"     65",
"    </a>",
"    ]. There was a higher likelihood of &ge;50 percent pain relief at one month for patients assigned to radiofrequency denervation of the L4 to L5 primary dorsal rami and S1 to S3 lateral branch compared to sham denervation (79 versus 14 percent), with benefits that persisted through six months. Because of the small sample size, more studies are needed to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prolotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolotherapy (also referred to as sclerotherapy) is a technique involving the repeated injection of irritants into ligaments and tendinous attachments, in order to trigger an inflammatory response that theoretically will lead to subsequent strengthening of ligaments and decrease in pain and disability. Prolotherapy injections are often supplemented by cointerventions, such as trigger point injections, manipulation, and exercises.",
"   </p>",
"   <p>",
"    One systematic review included five trials of prolotherapy, compared to local anesthetic or saline injections, for chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/66\">",
"     66",
"    </a>",
"    ]. There was no difference for short- or long-term pain or disability between prolotherapy and control intervention in three of the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Results from one trial that demonstrated short-term benefit for prolotherapy are difficult to interpret, because patients also received a number of co-interventions including forceful manipulation, injection of tender points, and exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/70\">",
"     70",
"    </a>",
"    ]. A fifth trial was confounded by differences in the type of manipulation given to patients in the prolotherapy and control groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/71\">",
"     71",
"    </a>",
"    ]. Based on these trial results, a guideline from the American Pain Society recommends against prolotherapy for chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the irritant nature of prolotherapy injections, most patients are expected to experience temporary increases in back pain and stiffness following treatment. Post-injection headaches suggestive of lumbar puncture occurred in two to four percent of patients in two trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39753/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=see_link\">",
"       \"Patient information: Low back pain in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=see_link\">",
"       \"Patient information: Low back pain in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidural glucocorticoid injections have been used in patients with radiculopathy, spinal stenosis, and nonspecific low back pain. Epidural glucocorticoids do not provide benefits beyond six weeks and have not consistently been shown to delay surgery in patients who are surgical candidates. We suggest a trial of epidural glucocorticoids for patients with radiculopathy due to a herniated disc (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest not giving epidural steroid injections for treatment of spinal stenosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest not treating with epidural steroid injections for nonspecific low back pain (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidural injection'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Evidence does not support use of facet joint and intradiscal glucocorticoid or anti-tumor necrosis factor injections. We suggest not performing these procedures for chronic low back pain (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Evidence is unavailable, unreliable, or contradictory regarding medial branch blocks, intradiscal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      injections, sacroiliac injections, or piriformis injections. We suggest not performing these procedures for chronic low back pain (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoid and other injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemonucleolysis, an enzymatic treatment for a herniated disc, can provide symptom relief resulting in delay or deferment of surgery for patients who do not wish to proceed to surgery. However, this procedure is less beneficial than discectomy surgery, can result in allergic reactions and increase short-term pain, and is not widely available in the US. We suggest chemonucleolysis, where available, for patients with symptomatic lumbar radiculopathy who wish to avoid surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chemonucleolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not treating patients with botulinum toxin for low back pain and not performing IDET, PIRFT, and radiofrequency denervation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest not performing prolotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Botulinum toxin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Electrothermal and radiofrequency therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Prolotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/1\">",
"      Deyo RA, Tsui-Wu YJ. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine (Phila Pa 1976) 1987; 12:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/2\">",
"      Cassidy JD, Carroll LJ, C&ocirc;t&eacute; P. The Saskatchewan health and back pain survey. The prevalence of low back pain and related disability in Saskatchewan adults. Spine (Phila Pa 1976) 1998; 23:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/3\">",
"      Croft PR, Macfarlane GJ, Papageorgiou AC, et al. Outcome of low back pain in general practice: a prospective study. BMJ 1998; 316:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/4\">",
"      van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Spinal radiographic findings and nonspecific low back pain. A systematic review of observational studies. Spine (Phila Pa 1976) 1997; 22:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/5\">",
"      Pengel LH, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ 2003; 327:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/6\">",
"      Frymoyer JW, Cats-Baril WL. An overview of the incidences and costs of low back pain. Orthop Clin North Am 1991; 22:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/7\">",
"      Pengel HM, Maher CG, Refshauge KM. Systematic review of conservative interventions for subacute low back pain. Clin Rehabil 2002; 16:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/8\">",
"      Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica: a systematic review. J Spinal Disord 2000; 13:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/9\">",
"      Luijsterburg PA, Verhagen AP, Ostelo RW, et al. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Eur Spine J 2007; 16:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/10\">",
"      Walsh TR, Weinstein JN, Spratt KF, et al. Lumbar discography in normal subjects. A controlled, prospective study. J Bone Joint Surg Am 1990; 72:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/11\">",
"      Carragee EJ, Tanner CM, Khurana S, et al. The rates of false-positive lumbar discography in select patients without low back symptoms. Spine (Phila Pa 1976) 2000; 25:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/12\">",
"      Carragee EJ, Tanner CM, Yang B, et al. False-positive findings on lumbar discography. Reliability of subjective concordance assessment during provocative disc injection. Spine (Phila Pa 1976) 1999; 24:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/13\">",
"      Carragee EJ, Alamin TF, Carragee JM. Low-pressure positive Discography in subjects asymptomatic of significant low back pain illness. Spine (Phila Pa 1976) 2006; 31:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/14\">",
"      Ohtori S, Kinoshita T, Yamashita M, et al. Results of surgery for discogenic low back pain: a randomized study using discography versus discoblock for diagnosis. Spine (Phila Pa 1976) 2009; 34:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/15\">",
"      Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) 2009; 34:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/16\">",
"      Cohen SP, Williams KA, Kurihara C, et al. Multicenter, randomized, comparative cost-effectiveness study comparing 0, 1, and 2 diagnostic medial branch (facet joint nerve) block treatment paradigms before lumbar facet radiofrequency denervation. Anesthesiology 2010; 113:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/17\">",
"      Arden NK, Price C, Reading I, et al. A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study. Rheumatology (Oxford) 2005; 44:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/18\">",
"      Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. Spine (Phila Pa 1976) 2009; 34:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/19\">",
"      Fukusaki M, Kobayashi I, Hara T, Sumikawa K. Symptoms of spinal stenosis do not improve after epidural steroid injection. Clin J Pain 1998; 14:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/20\">",
"      Manchikanti L, Cash KA, McManus CD, et al. Fluoroscopic caudal epidural injections with or without steroids in managing pain of lumbar spinal stenosis: one-year results of randomized, double-blind, active-controlled trial. J Spinal Disord Tech 2012; 25:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/21\">",
"      Koc Z, Ozcakir S, Sivrioglu K, et al. Effectiveness of physical therapy and epidural steroid injections in lumbar spinal stenosis. Spine (Phila Pa 1976) 2009; 34:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/22\">",
"      Serrao JM, Marks RL, Morley SJ, Goodchild CS. Intrathecal midazolam for the treatment of chronic mechanical low back pain: a controlled comparison with epidural steroid in a pilot study. Pain 1992; 48:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/23\">",
"      Riew KD, Park JB, Cho YS, et al. Nerve root blocks in the treatment of lumbar radicular pain. A minimum five-year follow-up. J Bone Joint Surg Am 2006; 88:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/24\">",
"      Riew KD, Yin Y, Gilula L, et al. The effect of nerve-root injections on the need for operative treatment of lumbar radicular pain. A prospective, randomized, controlled, double-blind study. J Bone Joint Surg Am 2000; 82-A:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/25\">",
"      Karppinen J, Malmivaara A, Kurunlahti M, et al. Periradicular infiltration for sciatica: a randomized controlled trial. Spine (Phila Pa 1976) 2001; 26:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/26\">",
"      Ng L, Chaudhary N, Sell P. The efficacy of corticosteroids in periradicular infiltration for chronic radicular pain: a randomized, double-blind, controlled trial. Spine (Phila Pa 1976) 2005; 30:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/27\">",
"      Armon C, Argoff CE, Samuels J, et al. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/28\">",
"      Cohen SP, White RL, Kurihara C, et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012; 156:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/29\">",
"      Sayegh FE, Kenanidis EI, Papavasiliou KA, et al. Efficacy of steroid and nonsteroid caudal epidural injections for low back pain and sciatica: a prospective, randomized, double-blind clinical trial. Spine (Phila Pa 1976) 2009; 34:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/30\">",
"      Iversen T, Solberg TK, Romner B, et al. Effect of caudal epidural steroid or saline injection in chronic lumbar radiculopathy: multicentre, blinded, randomised controlled trial. BMJ 2011; 343:d5278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/31\">",
"      Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of epidural steroid injections for low-back pain and sciatica: a systematic review of randomized clinical trials. Pain 1995; 63:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/33\">",
"      Khot A, Bowditch M, Powell J, Sharp D. The use of intradiscal steroid therapy for lumbar spinal discogenic pain: a randomized controlled trial. Spine (Phila Pa 1976) 2004; 29:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/34\">",
"      Simmons JW, McMillin JN, Emery SF, Kimmich SJ. Intradiscal steroids. A prospective double-blind clinical trial. Spine (Phila Pa 1976) 1992; 17:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/35\">",
"      Buttermann GR. The effect of spinal steroid injections for degenerative disc disease. Spine J 2004; 4:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/36\">",
"      Cohen SP, Wenzell D, Hurley RW, et al. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology 2007; 107:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/37\">",
"      Peng B, Pang X, Wu Y, et al. A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain. Pain 2010; 149:124.",
"     </a>",
"    </li>",
"    <li>",
"     Arain A. The effects of intradiscal methylene blue injection on discogenic low back pain. Thesis. Available at: file://doclib.uhasselt.be/dspace/bitstream/1942/12577/1/05232872009249.pdf (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/39\">",
"      Staal JB, de Bie R, de Vet HC, et al. Injection therapy for subacute and chronic low-back pain. Cochrane Database Syst Rev 2008; :CD001824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/40\">",
"      Coll&eacute;e G, Dijkmans BA, Vandenbroucke JP, Cats A. Iliac crest pain syndrome in low back pain. A double blind, randomized study of local injection therapy. J Rheumatol 1991; 18:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/41\">",
"      Sonne M, Christensen K, Hansen SE, Jensen EM. Injection of steroids and local anaesthetics as therapy for low-back pain. Scand J Rheumatol 1985; 14:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/42\">",
"      Hameroff SR, Crago BR, Blitt CD, et al. Comparison of bupivacaine, etidocaine, and saline for trigger-point therapy. Anesth Analg 1981; 60:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/43\">",
"      Carette S, Marcoux S, Truchon R, et al. A controlled trial of corticosteroid injections into facet joints for chronic low back pain. N Engl J Med 1991; 325:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/44\">",
"      Lilius G, Lassonen AM, Myllynen P, et al. The lumbar facet joint syndrome - Significance of inappropriate signs. A randomized, placebo-controlled trial. French J Orthop Surg 1989; 3:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/45\">",
"      van der Wurff P, Meyne W, Hagmeijer RH. Clinical tests of the sacroiliac joint. Man Ther 2000; 5:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/46\">",
"      Luukkainen RK, Wennerstrand PV, Kautiainen HH, et al. Efficacy of periarticular corticosteroid treatment of the sacroiliac joint in non-spondylarthropathic patients with chronic low back pain in the region of the sacroiliac joint. Clin Exp Rheumatol 2002; 20:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/47\">",
"      Wittenberg RH, Oppel S, Rubenthaler FA, Steffen R. Five-year results from chemonucleolysis with chymopapain or collagenase: a prospective randomized study. Spine (Phila Pa 1976) 2001; 26:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/48\">",
"      Gibson JN, Waddell G. Surgical interventions for lumbar disc prolapse. Cochrane Database Syst Rev 2007; :CD001350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/49\">",
"      Nordby EJ, Wright PH, Schofield SR. Safety of chemonucleolysis. Adverse effects reported in the United States, 1982-1991. Clin Orthop Relat Res 1993; :122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/50\">",
"      Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001; 56:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/51\">",
"      Urr&uacute;tia G, Kovacs F, Nishishinya MB, Olabe J. Percutaneous thermocoagulation intradiscal techniques for discogenic low back pain. Spine (Phila Pa 1976) 2007; 32:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/52\">",
"      Pauza KJ, Howell S, Dreyfuss P, et al. A randomized, placebo-controlled trial of intradiscal electrothermal therapy for the treatment of discogenic low back pain. Spine J 2004; 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/53\">",
"      Freeman BJ, Fraser RD, Cain CM, et al. A randomized, double-blind, controlled trial: intradiscal electrothermal therapy versus placebo for the treatment of chronic discogenic low back pain. Spine (Phila Pa 1976) 2005; 30:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/54\">",
"      Barendse GA, van Den Berg SG, Kessels AH, et al. Randomized controlled trial of percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic back pain: lack of effect from a 90-second 70 C lesion. Spine (Phila Pa 1976) 2001; 26:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/55\">",
"      Kvarstein G, M&aring;we L, Indahl A, et al. A randomized double-blind controlled trial of intra-annular radiofrequency thermal disc therapy--a 12-month follow-up. Pain 2009; 145:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/56\">",
"      Er&ccedil;elen O, Bulut&ccedil;u E, Oktenoglu T, et al. Radiofrequency lesioning using two different time modalities for the treatment of lumbar discogenic pain: a randomized trial. Spine (Phila Pa 1976) 2003; 28:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/57\">",
"      Nath S, Nath CA, Pettersson K. Percutaneous lumbar zygapophysial (Facet) joint neurotomy using radiofrequency current, in the management of chronic low back pain: a randomized double-blind trial. Spine (Phila Pa 1976) 2008; 33:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/58\">",
"      Leclaire R, Fortin L, Lambert R, et al. Radiofrequency facet joint denervation in the treatment of low back pain: a placebo-controlled clinical trial to assess efficacy. Spine (Phila Pa 1976) 2001; 26:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/59\">",
"      van Kleef M, Barendse GA, Kessels A, et al. Randomized trial of radiofrequency lumbar facet denervation for chronic low back pain. Spine (Phila Pa 1976) 1999; 24:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/60\">",
"      van Wijk RM, Geurts JW, Wynne HJ, et al. Radiofrequency denervation of lumbar facet joints in the treatment of chronic low back pain: a randomized, double-blind, sham lesion-controlled trial. Clin J Pain 2005; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/61\">",
"      Bogduk N. Lumbar radiofrequency neurotomy. Clin J Pain 2006; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/62\">",
"      Gofeld M. Radiofrequency facet denervation: a randomized control placebo versus sham procedure. Clin J Pain 2006; 22:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/63\">",
"      Oh WS, Shim JC. A randomized controlled trial of radiofrequency denervation of the ramus communicans nerve for chronic discogenic low back pain. Clin J Pain 2004; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/64\">",
"      Geurts JW, van Wijk RM, Wynne HJ, et al. Radiofrequency lesioning of dorsal root ganglia for chronic lumbosacral radicular pain: a randomised, double-blind, controlled trial. Lancet 2003; 361:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/65\">",
"      Cohen SP, Hurley RW, Buckenmaier CC 3rd, et al. Randomized placebo-controlled study evaluating lateral branch radiofrequency denervation for sacroiliac joint pain. Anesthesiology 2008; 109:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/66\">",
"      Dagenais S, Yelland MJ, Del Mar C, Schoene ML. Prolotherapy injections for chronic low-back pain. Cochrane Database Syst Rev 2007; :CD004059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/67\">",
"      Dechow E, Davies RK, Carr AJ, Thompson PW. A randomized, double-blind, placebo-controlled trial of sclerosing injections in patients with chronic low back pain. Rheumatology (Oxford) 1999; 38:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/68\">",
"      Mathews JA, Mills SB, Jenkins VM, et al. Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injections. Br J Rheumatol 1987; 26:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/69\">",
"      Yelland MJ, Glasziou PP, Bogduk N, et al. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized trial. Spine (Phila Pa 1976) 2004; 29:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/70\">",
"      Klein RG, Eek BC, DeLong WB, Mooney V. A randomized double-blind trial of dextrose-glycerine-phenol injections for chronic, low back pain. J Spinal Disord 1993; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39753/abstract/71\">",
"      Ongley MJ, Klein RG, Dorman TA, et al. A new approach to the treatment of chronic low back pain. Lancet 1987; 2:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7768 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39753=[""].join("\n");
var outline_f38_52_39753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERVENTIONAL DIAGNOSTIC PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUCOCORTICOID AND OTHER INJECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidural injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intradiscal injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Local or trigger point injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Facet joint injection and medial branch block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sacroiliac joint injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Piriformis syndrome injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHEMONUCLEOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BOTULINUM TOXIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ELECTROTHERMAL AND RADIOFREQUENCY THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intradiscal therapy: IDET and PIRFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiofrequency denervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prolotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7768|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/38/36451\" title=\"figure 1\">",
"      Lumbar epidural nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/38/7789\" title=\"table 1\">",
"      Meds for subacute LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/46/39661\" title=\"table 2\">",
"      Nonpharm Rx subacute LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/17/15646\" title=\"table 3\">",
"      Interventional Rx LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/23/44412\" title=\"table 4\">",
"      Surg vs nonsurg Rx LBP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12633?source=related_link\">",
"      Diagnostic testing for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18746?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_52_39754="Overview of the management of osteoporosis in postmenopausal women";
var content_f38_52_39754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of osteoporosis in postmenopausal women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/52/39754/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/52/39754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and treatment of osteoporosis consists of nondrug and drug or hormonal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An overview of the approach to therapy of osteoporosis in postmenopausal women will be presented here. The diagnosis and evaluation of osteoporosis in postmenopausal women, prevention of osteoporosis, and the management of osteoporosis in men and premenopausal women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three components to the nondrug therapy of osteoporosis: diet, exercise, and cessation of smoking. In addition, affected patients should avoid, if possible, drugs that increase bone loss, such as glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a growing interest in other nonpharmacologic therapies for osteoporosis. In animal models, mechanical stimulation from vibration produced anabolic effects on cancellous and cortical bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although whole body vibration platforms have been proposed as a nonpharmacologic therapy for postmenopausal osteoporosis, the available data from randomized trials show minimal to no improvement in bone mineral density with the use of whole body vibration platforms compared with sham vibration, walking, or no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In most trials, data were evaluated per-protocol, rather than intention-to-treat. None of the trials evaluated fracture outcomes. In addition, the safety of vibration therapy in elderly patients has not been carefully examined. Thus, there are insufficient data to recommend this therapy in postmenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Calcium/vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal diet for treatment (or prevention) of osteoporosis includes an adequate intake of calories (to avoid malnutrition), calcium, and vitamin D.",
"   </p>",
"   <p>",
"    Postmenopausal women (and older men) should take adequate supplemental elemental calcium (generally 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    in divided doses, at mealtime, such that their total calcium intake, including food calcium, approximates 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .) Calcium supplementation may also favorably affect serum lipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women should also ingest a total of 800 international units of vitamin D daily. Higher doses are required if they have malabsorption or rapid metabolism of vitamin D due to concomitant anticonvulsant drug therapy. Data on the efficacy of vitamin D replacement for osteoporosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H25#H25\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;When celiac disease is a major contributor to osteopenia, a gluten-free diet may result in improvement in bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the impact of protein intake on bone density are conflicting. While some studies suggest that higher protein intake may be associated with a lower risk of hip fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/10\">",
"     10",
"    </a>",
"    ] and bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], others suggest that high protein intake may increase bone resorption and calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, given the conflicting data, we do not recommend modifying protein intake as a strategy for preventing bone loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with osteoporosis (or seeking to prevent it) should exercise (prudently) for at least 30 minutes three times per week, as exercise has been associated with a reduced risk of hip fracture in older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. As an example, in a prospective cohort study of over 61,000 postmenopausal women, women who walked four hours or more per week had a 40 percent lower risk of hip fracture than those who walked &le; one hour per week (RR 0.6; 95% CI 0.4-0.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise also has beneficial effects on bone mineral density (BMD) in premenopausal and postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. A meta-analysis of 43 randomized trials (4320 participants) of exercise and bone mineral density in postmenopausal women showed a significant positive effect of exercise on BMD at the lumbar spine (mean difference 0.85, 95% CI 0.62-1.07) and trochanter (mean difference 1.03, 95% CI 0.56-1.49) compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/21\">",
"     21",
"    </a>",
"    ]. A variety of exercise types, including resistance training, jogging, jumping, and walking, was effective. The most effective type of exercise for BMD of the femoral neck was non-weight bearing high force exercise (eg, progressive resistance strength training), whereas a combined program (mixture of more than one exercise type) was most effective for lumbar spine BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/21\">",
"     21",
"    </a>",
"    ]. The meta-analysis was limited by loss to follow-up and the poor quality of allocation concealment and blinding.",
"   </p>",
"   <p>",
"    Overall, the beneficial effect of exercise on bone density is small. However, these changes reflect areal bone mineral density measurements. It is still uncertain how long-term exercise affects other measures of bone architecture. Therefore, if exercise does reduce the risk of fracture, it may relate to changes in parameters other than areal bone mass or to increased muscular strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/15,22\">",
"     15,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intensity of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no convincing evidence that high-intensity exercise, such as running, is of greater benefit than lower intensity exercise, such as walking. Because enjoyment of the regimen is important (the benefits of exercise are quickly lost after the woman stops exercising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/19\">",
"     19",
"    </a>",
"    ]), we recommend that women pick a regular weight-bearing exercise regimen that they enjoy to facilitate long-term compliance. Excessive exercise in premenopausal women may lead to weight loss and amenorrhea, thereby causing osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cessation of smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;We strongly recommend smoking cessation to all women concerned with their skeletal health because smoking cigarettes accelerates bone loss. One study, as an example, evaluated female twins who were discordant for smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/23\">",
"     23",
"    </a>",
"    ]. Smoking one pack per day throughout adult life was associated with a 5 to 10 percent reduction in bone density. Smoking may also negate the beneficial effect of estrogen therapy in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This may be mediated in part by acceleration of the metabolism of estrogen, thereby lowering serum estrogen concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above measures should be adopted universally to reduce bone loss in postmenopausal women. Postmenopausal women with osteoporosis or at high risk for the disease should be considered for drug therapy. Particular attention should be paid to treating women with a recent fracture, including hip fracture, because they are at high risk for a second fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/58/33706?source=see_link\">",
"     \"Medical consultation for patients with hip fracture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of 567 trials published between 2005 and 2011 confirmed the fracture prevention efficacy of multiple agents compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/27\">",
"     27",
"    </a>",
"    ]. Bisphosphonates (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , and teriparatide reduce the risk of vertebral fractures. Alendronate, risedronate, zoledronic acid, and denosumab reduce the risk of hip and other nonvertebral fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strontium ranelate (available outside of North America) has been shown to reduce vertebral fracture and, to a lesser extent, non-vertebral fracture. (See",
"    <a class=\"local\" href=\"#H14246434\">",
"     'Strontium ranelate'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Parathyroid hormone is an anabolic agent. In contrast to antiresorptive agents, PTH stimulates bone formation and activates bone remodeling. PTH 1-34 (teriparatide) reduces the risk of vertebral and non-vertebral fractures. It is typically used in postmenopausal women (or men) with severe osteoporosis and fracture or in patients for whom other osteoporosis therapies fail. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Choice of drug'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of high quality head-to-head drug comparison trials to determine the relative efficacy of the individual drugs, choice of therapy should be based upon efficacy, safety, cost, convenience, and other patient-related factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/28\">",
"     28",
"    </a>",
"    ]. For most postmenopausal women with osteoporosis, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    as first-line therapy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Choice of drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Candidates for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the highest risk of fracture are the ones most likely to benefit from drug therapy. Thus, selection of patients based upon fracture risk, as determined by a combination of BMD and clinical risk factors, is desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fracture risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, a WHO task force introduced a Fracture Risk Assessment Tool (FRAX), which estimates the 10-year probability of hip fracture or major osteoporotic fractures combined (hip, spine, shoulder, or wrist) for an untreated patient using femoral neck BMD and easily obtainable clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ). The technical aspects of FRAX are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H4#H4\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Fracture risk assessment tool'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The National Osteoporosis Foundation (NOF) released revised osteoporosis treatment and prevention guidelines based upon FRAX in conjunction with an updated US-specific economic analysis (",
"    <a class=\"graphic graphic_table graphicRef52512 \" href=\"mobipreview.htm?6/49/6939\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/29\">",
"     29",
"    </a>",
"    ]. The revised guidelines are similar to previous treatment recommendations.",
"   </p>",
"   <p>",
"    The NOF recommends treatment of postmenopausal women (and men &ge;50 years) with a history of hip or vertebral fracture or with osteoporosis based upon BMD measurement (T-score &le;-2.5). These recommendations are widely accepted, and clinical trial data support the use of bisphosphonates to prevent fracture in such individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of osteoporosis in men\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines also provide specific treatment recommendations for postmenopausal women with osteopenia on BMD (T-score between -1.0 and -2.5). In these individuals, the model suggests that treatment is cost-effective when the 10-year probability of hip fracture reaches 3 percent or the 10-year probability of major osteoporotic fractures combined is &ge;20 percent (",
"    <a class=\"graphic graphic_table graphicRef52512 \" href=\"mobipreview.htm?6/49/6939\">",
"     table 2",
"    </a>",
"    ). These criteria were chosen on the basis of a US-specific economic analysis, and they have not been assessed in clinical trials.",
"   </p>",
"   <p>",
"    The 10-year probability of hip and major osteoporotic fracture can be calculated for individual patients using the",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX algorithm",
"    </a>",
"    (click on Calculation Tool, and select country). The FRAX algorithm uses femoral neck BMD",
"    <span class=\"nowrap\">",
"     (g/cm2)",
"    </span>",
"    for calculation of fracture probability. BMD from non-hip sites has not been validated and is, therefore, not recommended for use.",
"   </p>",
"   <p>",
"    Intervention thresholds have been estimated for other countries based upon assessment of absolute fracture risk and country-specific analyses. The 2010 Osteoporosis Canada guidelines recommend pharmacologic therapy to patients at high absolute risk (&gt;20 percent probability for major osteoporotic fracture over 10 years) and to individuals over age 50 who have a fragility fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/30\">",
"     30",
"    </a>",
"    ]. For those at moderate risk (10 to 20 percent), the decision to treat should be based upon the presence of additional risk factors not considered in the risk assessment system and upon individual preference.",
"   </p>",
"   <p>",
"    In the UK, pharmacologic treatment was cost effective at all ages when the 10-year probability of major osteoporotic fracture exceeded 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/31\">",
"     31",
"    </a>",
"    ]. The UK National Osteoporosis Guideline Group recommends an age-dependent intervention threshold, which ranges from 7.5 to 30 percent for ages 50 to 80 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/32\">",
"     32",
"    </a>",
"    ]. For clinicians in the UK, intervention thresholds may be accessed directly from the",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX calculation tool website",
"    </a>",
"    (click on Calculation Tool, select UK, and then click on View NOGG Guidance after entering patient specific information).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We largely agree with the NOF recommendations. However, the benefit of treatment based upon absolute fracture risk, rather than BMD criteria alone, has not been assessed in clinical trials.",
"   </p>",
"   <p>",
"    The emphasis on absolute fracture risk will increase the proportion of elderly women who are candidates for therapy. As an example, in a study using data from the Study of Osteoporotic Fracture (SOF), a prospective cohort of community-dwelling Caucasian women &ge;65 years of age, application of the revised NOF treatment guidelines resulted in recommendations for pharmacologic therapy for 72 percent of women over 65 years of age and 93 percent of women over 75 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/33\">",
"     33",
"    </a>",
"    ]. Applying bone density criteria alone (BMD lower than -2.5 at lumbar spine or femoral neck) resulted in a treatment recommendation for 50 percent of women in both age groups.",
"   </p>",
"   <p>",
"    Thus, many more elderly women will be candidates for pharmacologic therapy using the new guidelines. Whether the selection of patients based upon clinical risk factors and BMD, rather than on BMD alone, improves benefit in elderly patients has not yet been established.",
"   </p>",
"   <p>",
"    In addition, the NOF economic analysis estimated drug costs based upon use of generic bisphosphonates. The use of more expensive drugs increases the 10-year fracture probability at which intervention is cost effective. NOF guidelines should not be applied to individuals living in different countries as the NOF guidelines are based upon a US-specific economic analysis. Intervention thresholds have been estimated for other countries, and country-specific guidelines are available or are in development. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fracture risk assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical application of fracture risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the US-adapted WHO fracture prediction algorithm and NOF recommendations provide general clinical guidance, osteoporosis treatment should remain individualized through shared decision-making between patient and clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 70 mg once weekly [orally]) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    35 mg once weekly, or 150 mg once monthly), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (150 mg once monthly [orally] or 3 mg intravenously every three months) are effective for both the prevention and treatment of osteoporosis (",
"    <a class=\"graphic graphic_figure graphicRef63767 \" href=\"mobipreview.htm?38/13/39134\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72430 \" href=\"mobipreview.htm?42/16/43277\">",
"     figure 2",
"    </a>",
"    ).&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    (ZA), 5 mg administered intravenously (IV) once yearly, is also effective for the treatment of osteoporosis. These drugs increase bone mass and reduce the incidence of fractures. When bisphosphonates are taken orally, precautions should be taken to avoid esophagitis. General principles of bisphosphonate administration, adverse effects, duration of use, and drug holidays are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Selective estrogen receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is a tissue selective estrogen receptor modulator (SERM) that is used for the prevention and treatment of osteoporosis. It increases bone mineral density and reduces the risk of vertebral fractures. Raloxifene also appears to lower the risk of breast cancer, does not stimulate endometrial hyperplasia or vaginal bleeding, and increases the risk of venous thromboembolism. Although it decreases serum total and low-density-lipoprotein (LDL) cholesterol concentrations, raloxifene does not appear to affect the risk of coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is another SERM used primarily for the prevention and management of breast cancer. It is not typically used for osteoporosis, but postmenopausal women who are receiving treatment with tamoxifen for breast cancer are probably receiving effective bone protection.",
"   </p>",
"   <p>",
"    We consider",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    one of the first-line drugs for prevention of osteoporosis. However, it is somewhat less effective than estrogen and bisphosphonates, although direct fracture prevention comparisons are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/35\">",
"     35",
"    </a>",
"    ]. There are nonskeletal considerations with raloxifene that may play an important role in the selection of patients for preventive therapy. Raloxifene reduces breast cancer risk but increases thromboembolic events and hot flashes.",
"   </p>",
"   <p>",
"    SERMs are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Estrogen/progestin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, estrogen-progestin therapy is no longer a first-line approach for the treatment of osteoporosis in postmenopausal women because of increased risk of breast cancer, stroke, venous thromboembolism, and perhaps coronary disease (although the risk-benefit profile in the unopposed estrogen trial was different) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible indications for estrogen-progestin in postmenopausal women include persistent menopausal symptoms and women with an indication for antiresorptive therapy who cannot tolerate the other drugs. In the Women's Health Initiative, both combined estrogen-progestin and unopposed estrogen treatment reduced hip and vertebral fracture risk (",
"    <a class=\"graphic graphic_figure graphicRef55425 \" href=\"mobipreview.htm?15/44/16077\">",
"     figure 3",
"    </a>",
"    ). The use of estrogen for osteoporosis is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone (PTH) seems an unlikely candidate for the treatment of osteoporosis because of its well-described deleterious effect on bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/37\">",
"     37",
"    </a>",
"    ]. However, intermittent administration of recombinant human PTH (both full-length 1-84 or fragment 1-34) stimulates bone formation more than resorption and is effective for fracture reduction in women with osteoporosis. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PTH is also effective in men with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;RANKL, a member of the TNF superfamily of ligands and receptors, is essential for the function of bone-resorbing osteoclasts; RANKL accelerates osteoclastogenesis when it binds to its receptor, RANK, but is blocked by osteoprotegerin, which is produced by osteoblasts.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a humanized monoclonal antibody against RANKL that reduces osteoclastogenesis. In several trials, it has been shown to improve bone mineral density (BMD) and reduce the incidence of new vertebral, hip, and non-vertebral fractures in postmenopausal women. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14246434\">",
"    <span class=\"h2\">",
"     Strontium ranelate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strontium ranelate is an orally active drug consisting of two atoms of stable strontium and an organic moiety (ranelic acid). In animal studies, strontium appears to inhibit bone resorption and increase or have a neutral effect on bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Its mechanism of action in humans is less certain. Based upon changes in markers of bone formation and resorption in postmenopausal women with osteoporosis, it appears to have a modest antiresorptive effect, with little effect on bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is available for use in Europe based upon the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a two-year clinical trial of 353 postmenopausal women with osteoporosis and at least one vertebral fracture who were randomly assigned to receive strontium ranelate or placebo, lumbar spine (LS) mineral density increased in a dose-dependent manner (maximum effect was with the highest dose used, 2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/43\">",
"       43",
"      </a>",
"      ]. In the second year of the study, the risk of new vertebral fractures decreased in the 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      group.",
"     </li>",
"     <li>",
"      In a second trial by the same investigators, 1649 postmenopausal women with osteoporosis and at least one vertebral fracture were randomly assigned to receive strontium ranelate (2",
"      <span class=\"nowrap\">",
"       gm/day)",
"      </span>",
"      or placebo for three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/44\">",
"       44",
"      </a>",
"      ]. The risk of new vertebral fractures was decreased significantly by 41 percent during the three-year study period (21 versus 33 percent; RR = 0.59, 95% CI 0.48-0.73; number needed to treat to prevent one fracture = nine).",
"      <br/>",
"      <br/>",
"      In addition, bone mineral density at the LS, adjusted for the strontium content, increased by 8 percent compared with the placebo group. It should be noted that a substantial proportion of the increase in BMD during strontium therapy is due to the physical effect of strontium accumulation in bone tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/45\">",
"       45",
"      </a>",
"      ]. The magnitude of change in BMD after strontium therapy, therefore, is not indicative of greater fracture risk reduction.",
"     </li>",
"     <li>",
"      In a larger trial of 5091 postmenopausal women with osteoporosis randomly assigned to receive strontium (2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or placebo for five years, the relative risk of non-vertebral fracture was decreased by 15 percent (incidence 19 versus 21 percent, RR 0.85, 95% CI 0.73-0.99) in the strontium group compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. In a post hoc analysis of a high risk group (age &ge;74 years and T-score &lt;-2.4 at baseline), the relative risk of hip fracture was decreased by 43 percent (incidence 7 versus 10 percent, RR 0.57, 96% CI 0.33-0.97). When the investigators pooled these results with their previously published trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/44\">",
"       44",
"      </a>",
"      ], they calculated that the effect of strontium was independent of baseline BMD, age, smoking, or number of vertebral fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of four trials (including those described above) concluded that there is reasonable evidence that strontium ranelate is effective for reducing the risk of vertebral fractures and, to a lesser extent, non-vertebral fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/49\">",
"     49",
"    </a>",
"    ]. Significantly more patients in the strontium than control group had diarrhea (6.5 versus 4.7 percent), venous thromboembolism (2.2 versus 1.5 percent), and pulmonary embolism (0.8 versus 0.4 percent).",
"   </p>",
"   <p>",
"    During post-marketing surveillance, severe skin reactions (DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens Johns, and toxic epidermal necrolysis) have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/50\">",
"     50",
"    </a>",
"    ]. In a study from France, 199 strontium-associated severe side effects were identified, of which approximately 25 percent severe skin reactions and 50 percent were venous thromboembolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/51\">",
"     51",
"    </a>",
"    ]. In an analysis of patients prescribed strontium by general practitioners in England, the crude incidence rate of venous thromboembolism within the first 12 months was 6.24 cases per 100 patient-years exposed, higher than the background incidence rate in the UK population but similar to the rate in elderly populations receiving treatment for postmenopausal osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/52\">",
"     52",
"    </a>",
"    ]. The risk of thromboembolic disease appears to be higher in patients with a history of venous thromboembolism or who are immobilized (temporarily or permanently). In a 2012 statement, the European Medicines Agency recommended that clinicians not prescribe strontium to patients with current venous thromboembolism (VTE), history of VTE, or to patients who are immobilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, it should be discontinued if a skin reaction develops, and treatment should not be restarted.",
"   </p>",
"   <p>",
"    There are few studies evaluating the long-term efficacy and safety of strontium. In an open-label extension study of two of the trials described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/44,46\">",
"     44,46",
"    </a>",
"    ], 237 postmenopausal women received strontium for an additional five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/54\">",
"     54",
"    </a>",
"    ]. The cumulative incidence of new fractures in years 6 to 10 was similar to that in years 0 to 5 (20.6 versus 18.5 percent, respectively). Over the 10-year period of continuous strontium treatment, lumbar spine BMD increased annually, whereas BMD of the femoral neck and total hip increased significantly until year 7 and then remained stable thereafter. In patients who had received strontium for 10 years, the annual incidence of venous thromboembolism was 0.4 percent. There were no cases of drug-related hypersensitivity skin reactions. Thus, for this small subset of patients, 10 years of strontium therapy was effective and safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calcitonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A less popular choice for treatment of osteoporosis is nasal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    , 200 international units daily. We prefer other drugs to calcitonin because of its relatively modest effect on BMD and weak antifracture efficacy compared with bisphosphonates and parathyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43173?source=see_link\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of clinical trials of calcitriol in postmenopausal osteoporosis have been mixed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, calcitriol has been reported to be effective in preventing glucocorticoid-induced and posttransplant-related bone loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Active vitamin D metabolites'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link&amp;anchor=H12#H12\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\", section on 'Calcitriol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link&amp;anchor=H11#H11\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated with calcitriol should be given a low-calcium diet and monitored for hypercalcemia, hypercalciuria, and renal insufficiency. These potential problems plus the lack of proven consistent benefit have appropriately limited the use of calcitriol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both bisphosphonates and estrogen inhibit bone resorption, they may act through different mechanisms. Several studies suggest that conjugated estrogens (0.625",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are equally effective in improving bone mineral density and that the combination is slightly more effective than either alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estrogen plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/56\">",
"     56",
"    </a>",
"    ], estrogen and androgen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/57\">",
"     57",
"    </a>",
"    ], estrogen plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/58\">",
"     58",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/59\">",
"     59",
"    </a>",
"    ] also appear to act synergistically on bone density. However, fracture data are unavailable for these combinations.",
"   </p>",
"   <p>",
"    We do not suggest combination bisphosphonate-estrogen therapy or bisphosphonate-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    therapy, as the additional BMD benefits are small and there is no proven additional fracture benefit. In addition, the indications for using estrogen have been limited since the results of the Women's Health Initiative were published. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H14#H14\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Combination therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several trials have reported that PTH plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (either started concurrently or prior to PTH) resulted in no additional benefit for spine or hip BMD compared with PTH alone, and the addition of alendronate may even attenuate the increase in BMD with PTH. Thus, we do not recommend concurrent PTH-bisphosphonate therapy. Combination therapy and bisphosphonate therapy after completing a course of PTH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H18#H18\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'PTH plus bisphosphonates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H22#H22\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'After PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some trials have reported that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    (either taken concurrently or prior to PTH) does not suppress the BMD response to PTH as much as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . Patients previously treated with raloxifene have a good BMD response to PTH, but the optimal management (continue versus discontinue raloxifene) is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H17#H17\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend bisphosphonates as first-line therapy for postmenopausal osteoporosis. We prefer oral bisphosphonates as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. In the absence of randomized trial data that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    reduces hip fracture risk, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    as our choice of bisphosphonate. Because oral alendronate is available as a generic and is very inexpensive, many insurers in the United States require prior approval for initial therapy with any bisphosphonate other than oral alendronate.",
"    <br/>",
"    <br/>",
"    IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , which has been demonstrated to reduce vertebral and hip fractures, is approved in many countries for the treatment of postmenopausal osteoporosis. It is available for individuals with gastrointestinal intolerance to oral bisphosphonates. IV ibandronate is also available; however, there is as yet no direct fracture prevention data for IV ibandronate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus on the optimal use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    . Although we prefer oral bisphosphonates as initial therapy, denosumab could be used as initial therapy in certain patients at high risk for fracture, such as older patients who have difficulty with the dosing requirements of oral bisphosphonates. In addition, denosumab may have a role in patients who are intolerant of or unresponsive to other therapies and in those with impaired renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strontium ranelate (available outside of North America) may be appropriate for some women who cannot tolerate or are unable to take oral or intravenous bisphosphonates. (See",
"    <a class=\"local\" href=\"#H14246434\">",
"     'Strontium ranelate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since the antiresorptive effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    are less than those of bisphosphonates, we reserve the use of this drug for patients who cannot tolerate any bisphosphonates or for women with osteoporosis and increased risk of invasive breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H31421397#H31421397\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given its cost, subcutaneous route of administration, long-term safety concerns, and availability of other agents, PTH is generally not used as a first-line drug for treatment or prevention of osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional therapies for postmenopausal osteoporosis are either under investigation or are approved and available in some, but not all, countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Vitamin K",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous vitamin K is required for the carboxylation of osteocalcin, which in turn allows osteocalcin to bind to hydroxyapatite mineral. A vitamin K2 preparation (menatetrenone) is widely used for the treatment of osteoporosis in Japan.",
"   </p>",
"   <p>",
"    Observational data suggest that low vitamin K consumption or impaired vitamin K status may be associated with an increased risk of fracture in older men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=see_link\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trial data suggest that vitamin K supplementation may reduce bone loss and fracture risk. This was best illustrated in a meta-analysis of 13 trials of oral vitamin K (phytonadione and menaquinone) supplementation for bone loss and fracture prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/62\">",
"     62",
"    </a>",
"    ]. Both supplements increased bone mineral density. Seven trials reported fracture data; all were in Japanese patients (primarily postmenopausal women with osteoporosis) and used menaquinone. Significant reductions were seen for vertebral, hip, and all non-vertebral fractures (odds ratio 0.40, 0.23, and 0.19, respectively with 95% CI of 0.25-0.65, 0.12-0.47, and 0.11-0.35, respectively).",
"   </p>",
"   <p>",
"    This report should be interpreted with some caution as fracture data are available only in Japanese women, who may have significant dietary differences from other populations. In addition, the magnitude of the fracture risk reductions seems unlikely, as it was far greater than what is seen for other proven therapies, such as bisphosphonates. Furthermore, in subsequent randomized trials in healthy, older, predominantly Caucasian men and women receiving calcium and vitamin D supplements, vitamin K (200, 500, or 1000 micrograms phylloquinone daily or 45 mg menatetrenone daily) did not have any effect on BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Based upon the available data, we, therefore, do not recommend routine vitamin K supplementation for the maintenance of skeletal health or the prevention of fractures in high-risk individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Tibolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibolone, a synthetic steroid whose metabolites have estrogenic, androgenic, and progestagenic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/66\">",
"     66",
"    </a>",
"    ], is used for osteoporosis management in some countries.",
"   </p>",
"   <p>",
"    Tibolone improves bone mineral density as demonstrated by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/35,67-69\">",
"     35,67-69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In early postmenopausal women without osteoporosis receiving tibolone (up to 2.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo for two years, a 3 percent increase in LS bone density was noted in the treatment group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In older postmenopausal women with established osteoporosis, tibolone increases LS bone mineral density by 5 to 12 percent over two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/68,69\">",
"       68,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tibolone also reduces vertebral fracture risk. The LIFT trial, a trial designed to examine the effect of tibolone on vertebral fracture in postmenopausal women, reported a reduction in the absolute risk of vertebral and non-vertebral fracture (8.6 and 6.9 per 1000 person-years, respectively, relative hazards of 0.55, 95% CI 0.41-0.74 and 0.74, 95% CI 0.58-0.93, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/70\">",
"       70",
"      </a>",
"      ]. However, this trial was discontinued early due to an excess risk of stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other effects of tibolone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H533432775#H533432775\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Tibolone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Folate/vitamin B12",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination folate and vitamin B12 therapy may lower fracture risk in elderly patients with residual hemiplegia after an ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/71\">",
"     71",
"    </a>",
"    ]. This approach has been studied in 625 elderly Japanese women and men randomly assigned to daily folate (5 mg) and vitamin B12 (1500 mcg orally) or placebo. Baseline levels of homocysteine were modestly elevated (approximately 2.7",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [20",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    in both groups (reference range 1.0 to 1.9",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [7.7 to 14.3",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    while B12 and folate levels were slightly low.",
"   </p>",
"   <p>",
"    Supplementation reduced the number of hip fractures compared with placebo (10 versus 43 per 1000 patient-years, respectively). The adjusted relative risk, absolute risk reduction, and number needed to treat for hip fractures for treatment versus placebo were 0.20 (95% CI 0.08-0.5), 7.1 percent (95% CI 3.6-10.8), and 14 (95% CI 9-28), respectively.",
"   </p>",
"   <p>",
"    Whether the risk reduction is due to the lowering of serum homocysteine or an increase in B12 is not known. In addition, it is not known whether this therapeutic approach will be effective in patients with normal baseline homocysteine, serum B12, and folate concentrations or in other populations.",
"   </p>",
"   <p>",
"    A predefined secondary analysis of the HOPE-2 trial suggests that this approach is not effective in individuals selected on the basis of cardiovascular disease (rather than fracture risk) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/72\">",
"     72",
"    </a>",
"    ]. In this trial, adults at high risk for cardiovascular disease were randomly assigned to treatment with daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (2.5 mg), vitamin B12 (1 mg), and vitamin B6 (50 mg) or placebo. Mean baseline homocysteine concentration was normal (1.55",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [11.5",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in both groups). Vitamin supplementation did not reduce the incidence of vertebral or non-vertebral fractures compared with placebo. The HOPE-2 trial is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of homocysteine\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the evidence is limited, we do not recommend supplemental",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    or vitamin B12 for the treatment of osteoporosis or primary prevention of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone (GH) and insulin-like growth factor-I (IGF-I) increase bone collagen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/73\">",
"     73",
"    </a>",
"    ] and DNA synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/74\">",
"     74",
"    </a>",
"    ] in vitro, and they stimulate bone growth and osteoblast activity in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Patients with growth hormone deficiency have low bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/78\">",
"     78",
"    </a>",
"    ]. Furthermore, in a study of 425 women above age 72 years, low serum IGF-I concentrations were associated with low BMD, although this was not true for men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/79\">",
"     79",
"    </a>",
"    ]. Administration of growth hormone to growth hormone deficient men and women has resulted in improvement in BMD in some, but not all, studies. In two randomized trials, GH treatment increased spine BMD in men but not in women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1833?source=see_link&amp;anchor=H7#H7\">",
"     \"Growth hormone deficiency in adults\", section on 'Bone mineral density'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of trials of growth hormone in women with osteoporosis who did not have growth hormone deficiency have been conflicting, and side effects were common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/80-85\">",
"     80-85",
"    </a>",
"    ]. These conflicting results plus the necessity for administration by injection make it unlikely that growth hormone will become a therapeutic option for patients with osteoporosis who are not growth hormone-deficient. IGF-1 therapy does not appear to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because men have higher bone density than women, it has been suggested that treatment with androgens might benefit women with osteoporosis. However, the effect of treatment with androgen plus estrogen on bone mineral density does not appear superior to the effect of estrogen alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/87\">",
"     87",
"    </a>",
"    ], and androgen has unwelcome virilizing effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, the presumed beneficial effects of testosterone on bone in men may be mediated by its conversion to estrogen, as evidenced by the marked improvement in low bone mass following estrogen therapy in men with aromatase deficiency, which impairs the conversion of androgen to estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend androgen therapy for osteoporosis management in women. Although testosterone replacement may improve bone density in women with hypopituitarism, data are limited, and there are no approved testosterone preparations available for use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and etiology of osteoporosis in men\", section on 'Estrogen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link&amp;anchor=H75832548#H75832548\">",
"     \"Androgen production and therapy in women\", section on 'Other possible benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Isoflavones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isoflavones (a type of phytoestrogen) are micronutrient substances that have properties similar to estrogen. Two types of isoflavones, genistein and daidzein, are found in soybeans, chickpeas, and lentils and are thought to be the most potent phytoestrogens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H8#H8\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Phytoestrogens'",
"    </a>",
"    .)&nbsp;Ipriflavone is a synthetic isoflavone derivative and is widely available as an over-the-counter product in many countries.",
"   </p>",
"   <p>",
"    Some studies have reported that phytoestrogens have a beneficial effect on markers of bone resorption, bone mineral density (BMD), and fracture risk in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/90\">",
"     90",
"    </a>",
"    ] and in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/91-95\">",
"     91-95",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/96-100\">",
"     96-100",
"    </a>",
"    ]. The differences may be due, in part, to the composition of the phytoestrogens studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a two year randomized trial of 389 postmenopausal women with T-scores of -1.0 or lower, genistein (54 mg daily) improved femoral neck and LS BMD compared with placebo (between group differences of 0.06 and 0.10",
"    <span class=\"nowrap\">",
"     g/cm2,",
"    </span>",
"    respectively, 95% CIs 0.05-0.07 and 0.08-0.12",
"    <span class=\"nowrap\">",
"     g/cm2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, clinical trial data on ipriflavone are more variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 198 women with low bone density, LS bone density did not decrease with oral ipriflavone (200 mg three times daily for two years) but did decrease with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/103\">",
"       103",
"      </a>",
"      ]. However, in the intention-to-treat analysis, there was no difference between the two groups.",
"     </li>",
"     <li>",
"      In a trial of 474 postmenopausal women with low bone density who were randomly assigned to receive ipriflavone (200 mg three times daily) or placebo (plus calcium 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in both groups) for three years, there were no differences in bone mineral density or vertebral fracture rates between the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/96\">",
"       96",
"      </a>",
"      ]. Lymphocytopenia occurred in 13 percent of the women taking ipriflavone, the clinical importance of which is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials that assess the effect of isoflavones on fracture as a primary outcome. Based upon available data, we do not recommend isoflavone supplements as a strategy to prevent or treat osteoporosis.",
"   </p>",
"   <p>",
"    Other effects of isoflavones are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H8#H8\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Phytoestrogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Fluoride",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is historical interest in fluoride as an anabolic agent for the treatment of postmenopausal osteoporosis. Although fluoride increases BMD substantially, clinical trials of fluoride have not consistently demonstrated fracture reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/104-108\">",
"     104-108",
"    </a>",
"    ]. While some studies demonstrated a decrease in the incidence of new vertebral fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/105,106,108\">",
"     105,106,108",
"    </a>",
"    ], others reported no change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/107\">",
"     107",
"    </a>",
"    ] or even an increase in non-vertebral fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/104,109\">",
"     104,109",
"    </a>",
"    ]. Fluoride impairs bone mineralization, even when the dose is as low as 20 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/109\">",
"     109",
"    </a>",
"    ]. Given the availability of other therapies, including parathyroid hormone (anabolic agent), we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend fluoride for the treatment of patients with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Emerging therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several novel therapies under investigation for the treatment of osteoporosis. They are in various stages of development. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sclerostin inhibitors &mdash; Sclerostin is produced by osteocytes and inhibits bone formation. Sclerostin knock-out mice have increased bone formation and high bone mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/110\">",
"       110",
"      </a>",
"      ]. In animal models and in a phase I trial in healthy adults, administration of a sclerostin monoclonal antibody increased bone mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/111-113\">",
"       111-113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Integrin antagonists &mdash; Integrins mediate the adhesion of osteoclasts to the bone surface, an important initial step for bone resorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cathepsin-K inhibitors &mdash; Cathepsin K is a protease expressed in osteoclasts that plays a role in osteoclast-mediated bone resorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/115,116\">",
"       115,116",
"      </a>",
"      ]. Cathepsin K degrades organic bone matrix, primarily type 1 collagen. Cathepsin-K inhibitors (eg, Odanacatib) inhibit matrix dissolution, decrease bone resorption, and improve bone mineral density in postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/117-121\">",
"       117-121",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MONITORING THE RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the response to therapy is important for identifying patients who may require a change in therapy (up to one-sixth of women taking estrogen or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    continue to lose bone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Changes in BMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/127-130\">",
"     127-130",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/131\">",
"     131",
"    </a>",
"    ], studies suggest that changes in bone mineral density during therapy correlate with reduction in fracture risk. In one study, the greatest fracture reduction occurred in those who gained BMD, although those with stable BMD still had fewer fractures than those who lost BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/127\">",
"     127",
"    </a>",
"    ]. A meta-analysis of 12 clinical trials concluded that improvement in spine bone mineral density accounts for a predictable but small part of the reduction in fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order for a change in bone mineral density to be considered significant, it should be greater than the \"least significant change\" (LSC) for the densitometer in question. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of dual-energy x-ray absorptiometry\", section on 'Precision assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BMD that is stable or improving is evidence for a treatment response. The finding of a BMD decrease greater than the LSC in a treated patient should trigger additional evaluation for contributing factors, which may include poor adherence to therapy, inadequate gastrointestinal absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. Calcium and vitamin D supplementation should be verified, and some evaluation for secondary causes of bone loss should be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of dual-energy x-ray absorptiometry\", section on 'Interpretation of BMD changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient is otherwise well and taking the drug and supplements correctly, the correct action is controversial. Some clinicians believe that the decrease in BMD truly reflects a treatment failure and would consider modification of the primary treatment for the osteoporosis. Others believe that the decline in BMD does not necessarily imply inadequate therapy, but could be ascribed to measurement error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/135\">",
"     135",
"    </a>",
"    ]. They would repeat BMD one year later, taking action only if the decline is reaffirmed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H36#H36\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Guidelines for monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several published guidelines for monitoring the response to osteoporosis therapy; all recommend follow-up BMD (DXA) testing. However, there is no consensus on the optimal frequency of monitoring and preferred site to monitor. The use of biochemical markers of bone turnover for monitoring response to therapy has not been addressed in current guidelines, and there are no prospective trials to define the most optimal approach for incorporating markers into monitoring strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach is similar to the ISCD guidelines (see",
"    <a class=\"local\" href=\"#H34\">",
"     'ISCD'",
"    </a>",
"    below). For patients starting on therapy, we suggest a follow-up DXA of hip and spine after two years, and if BMD is stable or improved, less frequent monitoring thereafter.",
"   </p>",
"   <p>",
"    Monitoring with markers of bone turnover is an additional option for patients who have conditions that might interfere with drug absorption or efficacy, such as small bowel resections or other types of malabsorption, or for patients who are reluctant to take anti-osteoporosis medications regularly. In such patients, we typically measure fasting urinary N-telopeptide (NTX) or serum carboxy-terminal collagen crosslinks (CTX) before and three to six months after starting bisphosphonate or other antiresorptive therapy. A decrease of greater than 50 or 30 percent in urinary NTX excretion or serum CTX, respectively, provides evidence of compliance and drug efficacy. The patient can be reassured that the next BMD measurement will likely be stable or improved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\", section on 'BTMs and osteoporosis therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, a decrease in markers of less than 30 percent may not necessarily indicate treatment failure. However, when this occurs, we question the patient about possible noncompliance or poor absorption (often related to an insufficient time interval between drug intake and food ingestion).",
"   </p>",
"   <p>",
"    This approach (with markers of bone resorption) is only useful with antiresorptive therapy, not with recombinant PTH (markers would increase). The approach to monitoring patients on recombinant PTH therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H43#H43\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     ISCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Society for Clinical Densitometry (ISCD) recommends follow-up BMD testing (DXA spine and hip) when the expected change in BMD equals or exceeds the least significant change (LSC), which is typically one to two years after initiation or change of therapy, with longer intervals once therapeutic effect is established. In conditions associated with rapid bone loss, such as glucocorticoid therapy, testing more frequently is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     AACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association of Clinical Endocrinologists (AACE) recommends repeat DXA of the LS and total hip every one to two years until stability is achieved, and every two years or at less frequent intervals thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     NAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The North American Menopause Society (NAMS) recommends DXA of the total hip every two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more conservative approach to monitoring takes the position that monitoring for efficacy of antiresorptive therapy is unnecessary, as only a minority of patients continue to lose bone on therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. This approach is used infrequently by clinicians but may be applicable to patients from remote areas without access to medical facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     MEDICAL INTERVENTION AFTER FRACTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and Europe, the majority of patients who have had fragility fractures (or are at risk for fracture) do not subsequently receive osteoporosis therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/140-142\">",
"     140-142",
"    </a>",
"    ], despite data demonstrating a beneficial effect in reducing the risk of a second fracture. As an example, in a retrospective review of 300 women over age 50 with a history of fracture, over 50 percent were not receiving any treatment for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/143\">",
"     143",
"    </a>",
"    ]. In a second community-based study of 60 women over age 65 with a recent hip fracture, only 13 percent were receiving adequate treatment for osteoporosis as defined by the National Osteoporosis Foundation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/144\">",
"     144",
"    </a>",
"    ]. Forty-seven percent of women were receiving partial, but inadequate treatment, while 40 percent were receiving no treatment at all.",
"   </p>",
"   <p>",
"    Similar observations have been reported for women with distal forearm fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/145\">",
"     145",
"    </a>",
"    ] and vertebral compression fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/146\">",
"     146",
"    </a>",
"    ]. In one retrospective study of 3492 postmenopausal women with a fracture of the hip, vertebra, or wrist, the older the patient was, the lower the likelihood of receiving drug therapy for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men are even less likely than women to be evaluated or treated for osteoporosis after a fracture. This was demonstrated in a retrospective analysis of 2264 women ages 50 to 89 and 540 men ages 65 to 89 who had sustained a fracture. After the fracture, 49 percent of women and only 4.5 percent of men were evaluated or treated for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/148\">",
"     148",
"    </a>",
"    ]. Thus, clinicians need to be educated regarding the importance of osteoporosis treatment after any osteoporotic fracture, particularly in the elderly and in men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rates of testing and treatment for osteoporosis in patients with fragility fractures may be improved by relatively simple interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/149-152\">",
"     149-152",
"    </a>",
"    ]. As an example, in a randomized, controlled trial of 272 patients over age 50 years with any distal forearm fracture, faxed reminders to clinicians (including treatment guidelines) and patient education resulted in a three-fold increase in the rate of osteoporosis testing and treatment when compared with a control group receiving standard care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/149\">",
"     149",
"    </a>",
"    ]. However, in another randomized trial, intervention to improve osteoporosis treatment after fracture was not successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/52/39754/abstract/153\">",
"     153",
"    </a>",
"    ]. In addition, even when the interventions are reported to be effective, overall long-term treatment rates for osteoporosis remain low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=see_link\">",
"       \"Patient information: Medicines for osteoporosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and treatment of osteoporosis consists of non-drug and drug or hormonal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest adequate calcium and vitamin D for all postmenopausal women with osteoporosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In general, we suggest 1200 mg of elemental calcium daily, total diet plus supplement, and 800 international units of vitamin D daily. Some patients require additional vitamin D supplementation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Important additional lifestyle measures include exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use for all postmenopausal women with osteoporosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for calcium and vitamin D supplementation as well as other lifestyle measures for postmenopausal women without osteoporosis are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link&amp;anchor=H28#H28\">",
"     \"Prevention of osteoporosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to nonpharmacologic therapy, we recommend that postmenopausal women with established osteoporosis (T-score &le;-2.5) or fragility fracture (hip or vertebral) be treated with a pharmacologic agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of high risk postmenopausal women with T-scores between -1.0 and -2.5, we also suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A reasonable cut point that may be cost-effective in some settings is a 10-year probability of hip fracture or combined major osteoporotic fracture of &ge;3.0 or &ge;20 percent, respectively. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Candidates for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of osteoporosis in postmenopausal women, we suggest bisphosphonates as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We prefer oral bisphosphonates as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most postmenopausal women with osteoporosis, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      over oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of drug'",
"      </a>",
"      above.) Oral ibandronate may be more convenient for patients, but a reduction in hip fracture risk has not been established in randomized trials.",
"     </li>",
"     <li>",
"      We suggest an intravenous bisphosphonate formulation for patients who cannot tolerate oral bisphosphonates or who have difficulty with dosing requirements, including an inability to sit upright for 30 to 60 minutes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      is the only intravenous bisphosphonate that has demonstrated efficacy for fracture prevention and is, therefore, our agent of choice. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      is an alternative option for patients who cannot tolerate oral bisphosphonates or who have difficulty with the dosing requirements and have impaired renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"       \"Denosumab for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      for postmenopausal women with osteoporosis (low bone mineral density [T score &lt;-2.5] and no fragility fractures) who cannot tolerate or are not candidates for any bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"       \"Selective estrogen receptor modulators for osteoporosis\"",
"      </a>",
"      .) Recommendations regarding raloxifene for the prevention of osteoporosis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link&amp;anchor=H25#H25\">",
"       \"Prevention of osteoporosis\", section on 'Selective estrogen receptor modulators'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      is also an option for such patients who are intolerant of or unresponsive to any bisphosphonates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"       \"Denosumab for osteoporosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Strontium ranelate is also an alternative (where available) for patients who cannot tolerate any bisphosphonates. (See",
"      <a class=\"local\" href=\"#H14246434\">",
"       'Strontium ranelate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest PTH therapy for postmenopausal women with",
"      <strong>",
"       severe",
"      </strong>",
"      osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture) who are unable to tolerate any of the available bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"       \"Parathyroid hormone therapy for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In postmenopausal women with",
"      <strong>",
"       severe",
"      </strong>",
"      osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture) who continue to fracture after one year of bisphosphonate therapy, we suggest discontinuing the bisphosphonate and switching to human recombinant PTH therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"       \"Parathyroid hormone therapy for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other candidates for parathyroid hormone are postmenopausal women with osteoporosis who are unable to tolerate bisphosphonates, or who have relative contraindications to bisphosphonates (achalasia, scleroderma esophagus, esophageal strictures), in addition to relative contraindications to SERMs (thrombosis, hot flashes), or for whom other osteoporosis therapies fail (fracture with loss of BMD in spite of compliance with therapy). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Parathyroid hormone'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348856\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the optimal strategy for monitoring patients on therapy. However, we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients starting on therapy, we suggest a follow-up DXA of the hip and spine after two years, and if BMD is stable or improved, less frequent monitoring thereafter.",
"     </li>",
"     <li>",
"      For patients with conditions that might interfere with drug absorption or efficacy or for patients who are reluctant to take anti-osteoporosis medications regularly, we typically measure fasting urinary NTX or serum CTX before and three to six months after starting bisphosphonates or other antiresorptive therapy. If the marker has not decreased by 50 (NTX) or 30 (CTX) percent, noncompliance or poor absorption, often related to an insufficient time interval between drug intake and food ingestion, should be considered.",
"      <br/>",
"      <br/>",
"      This approach (with markers of bone resorption) is only useful with antiresorptive therapy, not with recombinant PTH (markers would increase). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H43#H43\">",
"       \"Parathyroid hormone therapy for osteoporosis\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/1\">",
"      NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/2\">",
"      Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005; 353:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/3\">",
"      Rubin C, Turner AS, Bain S, et al. Anabolism. Low mechanical signals strengthen long bones. Nature 2001; 412:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/4\">",
"      Christiansen BA, Silva MJ. The effect of varying magnitudes of whole-body vibration on several skeletal sites in mice. Ann Biomed Eng 2006; 34:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/5\">",
"      Slatkovska L, Alibhai SM, Beyene J, Cheung AM. Effect of whole-body vibration on BMD: a systematic review and meta-analysis. Osteoporos Int 2010; 21:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/6\">",
"      Slatkovska L, Alibhai SM, Beyene J, et al. Effect of 12 months of whole-body vibration therapy on bone density and structure in postmenopausal women: a randomized trial. Ann Intern Med 2011; 155:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/7\">",
"      Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/8\">",
"      Reid IR, Mason B, Horne A, et al. Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med 2002; 112:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/9\">",
"      Bai JC, Gonzalez D, Mautalen C, et al. Long-term effect of gluten restriction on bone mineral density of patients with coeliac disease. Aliment Pharmacol Ther 1997; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/10\">",
"      Wengreen HJ, Munger RG, West NA, et al. Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah. J Bone Miner Res 2004; 19:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/11\">",
"      Sch&uuml;rch MA, Rizzoli R, Slosman D, et al. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/12\">",
"      Hannan MT, Tucker KL, Dawson-Hughes B, et al. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/13\">",
"      Rizzoli R, Bonjour JP. Dietary protein and bone health. J Bone Miner Res 2004; 19:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/14\">",
"      Kerstetter JE, Mitnick ME, Gundberg CM, et al. Changes in bone turnover in young women consuming different levels of dietary protein. J Clin Endocrinol Metab 1999; 84:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/15\">",
"      Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 129:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/16\">",
"      Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002; 288:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/17\">",
"      Kemmler W, von Stengel S, Engelke K, et al. Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: the randomized controlled senior fitness and prevention (SEFIP) study. Arch Intern Med 2010; 170:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/18\">",
"      Friedlander AL, Genant HK, Sadowsky S, et al. A two-year program of aerobics and weight training enhances bone mineral density of young women. J Bone Miner Res 1995; 10:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/19\">",
"      Dalsky GP, Stocke KS, Ehsani AA, et al. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 1988; 108:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/20\">",
"      Nelson ME, Fiatarone MA, Morganti CM, et al. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA 1994; 272:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/21\">",
"      Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; :CD000333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/22\">",
"      Turner CH. Exercise as a therapy for osteoporosis: the drunk and the street lamp, revisited. Bone 1998; 23:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/23\">",
"      Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994; 330:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/24\">",
"      Kiel DP, Baron JA, Anderson JJ, et al. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med 1992; 116:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/25\">",
"      Komulainen M, Kr&ouml;ger H, Tuppurainen MT, et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos Int 2000; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/26\">",
"      Byrjalsen I, Haarbo J, Christiansen C. Role of cigarette smoking on the postmenopausal endometrium during sequential estrogen and progestogen therapy. Obstet Gynecol 1993; 81:1016.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Healthcare Research and Quality. Treatment to prevent osteoporotic fractures: An update. file://effectivehealthcare.ahrq.gov/ehc/products/160/1048/lbd_clin_fin_to_post.pdf (Accessed on August 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/28\">",
"      Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int 2012; 23:797.",
"     </a>",
"    </li>",
"    <li>",
"     National Osteoporosis Foundation. Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis. file://www.nof.org/sites/default/files/pdfs/NOF_Clinicians_Guide2008.pdf (Accessed on April 18, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/30\">",
"      Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/31\">",
"      Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19:1395.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.shef.ac.uk/NOGG/index.html (Accessed on March 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/33\">",
"      Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 2009; 24:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/34\">",
"      Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/35\">",
"      Luckey M, Kagan R, Greenspan S, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004; 11:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/36\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/37\">",
"      Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990; 70:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/38\">",
"      Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008; 42:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/39\">",
"      Buehler J, Chappuis P, Saffar JL, et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001; 29:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/40\">",
"      Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993; 8:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/41\">",
"      Grynpas MD, Hamilton E, Cheung R, et al. Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone 1996; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/42\">",
"      Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009; 24:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/43\">",
"      Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/44\">",
"      Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/45\">",
"      Blake GM, Lewiecki EM, Kendler DL, Fogelman I. A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 2007; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/46\">",
"      Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/47\">",
"      Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/48\">",
"      Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/49\">",
"      O'Donnell S, Cranney A, Wells GA, et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006; :CD005326.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency. EMEA recommends changes in the product information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. Press Release (2007). file://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015592.pdf (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/51\">",
"      Jonville-Bera AP, Autret-Leca E. [Adverse drug reactions of strontium ranelate(Protelos(&reg;) in France]. Presse Med 2011; 40:e453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/52\">",
"      Osborne V, Layton D, Perrio M, et al. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 2010; 33:579.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/03/WC500124208.pdf (Accessed on March 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/54\">",
"      Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2012; 23:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/55\">",
"      Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/56\">",
"      Meschia M, Brincat M, Barbacini P, et al. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993; 53:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/57\">",
"      Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/58\">",
"      Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/59\">",
"      Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/60\">",
"      Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999; 69:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/61\">",
"      Booth SL, Broe KE, Peterson JW, et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab 2004; 89:4904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/62\">",
"      Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/63\">",
"      Booth SL, Dallal G, Shea MK, et al. Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 2008; 93:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/64\">",
"      Bolton-Smith C, McMurdo ME, Paterson CR, et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 2007; 22:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/65\">",
"      Binkley N, Harke J, Krueger D, et al. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res 2009; 24:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/66\">",
"      Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/67\">",
"      Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001; 86:4717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/68\">",
"      Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/69\">",
"      Geusens P, Dequeker J, Gielen J, Schot LP. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991; 13:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/70\">",
"      Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/71\">",
"      Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 293:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/72\">",
"      Sawka AM, Ray JG, Yi Q, et al. Randomized clinical trial of homocysteine level lowering therapy and fractures. Arch Intern Med 2007; 167:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/73\">",
"      Canalis EM, Hintz RL, Dietrich JW, et al. Effect of somatomedin and growth hormone on bone collagen synthesis in vitro. Metabolism 1977; 26:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/74\">",
"      Canalis E. Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 1980; 66:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/75\">",
"      Isgaard J, Nilsson A, Lindahl A, et al. Effects of local administration of GH and IGF-1 on longitudinal bone growth in rats. Am J Physiol 1986; 250:E367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/76\">",
"      Thorngren KG, Hansson LI. Stimulation of longitudinal bone growth by hypophyseal hormones in the hypophysectomized rat. Acta Endocrinol (Copenh) 1977; 84:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/77\">",
"      Spencer EM, Liu CC, Si EC, Howard GA. In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 1991; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/78\">",
"      Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/79\">",
"      Langlois JA, Rosen CJ, Visser M, et al. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 1998; 83:4257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/80\">",
"      Aloia JF, Zanzi I, Ellis K, et al. Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab 1976; 43:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/81\">",
"      Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975; 7:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/82\">",
"      Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/83\">",
"      Aloia JF, Vaswani A, Kapoor A, et al. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 1985; 34:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/84\">",
"      Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994; 79:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/85\">",
"      Holloway L, Kohlmeier L, Kent K, Marcus R. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997; 82:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/86\">",
"      Friedlander AL, Butterfield GE, Moynihan S, et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 2001; 86:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/87\">",
"      Erdtsieck RJ, Pols HA, van Kuijk C, et al. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res 1994; 9:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/88\">",
"      Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/89\">",
"      Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/90\">",
"      Yamazaki I, Shino A, Shimizu Y, et al. Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. Life Sci 1986; 38:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/91\">",
"      Nikander E, Mets&auml;-Heikkil&auml; M, Ylikorkala O, Tiitinen A. Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J Clin Endocrinol Metab 2004; 89:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/92\">",
"      Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001; 86:5217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/93\">",
"      Zhang X, Shu XO, Li H, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 2005; 165:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/94\">",
"      Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res 2007; 22:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/95\">",
"      Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 2007; 146:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/96\">",
"      Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001; 285:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/97\">",
"      Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004; 292:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/98\">",
"      Cheong JM, Martin BR, Jackson GS, et al. Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab 2007; 92:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/99\">",
"      Vupadhyayula PM, Gallagher JC, Templin T, et al. Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women--a 2-year randomized, double-blind, placebo-controlled trial. Menopause 2009; 16:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/100\">",
"      Levis S, Strickman-Stein N, Ganjei-Azar P, et al. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med 2011; 171:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/101\">",
"      Ricci E, Cipriani S, Chiaffarino F, et al. Soy isoflavones and bone mineral density in perimenopausal and postmenopausal Western women: a systematic review and meta-analysis of randomized controlled trials. J Womens Health (Larchmt) 2010; 19:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/102\">",
"      Liu J, Ho SC, Su YX, et al. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone 2009; 44:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/103\">",
"      Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997; 61:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/104\">",
"      Riggs, BL, Hodgson, SF, O'Fallon, WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/105\">",
"      Pak CY, Sakhaee K, Adams-Huet B, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/106\">",
"      Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998; 129:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/107\">",
"      Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998; 8:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/108\">",
"      Rubin CD, Pak CY, Adams-Huet B, et al. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001; 161:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/109\">",
"      Reid IR, Cundy T, Grey AB, et al. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/110\">",
"      Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/111\">",
"      Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/112\">",
"      Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/113\">",
"      Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/114\">",
"      Murphy MG, Cerchio K, Stoch SA, et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005; 90:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/115\">",
"      Tavares FX, Boncek V, Deaton DN, et al. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. J Med Chem 2004; 47:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/116\">",
"      Vasiljeva O, Reinheckel T, Peters C, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007; 13:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/117\">",
"      Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010; 25:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/118\">",
"      Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 2011; 26:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/119\">",
"      Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011; 26:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/120\">",
"      Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012; 27:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/121\">",
"      Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013; 98:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/122\">",
"      Greendale GA, Wells B, Marcus R, Barrett-Connor E. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 2000; 160:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/123\">",
"      Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/124\">",
"      Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999; 84:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/125\">",
"      Adler RA, Favus MJ. Following BMD in patients on bisphosphonates: another perspective. J Bone Miner Res 2009; 24:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/126\">",
"      Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 2009; 24:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/127\">",
"      Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999; 42:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/128\">",
"      Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/129\">",
"      Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/130\">",
"      Eastell R, Vrijens B, Cahall DL, et al. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 2011; 26:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/131\">",
"      Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/132\">",
"      Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/133\">",
"      Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom 2003; 6:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/134\">",
"      Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/135\">",
"      Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000; 283:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/136\">",
"      Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/137\">",
"      Binkley N, Bilezikian JP, Kendler DL, et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aace.com/pub/pdf/guidelines/OsteoGuidelines2010.pdf (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/139\">",
"      North American Menopause Society.. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/140\">",
"      Solomon DH, Finkelstein JS, Katz JN, et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003; 115:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/141\">",
"      Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003; 88:3482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/142\">",
"      Solomon DH, Brookhart MA, Gandhi TK, et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 2004; 117:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/143\">",
"      Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998; 57:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/144\">",
"      Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc 2001; 49:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/145\">",
"      Cuddihy MT, Gabriel SE, Crowson CS, et al. Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med 2002; 162:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/146\">",
"      Neuner JM, Zimmer JK, Hamel MB. Diagnosis and treatment of osteoporosis in patients with vertebral compression fractures. J Am Geriatr Soc 2003; 51:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/147\">",
"      Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003; 163:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/148\">",
"      Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/149\">",
"      Majumdar SR, Johnson JA, McAlister FA, et al. Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ 2008; 178:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/150\">",
"      Feldstein A, Elmer PJ, Smith DH, et al. Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 2006; 54:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/151\">",
"      Solomon DH, Polinski JM, Stedman M, et al. Improving care of patients at-risk for osteoporosis: a randomized controlled trial. J Gen Intern Med 2007; 22:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/152\">",
"      Majumdar SR, Beaupre LA, Harley CH, et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med 2007; 167:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/52/39754/abstract/153\">",
"      Bliuc D, Eisman JA, Center JR. A randomized study of two different information-based interventions on the management of osteoporosis in minimal and moderate trauma fractures. Osteoporos Int 2006; 17:1309.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2064 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-99E93ED354-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39754=[""].join("\n");
var outline_f38_52_39754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Calcium/vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intensity of exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cessation of smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Candidates for therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Estrogen/progestin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Denosumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14246434\">",
"      Strontium ranelate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calcitonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Calcitriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Vitamin K",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Tibolone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Folate/vitamin B12",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Growth factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Androgens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Isoflavones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Fluoride",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Emerging therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MONITORING THE RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Changes in BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Guidelines for monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - ISCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - AACE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - NAMS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      MEDICAL INTERVENTION AFTER FRACTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348856\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2064|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/13/39134\" title=\"figure 1\">",
"      Alendronate dose osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/16/43277\" title=\"figure 2\">",
"      Alendronate prevents bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/44/16077\" title=\"figure 3\">",
"      HRT and hip fracture WHI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2064|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/21/2395\" title=\"table 1\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/49/6939\" title=\"table 2\">",
"      Treatment guidelines osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/58/33706?source=related_link\">",
"      Medical consultation for patients with hip fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=related_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_52_39755="Classification dystonia";
var content_f38_52_39755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of dystonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Age of onset",
"       </td>",
"       <td>",
"        Early (young) onset: &lt;26 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late (adult) onset: &ge;26 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"5\">",
"        Body distribution",
"       </td>",
"       <td>",
"        Focal: single body region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental: contiguous body regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized: both legs and at least one other body region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multifocal: noncontiguous body regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemidystonia: one half of the body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"8\">",
"        Etiology",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Primary:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dystonia is the only sign; may be sporadic or inherited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Secondary:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dystonia associated with a defined etiology or associated with other neurological abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dystonia plus: dystonia is a prominent sign, but is associated with another movement disorder. There is no evidence of neurodegeneration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heredodegenerative: dystonia is a prominent sign, along with other neurological features, of a heredodegenerative disorder.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Genetic:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        May be primary or secondary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39755=[""].join("\n");
var outline_f38_52_39755=null;
var title_f38_52_39756="Drug regimens TB in HIV";
var content_f38_52_39756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug regimens for culture-positive pulmonary tuberculosis caused by drug-susceptible organisms (modified for use in HIV-infected patients)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"       Initial phase",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"       Continuation phase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle2\">",
"       Drugs",
"      </td>",
"      <td class=\"subtitle2\">",
"       Interval and doses*, minimal duration",
"      </td>",
"      <td class=\"subtitle2\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle2\">",
"       Drugs",
"      </td>",
"      <td class=\"subtitle2\">",
"       Interval and doses*&bull;, minimal duration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       1",
"      </td>",
"      <td>",
"       INH",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Seven days per week for 56 doses (8 wk) or 5 days/wk for 40 doses (8 wk)&Delta;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       INH/RIF",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Seven days per week for 126 doses (18 wk) or 5 days/w for 90 doses (18 wk)&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RIF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PZA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       EMB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       2",
"      </td>",
"      <td>",
"       INH",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Seven days per week for 14 doses (2 wk), then twice weekly for 12 doses (6 wk) or 5 days/wk for 10 doses (2 wk)&Delta;, then twice weekly for 12 doses (6 wk)",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       2",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       INH/RIF",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Twice weekly for 36 doses (18 wk)&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RIF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PZA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       EMB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       3&sect;",
"      </td>",
"      <td>",
"       INH",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Seven days per week for 56 doses (8 wk) or 5 days/wk for 40 doses (8 wk)&Delta;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       3",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       INH/RIF",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Seven days per week for 217 doses (31 wk) or 5 days/wk for 155 doses (31 wk)&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RIF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       EMB",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: If rifampin is being replaced with rifabutin, please see table \"Rifabutin and HAART\" for dosing recommendations.",
"    <div class=\"footnotes\">",
"     EMB: ethambutol; INH: isoniazid; PZA: pyrazinamide; RIF: rifampin; DOT: Directly observed therapy.",
"     <br>",
"      * When DOT is used, drugs may be given 5 days/week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicated this would be an effective practice.",
"      <br>",
"       &bull; Patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31-week; 217 doses [daily]) continuation phase.",
"       <br>",
"        &Delta; Five-day-a-week administration is always given by DOT.",
"        <br>",
"         &loz; Not recommended for HIV-infected patients with CD4+ cell counts &lt;100 cells/microL.",
"         <br>",
"          &sect; 3 = offer when 1 and 2 cannot be given.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from MMWR Morb Mortal Wkly Rep 2003; 52(RR-11):3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39756=[""].join("\n");
var outline_f38_52_39756=null;
var title_f38_52_39757="PHHI genetics and diazoxide responsiveness";
var content_f38_52_39757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Diazoxide responsiveness in different types of persistent hyperinsulinemic hypoglycemia of infancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 347px; background-image: url(data:image/gif;base64,R0lGODlhEQJbAcQAAP///wCZZv+ZMwAAAMzMzGZmZt3d3YiIiERERLu7u5mZmSIiIjMzMxEREVVVVXd3d+7u7qqqqkBAQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAARAlsBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKlzDAclBgsFIgYMAwOtqri5fAq1tyMMDbEADg4ABAMEusrLdQi+ww4Fwg0JIs7M2Nls1yIHDADSAAYDBiIFD9rp6mPcEQvl4ePl4Ogjtff4BPr7/P3+/wADChxIsKDBgwgTKlzIsKHDhxAjSpxIsaJFgDm4HcA3YAEAaiJYsRiwrqTJJtxI/4SDZgzZyJMwYwrhda/aiJWzerUgKbOnTyw8fwoFxLGo0aNG3QQdynTPgABQo0qdSrVq1KVqsDbdWuep1a9gryrlStaO17BoqWpFs7as2zVn08oN0NZM3bd4y8Sdi/YuGb95A3/ZyxcsYDGHBSvOQriw1cRgIC+ePKWxY7VjKWvuYvmyVMleQONCSrq06dOoU6tezbo1vkOdPUMVzYV2KtuocMuJLVs3UJm+SwV/w9vz8CrHRSUPtRyubMOZYTb/ND1N8cvVn2TntDT1bdjPv25vMl5T97TlDaUfc93x+iTvLZ3v+119+MfRT84P6xcBAh0JDGCTCAFe4R8Q8UV2X/9VCRrR4CT7QScCPg4kQ0SBeDzI2YKYtaFhJBGKZ081EDjQwDxCYHjHh1u0VxiLQcDoSIj4TThgOOFsVEssNO0IgI4LEPAKOgY0cIA8P9bSAE8P1MKAhSMsoIAD5CiwZAMKAGBlLVkugEAt/yXZUTJW0iKgMWbGIs04Fkaj5ZVZyiAjUBxONacPdy5CI4MjjqCARyvJ4pIIESATYDUPeHRMBAzEIs+hABT6Y5gPhBklAskk8E6kDUCApZboeCkOlpAm+maWBXzjJgHFhOMmBIZuGkGncoJXp1geAkfCdUGdKcKf4MSSwJe12LTopCLASuYA34hDzgFhFkhsLR6RIGX/NxwZgECjcV4bLLTJIgOslh4dEMwt4cwKgTdi3oPiC3kidyuubMSbyJ4dAuBrsPw2UIy+1RR5C7gAKBspsxA4awDB0tZzgrfslqBAqsV468ADBCs77rgEFIDAAhCsJOW1Eddgb2XzzpafSfja2WeJJwYLawRaCgjBAg5DWoCiAzBajDyzJlMASeaSKUyUcQaYJQEMzJIMuwu0QgA1Onu0sUcIZBlgyMKYS6vSaM5wshQu8jU2DmcX0vJn9tyDqTmx6PhlAj0O8B+QQuI86pHkgOMkT0MPYGQJ3v645AAFlEhtNQscPjC1ZFYLrI628Ousw+b6WKt9Kadtg+eDrE2v/xqFXwE6eSnTtXJJoqvMRulWnM5E2XPJvrl0u6JWn9qp2x6D734A34fwR9Au15wiYVtLPTlV/lJMxDtl67ww0uRL1gdXQ0xLUKYQvR7f5xH+EMajB0VKu5YDEgDoozD+irpyTv35z3QTcN/0PI879NPfOmf7EYgTkvLXNqNc5IAITKBE3mcWBTrwgOXry0My8owDOOwjNkmeChjYlfjxrnP0GwEC/jWC7R2je+7zoH76V6fq4aMaHHGUmeqXQv7Z8IPzy9UN9aW73LCQQxw0QRDn0B0BGPGISDziEAfzwwUt0R4qHEASp2jEJ3Kmifexor6iSMUp9sdSN4DUCFQkhv8D/Q6L4dGiblxzGrXtqotJ7NU9KlQEMnZQfv5bHQwiyB832gOOSOwViUz0LiDYkQ5azAEfJVSvz/XOjxMCpBL7BDd+UY5H+Igb5Ia0NyTpaEkiaBKzUOita3kJTCKQEpUMsKVPbWkAXSJWmPD2JjNVg2k+WtOg3CTKJ5UgkWh7pA5psEgREaKIkhSAIP0EqKM5C0qFIkCpeMYoR5EDUpIiWKUI161YQmAcNPNSpmTVKVeG6j9FUsA0TwUOVcWCVfx6FTK0CcYt4rGFeoSXMEP3xmQu81fNBMCwaiKCY2XMJbxoljwYRpJpdYSbqexSNwEAsWxtqwAT/VaYNCa5cp3/q5LqYpdDqwXFewIxny4oZo34+Ud/UpJf4fCXjfbWjY26pFAMSNhCo9XQC0KUohKNKFC70SwSTIwBFYvTxQ5KgKsV1GMgE9mfsoQAn+4Kjc9RoyNBeMx+SnKZMINH4npWswTcLGdn2llLfKawoPnNcEYrAQPQYaWgDtVbYGOa0370jagZg2pptVpH2ae1AXCtGw2gVdG05Ex74jCPwxTbPgWBzK8W0G4WyhGYBFS3u21SbwJDUuBoYQ4l1S9AzPpUKe1quB0priOMc5zygkQugLarFTgZgMMCN7irmtSJKN3JZANRWUACcwWwKx5WexPckQyXKF417h6S66DlGqe5/ytQKZ+6etnS7O6Yz2XLVnPI0v09Fp+RlVN4g6fC0K3XLuOFbHlX+NssYneD7+XDceFiXezc13v5dQobB0zgAhv4wKrpr3v+674AbyYw2s0Xf03m4AfjJcIuS+/vKmxht2CYbRreI4c7TJYPjy4r8UUviSljYtc1ksJcXfFkWqy6EOszxjJWDI21CmPy5lgwO2bwCYL8Yx2PmIk9lm+R80LkFxPzyEvuSZOboMHm3cLKO0nxSaPMZCj3wHolLMYJWTLm7GoZuFy+sJd9kJL1XcPNNBTime2b5rdMmQncGOA59GxVOSdZxXUu8Zp7kGf87dnQF0SKQ3b8wEY7+tGQjv+0pCfdaEY7hIIjWJ9INB3nX845jYH28KB5kBITusTUKBzyp7Ma6rLcOQl1C9gMZTFr/UkWx61myqvF++ct57opuz7DGkf962UEG769RnOxh3JsvayauctmNrF/k2w6R/snzf7Ls697bWxP23Tb9m+3fZJt9oR7weOW8rdjd+4XpVvduLZOu832buCsGznzrl29oXdvKgw73vtOR7kR8zkEcyTg+ul3ZT6XzIZ7EeEsUzjZGO7wiisT4qyTeBTWaPGK7xfjf9E4FDje8YZ/HOSIEbl2KF5yy6JcGwMPA8lbLt2XZyPmkWE5zbt4cpuHRuVOmPnOqdhzn9cG6OTR+dD/42h0ZuAcycRcOs+bbmykz07pUq8i1ZXx9NBgPetF37rprL4EoWdd62IfDdmVYPazhz3t/l47fL4u9bfDnWxyR0LbwX732+RduSY7O9P7foquXzHwgp8k4U1h+NrQfel2XzzqAO4EXA7gX1i2tZwSr3jJj6LxQgDt4FCt+d9xHu2eV87fW+BXADAgS3Au/R5Pf/HUq57yTSDAAhhQVYWZo8+eRjznI297va+eBc4IGTL4nDsDNkSKp0cGpadP/epb//rYj4ilG9KDY9wkFpyWPbxoT/ziO+j4KoBVK17RCtKbWfiJL7/5iQD6IPypFpiv9fujHv35Uwf95PN4Qyd///4XIwAoBHtXdwXYCfXHGAK4cwS4gHhygDHygDQXgRLIAw1Ibfw3fBloHhSIIBbYchj4gYoUgj+QgJBngpiwgeAGf4JXgiyYb8cjZEJEfjMoHyiIJyNYcjKYg7fmYygGg24HhJTgguxGhHxnhJKAhPimhArIhCCygz2gggMohVOIe84GhSuIhY/ghP7Wgx33g17oXFqobVx4hWXYCGC4cGkIgWvIhlSogWJocWQYhw12hub2hheIh3oyhztghXDoh/cCiDogiH1IiIjQhhPHhySoiItoiIpUhx4HiQrmbjaWUjhoieflaxPWgfHHiZ2obJ8oNpsoipQliWhDiQ53h/+cyIgbx4omh4rupYcE54g+SIupaIsyJ4supYtEoYo3gIiPCIx/AIs4cH88kXn7Z4r9Z4zBY4izEici4H4b5IsuB436ZYgaJAKx14yb94za6BSACCsL4CTfhGjip4niOI7iA4jgVDBzxXzdlQ/PR37Zl4/6uI/82I8KtH0MgScWAi7hB46m147uuCKGeCA3035iNijXiItjmJDgY4jNk386sY47cYoUaRbC+DnYWHMd6ZG8mHMSaYcjqZAlCXXO6IEp2RUfaTIhCUeuaInIuHInWYkviUgxSUwzOXU7SUQ9KTY/SXRBKZQr6XU52YpHuRtDeTstGYpNCQc3GXRF+XD/U0kcT3lGSzmLWakUW7lHVzl4X1kvYQkvYxlIZekhZ5lSadl5a2kdbZllXfmLcSmXSXl4oBiDd5kVc6mRI8GRfakXf2mQs4eQg8kehRmRe1mEiWkXi+k9b4l6j6mYeel4dZmNlZlyl9kik1l7m8mZQihvmSmSoakgnakFxJiLpylzkVlDjbmErTkYr6lqpUmTs4mao8lrsRmFubkhqemAtwmUv3l0wcmBUcmXxWmcuylsn1mTkFiVSTecRrmcLaKKryAMzMiYyemY1skYqggMwmCNkkmdWPmddHKcP0AMK/GN3BmOLomeY6eePcAu8aCOhjl+iCmfeEefO+AOYuV7/wQ0IUexaPjojwiaoAq6oAoKkAtRnxzhEQX5ngcZn/wZd/7pAytBnrDZnbJ5oSiToT2AE/pHoYdpoSC6cbXpZ73ZhSnan82JbC2qhi+qoiLaiDM6iDU6cisafDmaiDuqHT3qWz9ajEEadENaUkXKmkc6eTG6hUs6kU3qpEo2hFGKklM6O0k6Ic+ZpVp6o7FonmTppcYHpiPXpWQKH1vqWB7qm2l6fmaKk1eqk28Kp0+KhnPKlHVqp1VKmnnqlXtKf2u6mlIaqOQzqGhqqAiIqGKqloq6qHFqlY0Kl486gZE6nX9ql5VqqXe6h5mqmZuqgYz6qaYZqoE4qm3qoqZ6qv+XenWTSpmreoKtWnaJGquy2qm3SKq4aauHiKrwKZW8Gkyzyna1GqzVBmqZuJH7aawbNqxz96qgyaxP5qx6V6zS2qy42ovQCp2KKJ0zQDnMU6LlqavEea3qRa0ugD2Foj0PmWosmqo0aq7Y2qeVoT420T62Sa7VKa/zCmhUcAD3Mw/nAJjZJZj8Klzo+gIBJCgCm2gFeo/Rx6ASO7EUW7EP5KAK8QMWRAITOq7wqqMHm1ILSULV2K4Eu0EGG7L4lbAjkUniIK4d+qvKqbIIm60mqa/nSbPZ5asVCqw6u7I2y5Iy650/C2AsS3/WqncG9xpT6a20uq1IerQZ6LTECrX/VOqvO0m1z4qzY8p2a5puWlutVvulQWuMYQt4XOuoZEuvKXm21TW2Zfe14+a2RUCoWLq2WPuSdIu0cOu1UiuBexuAfaumf7uAgYuASVs8cttth1uBg1umZQuMjSuCj6u4hVuAk5uCicunedu2PHuiPuu3kauLmcuDlcu5nhiUpVuFm1u3i3ttq0uHp+u6l+t/sRuIrSuotTt/S8u0TvaxQBq3u2t+0Ieifgq8Riq8oxuIvVsLc5uyzjm7uru8vTq80gG9Moq8TKq8bIu6pLhsxRu6xzu0Hyq63Uu71Eti4TuzpUi+bmq+neu91lZ2zcutaUup49uz7Au/qUu46Sus//+rHtgLpdpbqNwbv+h7vtOrwE04wHhawHd7wP0LuQwMqQGsNg4cBdvpse6rqvz7vf5bwQb4t/UrI+tLtFjAofkKwXQqwSBMwQi8wDFswSIcIxkMBe7JwfqLwiE8wzTswyN8wdMqxNILBfRoovppvDA8wZZLxEFYw5wKxSl4w05wxPVYwlicxVq8xVzcxV78xWAcxmJsGkXQsTHLm7+bv2qcvVYqBCr8rmscve3bxnFMwEGwwWcsx2mMxnOsx3SMo39cx566x34syK7ax3ycyIasrYR8po1cyJCsyGy8yEogAUcwLj4wLpbsBpu8Bp3MBp+cBqGMAwPEBKNMBdwANv9J0gp1syOU0zQqgMlfRlI2kABmgjjJsC8DNA4wNEfds01LoCIFMg74cyYO5QsbgSIb0WlHkBLOvC8UMpCWQjBSYMv3UACZ5csqsi0JkwS7vC8kUMqGcA1iRFEMUFTIUlPWQLImIMs84M4zcAz1QADYo8v4w8sAUzCE5Cx2wwTCTBLjEAwzha+zgj/mjM5L4MxXxiwOcyZhlc4QDQXyXFDYsy3lYAAOoE48YUZK8M0DEs4GPc4HMDU0U1AnApHUTDDu3Ep00wC2JFD3kFMUJUupRNNosjy1dQMI0FgzxbCCAkM3cjTUnAT/7CzJnM/tsyj4MzVs4gQKXVOz8lI5Ms3/9eTUPB0ghVQgqdIEHj0OxLJ+fZMqBpAq57gpzRMLD/CQ2vMAXp2RZzBCnzICaT0MmEPV8uhMkHIAB1BX7UQ4reAl6RhOCBDYnhIw1ADPMtAAJf1LA+LR+Wxb6hzMReEsCVAAxWDMr/EKETBAc30xTs0Rt7BpJb0vk8MRVd0Eim0CJTNGiCPTTNDVulUz6TjWMp0qyaA3B5JOUb0R6KDY40BXhoUGX8J7HEszVjICKe023RzZkA0sY30Pfz1Rq4Va96AAiB0DqU3MsPTYAtrUpE1SQ40ERc3LvGzMzyASA5Tax40S1yM1wW3ZPV1bKX3aTJDd1b3aBMIs4OzN97x8/30jD17t2isRDr6S1srCCg1wDLMtoGZwDY1CKBxhE/ONAkPtVA4Ay9ewWkMFVFtjVLRMAzu9K1lizxaCJPsSKOF9BOOdVnPDPs9QFApQKC/E3iLUCqKkJAlz4nFj11IQ4vag0VlNEm61BE2tMEgC4PptEwMeCwVeDBfTAB/hAOj03yFNBtfQkJZjORN+Anm914M1V8bgVxq+Wp4SCyVCNx8+AwEiDLAy4h8tKuxTLQ69z8xN1EExzGdCzNWAr74XKIGiBE9dONcy5zGz5VGw5uGSJeecDBit0d2wKUsA5x/je0i+MAluOeFwIFOTJbwNAE0C1hdd5exwZUayPpySMP+GrtpKgua2lQBLwgBiLt0TZc12w0pprua3jM08VBOW50u7jlmCAt1KsOISbt4nIA+FPQLqgmft7erLvU348DYQneJOQOu4XDCBc3nSFBQPAMtK0OuMTuUG4EkJvuQvqznHUA0BEu6hXkhF++7wHu/yPu+IsBH0HhN/XgL5fu8nse/fx++4UCaCkygdEaDBQt0IQN05hfDjQiUI005lXQ6vRI0A/wh8/TGMgw7mvu9+tRKTsykPbtsU1dtZogDAV/GJMC4EgyPCwPKykO24JQzA0g5Qbu4XRfEo3wgqHyYuD1PjieExb1s0j+kyTzE5b/HVsvJo/Q1Mg9ZhAua6Z+NcYfLxBgABId/yBbBX+H30KZ/0PO8oZf3gU2M3rs4sfjX2WVMtDl/bWP9aC/DRXB/3cj/3dF/3dn/3eJ/3er/3fN/3fv/3gB/4gj/4hF/4hn/4iJ/4ir/4jD8CIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Responsiveness to diazoxide treatment among 288 patients with persistent hyperinsulinemic hypoglycemia of infancy (PHHI). Diazoxide responsiveness varies depending on the genetic defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Flanagan SE, Kapoor RR, and Hussain K. Genetics of congenital hyperinsulinemic hypoglycemia. Seminars in Pediatric Surgery 2011; 20:13.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39757=[""].join("\n");
var outline_f38_52_39757=null;
var title_f38_52_39758="ST resolution vs TIMI flow";
var content_f38_52_39758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Improvement in TIMI flow grade is associated with ST segment resolution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The reperfusion regimens used in the TIMI-14 substudy were tissue plasminogen activator (tPA) and combinations of abciximab plus reduced-dose tPA, whereas the fibrinolytic agent used in the HIT-4 study was streptokinase. In both studies there is a direct relationship between the degree of ST segment resolution and the TIMI flow grade achieved (p &lt;0.001 for the correlation between ST resolution and TIMI 3 flow; p &lt;0.001 for correlation between ST resolution and infarct-related artery patency, ie, TIMI 2 + 3 flow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39758=[""].join("\n");
var outline_f38_52_39758=null;
var title_f38_52_39759="Proximal fifth metatarsal fracture zones";
var content_f38_52_39759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Schematic representation of fracture zones for proximal fifth metatarsal fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_52_39759=[""].join("\n");
var outline_f38_52_39759=null;
